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ABSTRACT 
Members of the genus Campylobacter are a major cause of food-borne disease 
worldwide. They can colonize the intestinal mucosa of poultry, to high levels 
leading to contamination of meat, at slaughter. Their numbers can be reduced in 
different ways including chicken treatment with bacteriophages. For such 
treatments to be successful, in depth understanding of the bacteriophage that 
infects and kills campylobacters is vital. The work in this thesis describes: 
isolation and comprehensive characterisation of bacteriophage candidates for 
future therapy applications. 
In order to increase the available stocks of characterized candidate 
bacteriophage, a number of attempts were made to isolate bacteriophages from 
poultry excreta. The new isolates together with some uncharacterized phages 
from our laboratory stocks were characterized with respect to their host range 
and genomic size. Some bacteriophages preparations in previous studies showed 
genomes of different sizes and a number of attempts were done for their 
separation. This raised questions about the relationship between the two different 
sized genomes. Prior to this work, a co isolate pair had been successfully 
separated and the sequence of the larger genome, CP220, was determined. Part 
of the work here, was performed to extend this study by obtaining the sequence 
of the smaller co isolate, CPX and compare it to CP220. They did not appear to 
have any identifiable relationship at the genetic level, but the availability of the 
CPX sequence will further extend our knowledge of bacteriophage genetics and 
this phage has clear therapeutic potential. Attempts were also made to separate 
and characterize a second co-isolate pair but these were unsuccessful. 
The availability of the DNA sequence of CP220 allowed a much closer 
molecular characterisation and comparison of Campylobacter phage genomes, 
than had previously been possible. One area that was investigated in this study 
was the presence of repeat regions identified in the CP220 genome, which were 
amplified by PCR, but could not be cloned in E. coli. Furthermore, genes 
encoding potential lysins were identified in the CP220 genome and they were 
amplified, cloned and attempts were made to express the proteins, which may 
have potential therapeutic value. One gene product was successfully expressed 
and showed evidence of lytic activity on Campylobacter and other bacterial 
genera. 
In summary, this thesis describes a much closer examination of molecular 
biology of Campylobacter bacteriophage than had previously been possible, 
including the determination of the sequence CPX phage. 
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1.1 The Genus Campylobacter 
1.1.1 General Characteristics 
Campylobacters are Gram-negative non-saccharolytic, non-spore forming 
bacteria (Newell and Fearnley, 2003). The cells have a spiral shape with 
approximate dimensions 0.2-0.8 )lm wide and 0.5-5.0 )lm long. Most 
Campylobacter spp. are motile with a single polar unsheathed flagellum at one 
or both ends of the cell. Some, like C. gracilis, are non-motile and others, like 
C. showae, have multiple flagella (Debruyne et al., 2008). Campylobacters are 
found as part ofthe normal gastrointestinal flora of many domestic animals and 
pets (Corry and Atabay 2001; Shen et al., 2001). Campylobacters were not 
differentiated from "true" Vibrio spp. until 1963 by Sebald and Veron (1963). 
This differentiation was due to many reasons including: low G+C DNA base 
composition, their non-fermentative metabolism and their microaerophilic 
growth requirement (On, 200 I). Campylobacter species are fastidious in their 
in vitro growth requirements and have little or no global stress response 
mechanisms against harsh environmental conditions (Murphy et al., 2006). The 
G+C content of the DNA ranges from 29 to 47 mol %. The number of distinct 
Campylobacter species and subspecies varies from author to author, due to new 
species being discovered and some being reclassified in to different genera. 
Currently there are 24 species with eight subspecies assigned to the genus 
Campylobacter (Debruyne et al., 2008; 2009, 2010a and b; Rossi et aI., 2009; 
Zanoni et al., 2009; Vandamme et al., 2010). The Campylobacter species 
currently recognised are listed in Table 1.1. Campylobacter jejuni is recognised 
as the most prevalent human enteropathogenic Campylobacter species, 
followed by C. coli. Most of this review is concentrated on these two species 
2 
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because they account for the majority of human disease. Campylobacter jejuni 
has two subspecies; C. jejuni subsp. jejuni and C. jejuni subsp. doylei that 
differ in their biochemical characteristics (Debruyne et al., 2008). The 
complete genome sequence of C. jejuni NCTC 11168 was first published by 
Parkhill et af. (2000). 
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Table 1.1 Campylobacter species 
Campylobacter Sources References 
species 
e./etus Sheep, cattle, ungulates, fowl, reptiles and McFadyean and 
humans Stockman 1913 
e. Pigs, hamsters, cattle faeces, deer and Debruyne et al. 
hyointestinalis human blood 2008 
e. lanienae Faecal samples of abattoir workers, pigs Logan et at. 2000 
e. sputorum Cattle faeces, sheep, humans, bulls, pigs On et al. 1998 
Atabay et al. 1997 
e. mucosa/is Pigs, porcine oral cavity Tyrrell et 01. 2003 
e. concisus Humans Tanner et 01. 1981 
e. curvus 
e. rectus Humans Tanner et al. 1981 
e. gracilis 
C.showae Humans Etoh et 01. 1993 
e. hominis Humans Lawson et 01. 1998 
e.jejuni Cattle faeces, humans Smith and Orcutt 
poultry 1927 
Atterbury et 01., 
2003a 
e. coli Cattle faeces, humans Smith and Orcutt 
1927 
Pigs Jensen et 01., 2006 
e. lari Seagulls, river water, shellfish, humans Endtz et 01. 1997 
e. insulaenigrae Seals, porpoise, elephant seals Stoddard et 01. 
2007 
e. canadensis Whooping cranes Inglis et 01. 2007 
e. upsaliensis Humans, cat faeces, dog faeces Debruyne et 01. 
e. helveticus 2008 
e. ureolyticus Intestinal biopsy specimens and faeces Vandamme et 0/. 
samples of children with newly diagnosed 2010 
Crohn's disease 
e. cuniculorum Rabbit Zanoni et 01., 2009 
e. peloridis Shellfish and humans Debruyne et al., 
2009 
e. avium Poultry Rossi et 01.,2009 
e. subantacticus Wild birds in the sub-Antarctic region Debruyne et 01., 
2010b 
e. volucris Gulls Debruyne et al., 
20lOa 
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1.1.2 Biochemical Properties 
Many of the Campylobacter species (Table 1.1) have similar biochemical 
properties, such as the ability to reduce fumarate to succinate and the absence 
of hippuricase, with the exception of C. jejuni in the case of the latter 
characteristic (Debruyne et al., 2008). All Campylobacter species are oxidase 
positive, (except C. gracilis, which obtains energy from amino acids or 
tricarboxylic acid cycle intermediates), as they are unable to ferment or oxidize 
carbohydrates (Vandamme, 2000). Moreover, most of the species cannot 
reduce nitrate and they give negative results in the methyl red reaction and 
indole tests (Debruyne et al., 2008). 
1.1.3 Isolation Techniques 
Campylobacters are fastidious in their growth requirements and very sensitive 
to stresses, thus their isolation is challenging. The use of selective media for 
Campylobacter isolation is recommended, depending on the sample type (Bu 
and Kuo, 2011). Different workers isolated Campylobacters using different 
media containing different combinations of selective agents including: 
cefoperazone, cycloheximide, trimethoprim, rifampicin, vancomycin or 
polymyxin B. A number of media that are based on blood and antibiotics such 
as: Skirrow's. Butzler's and CampyBAP are considered as the commonly used 
media for Campylobacter isolation (Baylis et al., 2000; Granato, et al., 2010). 
Some selective agents have inhibitory effects on damaged cells, thus a 
suspension is first made in basal broth followed by the addition of a selective 
agent after a short period of incubation, with a gradual increase of incubation 
temperature between 37 and 41.5 °C (ISO; 1995,2006). 
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To improve the recovery of these bacteria from samples having low numbers, 
enrichment by filtration can be beneficial (Hu and Kuo, 2011). In addition, 
enrichment is required in samples having injured cells resulting from different 
stresses during food processing and storage (Rosenquist et al., 2006). The use 
of filtration was described by Butzler et al. (1973) for the isolation of Vibrio 
from stools of children and adults having diarrhoea. Filtrates of faecal 
suspensions were passed through membrane filters (mean pore size 0.65 Jlm) 
and then cultured on non-selective agar. This step is not required for isolating 
campylobacters from chicken excreta samples as the use of selective broth and 
direct plating on selective media resulted in maximum recovery values (Mason 
et aI., 1999). 
Routine selective methods developed to isolate C. jejuni and C. coli from 
human patients in diagnostic laboratories, are not considered practical for the 
large number of samples that are processed daily, so their numbers may be 
underestimated. Also, they are generally unsuitable for the isolation of the 
other members of the Campylobacter genus that cause human disease. Methods 
that are suitable for the isolation of these include the use of detection methods 
that avoid selective isolation media such as the membrane method of Steele 
and McDermott (1984) or the method used by Lastovica et al. (1989) that can 
detect a greater variety of Campylobacter species as well as Arcobacter spp .. 
Cefoperazone amphotericin teicoplanin (CAT) agar was developed by Aspinall 
et al. (1993) through modifications of modified charcoal cefoperazone 
deoxycholate agar (mCCDA) with the use of different antibiotic levels for the 
isolation of C. upsaliensis as well as the thermophillic campylobacters. This 
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medium was used by Corry and Attabay (1997) in comparison to mCCDA, for 
the isolation of a number of Campylobacter and Arcobacter strains and its 
efficiency in this respect was proved. In addition, Aspinall et al. (1996) 
reported that the use of CAT media, rather than the membrane filtration 
techniques on Blood Agar (BA) plates, resulted in fewer competitors. 
A large number of comparisons of the various enrichment and cultural methods 
have been described in the literature for the isolation and enumeration of 
campylobacters from different sources. A standard method was published by 
The International Organization for Standardization (ISO) which included the 
use of Bolton broth for enrichment step followed by culturing on mCCDA 
selective media and any alternative medium to be chosen by the person 
performing the experiment (ISO 10272-1, 2006). Lynch et al. (2010) 
developed a universal protocol for growing 17 species and three subspecies of 
Campylobacter. It involves an enrichment step for 24 h in Campylobacter 
enrichment broth (CEB), at 37°C under a low oxygen atmosphere containing 
2.5 % O2, 7 % lh 10 % CO2 and 80.5 % N2, followed by centrifugation and 
filtration on to Anaerobe Basal Agar (ABA). 
Different studies have been performed to compare direct plating and 
enrichment. One such study involved a comparison of mCCDA, Karmali and 
Preston agar with or without enrichment in Exeter broth for Campylobacter 
isolation from the caecal contents of chickens. It was found that enrichment did 
not improve the isolation rate. For direct plating, mCCDA showed a higher 
isolation rate than Karmali and Preston agars (Rodgers et al., 2010). Similar 
findings were reported by Kiess et al. (2010) for isolating campylobacters from 
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broiler litter using a different set of media. Regardless which media is used, 
direct plating proved more effective for the recovery of campylobacters 
compared with the use of an enrichment step that was performed in CEB. All 
of the five media compared: Campy-Line agar (CLA), Campy-Cefex agar 
(CCA), modified CCA, Campylobacter agar plates (CAP) and mCCDA 
showed similar iso lation rates. Most recently, U garte-Ruiz et al. (2012) 
described a comparison between direct plating on mCCDA or Campyfood agar 
(CF A) with enrichment using Bolton or Preston broths for the isolation of 
campylobacters from poultry faeces, neck skin and packed fresh meat. They 
concluded that direct plating is better than enrichment in samples like faeces 
and neck skin because of the presence of high contamination levels. For 
samples with less contamination such as poultry meat, then Preston broth 
showed better recovery rates than Bolton broth recommended by the ISO 
standard. They also, reported that plating on mCCDA was not significantly 
different from CF A, yet direct plating on CF A was better because of the ease 
of colony identification. 
Another recent companson was provided by Habib et al. (2011), who 
compared direct plating and enrichment using three different broths (Preston, 
Bolton and Campyfood) and three selective media including mCCDA, CF A 
and Brilliance Campy count agar (BCC) for isolating campylobacters from 
chicken meat samples. Bolton broth was a good choice of enrichment broth for 
Campylabaeter growth and competitor inhibition. Yet, Preston broth performed 
better than Bolton broth regardless of the subsequent plating media. Isolation 
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usmg CF A and BCC media was easy and precise and they were good 
alternative media to mCCDA. 
The optimum temperature for C.jejllni is generally agreed to be between 37°C 
and 43 °C. It lacks the ability to grow below 30°C and above 47 °C under a 
microaerobic atmosphere. These gaseous conditions can be generated by using 
a gas generating kit, Campy-pack system or an evacuation replacement method 
where the air is removed from the incubating jar and replaced with a gas mix 
containing 80% nitrogen, 15% carbon dioxide and 5% oxygen (Barros-
Velazquez et al., 1999). 
1.1.4 Campylohacter Confirmatory Tests 
Different methods can be used to distinguish campylobacters from other 
bacterial genera following their isolation on selective media. On mCCDA, 
campylobacters appear as flat, moistened greyish colonies. 
Gram stain can be used to differentiate campylobacters which are Gram-
negative from Gram-positive bacteria, based on the chemical and physical 
properties of the cell wall. In addition to that, their morphology and motility 
can be examined using phase contrast microscopy. Oxidase test is another 
biochemical technique that is used to identifY the campylobacters that produce 
cytochrome oxidase from those that do not. 
Latex tests, usmg particles coated with antibodies that agglutinate in the 
presence of Campylobacter antigens, can be performed to confirm the presence 
of C. jejllni or C. coli colonies picked from agar plates (Nacharnkin and 
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Barbagallo, 1990). Commercially available systems include: Campyslide 
system, Meritec-campy system and Microscreen methods (Hazeleger et al., 
1992). 
1.1.5 Discrimination Between Campylobacter Species 
A number of phenotypic and genotypic methods have been proposed and used 
by different scientists in order to differentiate between bacteria at the species 
and subspecies level, each with its own advantages and disadvantages. 
Biotyping methods are based on variation in the metabolic activities of the 
species to enable discrimination (Eberle and Kiess, 2012). A number of tests 
may be used to differentiate between different species of Campylobacter. For 
example, a positive hippurate test distinguishes C. jejuni from other 
campylobacters, because it alone produces the hippuricase enzyme. Catalase 
production, sensitivity to nalidixic acid or cephalothin, indoxyl acetate 
hydrolysis and growth at different temperatures are all tests which are used to 
differentiate between the other species (Vandamme, 2000). Different systems 
have been proposed to distinguish between C. jejuni, C. coli and C. lari. The 
system proposed by Skirrow and Benjamin (1980) was based on the ability of 
the species to grow at 25 °C and 43 °C, susceptibility to nalidixic acid, 
hippurate hydrolysis and hydrogen sulphide production in iron-containing 
media. On the other hand, another system developed by Lior (1984) was based 
on hippurate hydrolysis, rapid production of hydrogen sulphide and DNA 
hydrolysis. 
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Whilst many different molecular methods have been developed to improve 
bacterial identification to species level, the fairly recent availability of many 
genome sequences meant that PCR amplification has become the method of 
choice to distinguish between species, as it is quick and cheap. Thermophilic 
campylobacters (c. jejuni, C. coli, C. lari and C. lIpsaliensis) from clinical 
samples were discriminated by Eyers et al. (1993) using PCR amplification of 
23S rDNA gene. Multiplex PCR is a rapid and easy method that has a high 
sensitivity and specificity. It is based on using specific primers designed from 
known DNA sequences to produce peR fragments of a size present only in 
members of the species to be distinguished. Several sets of primers are used, 
hence the term "multiplex". This method was used by Wang et al. (2002) to 
distinguish between different species of Campylobacter from clinical and 
environmental samples. The amplification was based on hipO and 23S rDNA 
genes from C. jejuni, glyA gene from C. coli. C. lari and C. lIpsaliensis and 
sapB2 gene from C. fetus subsp. fetus. The detection of products from 
multiplex peR has moved on from separation of amplified fragments by gel 
electrophoresis to real time peR where, through the use of labelled probes, a 
fluorescent signal is detected directly during the amplification. In addition of 
being a rapid, sensitive and effective method, it has the advantage of 
quantification as well as identification and can be used directly without a need 
for culture. Campylobacter jejuni and C. coli were successfully detected and 
discriminated from each other in faecal, feed and environmental samples 
(Leblanc-Maridor et al., 2011). 
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1.1.6 Fine Discrimination Between Campylohacter Strains 
Historically many systems (phenotypic methods) have been proposed to 
differentiate between Campylobacter strains including serotyping and phage 
typing. However, subtyping campylobacters and differentiation became 
considerably easier with the development of molecular techniques (genotyping 
methods), like: multilocus sequence typing (MLST; Dingle et al., 2005), 
Amplified Fragment Length Polymorphism (AFLP; Lindstedt et al., 2000) and 
fia typing (Meinersmann et al., 1997; Muller et aI., 2011).Two recent reviews 
of Campylobacter typing methods cover the advantages and disadvantages of 
the most commonly used methods (Eberle and Kiess 2012; Clark et al., 2012). 
Serotyping was one of the major methods used for Campylobacter strain 
discrimination before being superseded by molecular techniques. It is not 
widely used now, as many laboratories do not have the expertise or the antisera 
required for performing the assays (On et al., 2008). The system is based on 
the detection of the surface antigens and the differences between them 
(Wiedmann, 2002) using different antisera. The first serotyping method 
performed by Berg et al. (1971) placed campylobacters into three serotypes on 
the basis of their heat stable antigens. Later methods include the Penner and 
Hennessy (1980) system and Lior et al. (1982) system, were based on the 
identification of heat stable and heat labile antigens respectively. 
Phage typing is another phenotypic method that has been applied to 
discriminate between strains of Campylobacter (On et al., 2008); however, this 
was superseded by molecular methods. Susceptibility to selected phages is 
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used for such discrimination. It was used in conjunction with serotyping to give 
better discrimination (Frost et al .. 1999). The technique involves inoculating a 
bacterial lawn, made from the strain to be tested, with different phages and 
examines their reaction pattern to these reference phages (Grajewski et al., 
1985). This scheme was described by Frost et al. (1999) where the individual 
Campylobacter phage types were defined as two or more different 
Campylobacter isolates giving the same phage reaction pattern. Different 
schemes were described worldwide including in the United States (Grajewski 
et al.. 1985), United Kingdom (Salama et al .. 1990) and Canada (Khakhria and 
Lior, 1992) but they shared some common phages. 
Compared to the phenotypic methods, genotyping methods are more sensitive 
and can provide higher levels of differentiation, reproducibility, standardization 
and typeability (Wassenaar and Newell, 2000; Wiedmann, 2 0 ~ 2 ) . . MLST has 
become a favoured genotyping method with the advantage of precision and 
differentiation by directly sequencing the amplified DNA of a specific set of 
genes especially those with housekeeping function (On et af., 2008). This 
method was introduced by Maiden et af. (1998) in order to compare typing 
results between different laboratories. Dingle et af. (200 I) developed this 
method to differentiate C. jejuni strains after which Miller et al. (2005) 
extended this method for C. jejuni, C. coli, C. lari and C. upsaliensis. It has 
the advantage of reproducibility, ease of interpretation, yet it can be relatively 
expensive (Levesque et al., 2008). 
Amplified fragment length polymorphism (AFLP) is a method used to 
fingerprint C. jejuni subsp jejuni strain and does not require a preVIOUS 
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knowledge of genomic DNA sequence. This method was developed by Vos et 
af. (1995). It involves amplification of DNA fragments that were initially 
digested with two restriction enzymes and ligated to nucleotide adaptors that 
serve as a template on which primers anneal. Following electrophoresis, the 
fragments produced are detected using sequencer or by a fragment analyzer 
(On et al., 2008) to produce a fingerprint, unique to the strain tested. Forty 
distinct patterns of ninety one C. jejllni strains were distinguished using this 
method (Lindstedt et al., 2000). 
The sequences of the Campylobacter flagella genesjlaA andjlaB can be used 
as a basis for discrimination in two different ways (fla typing methods). The 
first one is fla-RFLP which combines PCR amplification with RFLP 
(restriction fragment length polymorphisms), where the PCR amplicons are 
digested, electrophoresed and documented using software to identify the RFLP 
profiles. This method is simple, reliable and useful for subtyping C. jejllni and 
C. coli strains. It was successfully used for typing 26 Campylobacter strains 
from nine laying hens and resulted in the discrimination of 13 C. jejllni and 13 
C. coli strains (Muller et al., 2011). To overcome problems associated with 
reproducibility and variations between different laboratories, another way ofjla 
typing method was developed which uses the jla-SVR (short variable region). 
Short variable regions were identified in the sequenced jlaA gene and used as a 
template on which primers were designed for amplification. Following 
electrophoresis, the fragments are sequenced and compared to the reference 
SVR from data bases available (Meinersmann, et al., 1997). 
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1.1.7 Growth and Survival of C.jejuni and C. coli 
Campylobacter jejuni and C. coli are thermophilic with 42°C thought to be 
their optimum (Park, 2002). These strains do not grow at temperatures of 55°C 
or above. For that reason, Levin (2007) suggested that these organisms should 
be described as thermo tolerant rather than thermophilic. Campylobacter jejuni 
and C. coli are sensitive to NaCl concentrations of2 % and above (Park, 2002) 
with, 0.5 % NaCI thought to be optimum for their growth. The optimum pH for 
Campylobacter growth is between 6.5 to 7.5 with pH 4.9 thought to be the 
lowest and pH 9.0 to be the highest that strains of C. jejuni and C. coli can 
tolerate (Silva et al., 2011). 
Although large numbers of studies have been performed on Campylobacter 
survival they cannot be easily compared with each other as they are done under 
different conditions. For example survival at a particular temperature will be 
influenced by the atmosphere provided and by the medium in which the 
bacteria are heated, whilst the enumeration method, often using antibiotic 
containing selective agar, may significantly affect recovery of damaged cells. 
However it is clear that campylobacters can be easily inactivated by heat 
treatments. They were inactivated completely from ground beef cooked in the 
oven at 190 and 218°C when the internal meat temperature reached 70°C. 
Similar inactivation was achieved at both temperatures, yet at 218°C the meat 
internal temperature increased faster (Stern and Kotula, 1982). Freezing and 
thawing reduces Campylobacter spp. populations (Stem and Kazmi, 1989). 
However, freezing does not eliminate campylobacters from contaminated foods 
(Lee et at., 1998) and can act to preserve viability. It was reported that freezing 
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ground beef at -15°C resulted in the reduction of Campylobacter cell numbers 
within three days, followed by stabilization of numbers, until the end of the 
incubation period (Stem and Kotula, 1982). 
1.1.8 Campylobacter Sources 
Chickens are widely believed to be the main source of campylobacters that 
cause human disease; however, they are not the only source. Other sources 
include: turkeys, ducks, lambs (Humphrey et al., 2007), rodents, insects 
(Newell and Fearnley, 2003), cattle (Stanley and Jones, 2003), sheep (Scott et 
al., 2012), pigs (Nielsen et al., 1997; Harvey et al., 1999) and other avian 
species. The drinking of untreated water or rain water (Nygard et al., 2004), 
ground water (Hanninen et al., 1998), and raw milk (Blaser et al., 1979) can be 
sources of these bacteria. Lastly, campylobacters can be isolated from shellfish 
if they were grown in Campylobacter-contaminated waters (Wilson and 
Moore, 1996). 
1.1.9 Campylobacter in Poultry 
It was reported by Meldrum et al. (2006) that the incidence of campylobacters 
in whole raw retail poultry meat in the UK was high, with the number of birds 
testing positive being 68-73.1% in Wales, 83.3% in England and 57% in 
Northern Ireland. 
A recent European Food Safety Authority survey indicated that campylobacters 
were present in more than 80 % of UK broiler chickens in common with many 
member states but with the exception of certain Scandinavian countries where 
16 
Chapter 1 
the incidence was low (Norway 5.1 %" Sweden13.2 % and Denmark 16.5 %). 
On the other hand the incidence in Finland showed a marked difference 
between the fIrst and second halves of the year, where the incidences were 1.8 
% during January to May and 6 % through June to October (EFSA, 2011). 
Campylobacter colonization levels of individual chickens is high and falls 
within the region of 5 to 9 10glO CFU g-I of the caecum content (Rudi et al., 
2004; Atterbury et aI., 2005). Colonization occurs widely in the avian intestine 
with the Caeca, large intestine and cloaca carrying notably high populations of 
campylobacters (Beery et al., 1988; Chaveerach et al., 2004). Seven 
Campylobacter specIes and two subspecies have been isolated from 
commercial chickens in Ireland. Those include C. coli, C. concisus, C./etus, C. 
hyoilei, C. jejuni sub jejuni, C. jejuni sub doylei, C. lari and C. mllcosalis 
(Lynch et al., 2011). 
Campylobacters are part or the normal intestinal flora of chickens, yet previous 
studies reported the role of C. jejuni in the development of focal hepatitis in 
chickens (Peckham, 1958 cited in Jennings et al., 2011). It is a disease 
characterized by the presence of focal lesions in the liver that are 1-2 mm in 
size and greyish to whitish in colour (Burch, 2005). Liver from diseased and 
normal commercial chickens was examined and it was found that 
campylobacters were present in both of them but those with signs of focal 
hepatitis had higher rate of isolation. Failure to replicate the disease in healthy 
chickens using campylobacters isolated from diseased chicken, indicates that 
unknown factors are involved in its development (Jennings et aI., 2011). 
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1.1.10Campylobacter Transmission in Poultry 
1.1.10.1 Vertical Transmission 
It was suggested that Campylobacter could be transmitted to flocks through 
contaminated eggs, but this has not been conclusively proven (Callicott et al., 
2006), thus there is a debate about this way of transmission. Many strains have 
been isolated from the reproductive tract ofpoultry including the oviduct (Buhr 
et aI., 2002), but it is still unknown whether the strains isolated have caused 
embryo colonization or not. 
In an experiment performed by Allen and Griffiths (2001) to assess egg shell 
colonization and penetration, it was found that egg shells are permeable to 
C. jejuni when immersed in a strain suspension, thus eggs can be contaminated 
by any contact with faeces. With such a contamination method, the bacteria 
were found in the inner shell or membranes but not in the egg content (Neill 
et al., 1985), which may only be contaminated when in contact with faeces via 
shell cracks (Doyle, 1984). If vertical transmission were to occur, 
campylobacters would be expected to be detected immediately after hatching 
from Campylobacter colonized parent flocks; however this seldom happens 
with first detection usually occurring at around 3 weeks (Newell and Fearnley, 
2003). 
In an experiment performed by Cox and others (2009), it was found that 
C. jejuni can disseminate to the lymphoid organs of day-old broiler chicks and 
remain there for an extended time after oral or intra-cloacal inoculation. In 
addition, campylobacters were isolated from eggs and hatchery fluff which 
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may indicate the possibility of this route of transmission. On the other hand, in 
around 60,000 progeny parent breeders, hatched from eggs that their parent 
flocks were positive for campylobacters, no evidence was found for any 
vertical transmission (Callicot et al., 2006). 
1.1.10.2 Horizontal Transmission 
Horizontal transmission of campylobacters is the most likely way in which 
poultry flocks become infected. Once the pathogen is transmitted, it is difficult 
to eliminate. Although broiler chickens normally live in a closed environment 
in barns, campylobacters are ubiquitous in the environments around the broiler 
houses, which could result in flock contamination when they enter the houses 
(Stern et al., 2001). They can colonize chickens in several ways, such as 
consumption of contaminated feeds, or through contaminated broiler house 
equipment, boots (Wing strand et al., 2006; Lindqvist and Lindblad, 2008) or 
coverall of personnel (Humphrey et al., 2007), or through the transfer of 
excreta from one batch to the next, or from consumption of contaminated water 
(Hald et a/., 2001). 
For campylobacters to colonize an entire flock in a short time, it needs only 
one infected bird (Newell and Fearnley, 2003). Several studies on the 
prevalence of Campylabaeter in broiler flocks reported that flock infection 
depends on various factors that include: implementation of biosecurity 
measures in farms, inadequate disinfection between chick placements, multi-
unit sites, flock thinning (partial depopulation of the flock), the presence of 
other animals on the farm, the presence of rodents, seasonal insects (Berndtson 
19 
Chapter 1 
et al., 1996, Newell and Fearnley 2003; Bouwknegt et at., 2004; EFSA 2007) 
and the season. Wills and Murray (1997) perfonned a study to find out the 
variations in temperatures in different seasons and they found that in warmer 
months (May to October), the percentage of campylobacters in chicken was 
high (87-97 %), whereas during months of lower temperatures in December 
and January, the percentages were 7 % and 33 %, respectively. 
The age of the broiler plays a role in colonization. Three week old birds are 
more susceptible than one to two weeks old birds, and this is thought to be due 
to maternally derived, circulating, anti-Campylobacter, immunoglobulin Y 
antibodies which decline after hatching (Sahin et al., 2003; Cawthraw and 
Newell, 2010). Cawthraw and Newell (2010) also reported that, the reasons 
for increased susceptibility between 0 and 3 days after hatching, followed by 
reduced susceptibility until around three weeks in unknown. 
1.1.11 Contamination of Poultry Meat 
Contamination of poultry meat from Campylobacter colonised birds occurs 
during slaughter and processing steps such as defeathering, evisceration and 
the cooling of carcasses (Kramer et al., 2000; Keener et at., 2004; Reich et al., 
2008). The content of the intestinal tract maybe transferred to the surface of the 
skin if the intestines leak or rupture during processing where the contents may 
remain in the cervices and channels (Chantarapanont et aI., 2003). 
Campylobacters will persist on the surface of the poultry meat until the 
conditions are favourable for their growth and multiplication. 
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1.1.12Campylobacter Food-Borne Disease 
Campylobacter jejuni has been found to be a major cause of food-borne illness 
(gastroenteritis) in many parts of the world (Griffiths and Park, 1990; Blaser, 
1997; Friedman et al., 2000), including the United Kingdom (Friedman et al., 
2000; Newell et aI., 2010). Campylobacters were known as disease causative, 
in animals since 1909, but were not known to be involved in human diseases 
until about 1980 (Vandamme, 2000). 
Campylobacter spp. can lead to a number of sequelae including: reactive 
arthritis (Overell and Willison 2005; Ternhag et al., 2008), which is a sterile 
auto-immune post-infectious process that affects some joints (Peterson, 1994; 
AlIos and Blaser 1995); Guillain-Barre syndrome (Nachamkin, 2002), which is 
autoimmune demyelinating disorder of the peripheral nervous system leading 
to symmetrical weakness of the limbs, respiratory muscles and loss of reflexes, 
that may become chronic or lead to death in the acute phase (Mishu et al., 
1993; Mishu and Blaser 1993; AlIos, 1997) and Miller Fisher syndrome which 
is a variant of Guillain-Barre syndrome (Othsuka et al., 1988). Other sequelae 
include meningoencephalitis and encephalopathy but these are rare (Van der 
Kruijk et at., 1994). Recently, C. jejuni was reported to be responsible for 
causing acute encephalopathy in a young female patient with symptoms of 
fever, headache, abdominal cramps, watery diarrhoea and rapid onset of 
neurological deterioration (Lepur et ai., 2012). Spondylodiscitis is caused by 
inflammation of the intervertebral disc space and the area adjacent to it and has 
been associated with C. fetus infection and latterly C. jejuni has also been 
implicated (Tappe et al., 2012). Recently, C. concisus which is known to cause 
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chronic intestinal diseases (Kaakoush et al., 2011) was found in faecal material 
from patients suffering with Crohn's disease (Man et al., 2010; Kaakoush et 
at., 2011) which is a serious inflammatory bowel condition. It is important to 
understand that campylobacters are not the only pathogens present in the 
intestines. Thus, they are not necessarily the cause of this disease (see van Heel 
et al., 200 I) and their roles as causative agents, if any, need to be investigated. 
Reports by the European Food Safety Authority (EFSA) and European Centre 
for Disease Prevention and Control (ECDC) within the last five years indicate 
that campy10bacteriosis is the most frequently reported food-borne bacterial 
disease in Europe followed by salmonellosis and yersiniosis (EFSA, 2007). 
The infection rate in developed countries has been estimated to be between 20 
and 60 people per 100,000 per annum (Acheson, 2001). Campytobacter 
infection is the main cause of bacterial enteritis in England and Wales. More 
than 65,000 cases were reported in the United Kingdom with 195,000 in the 
European Union in 2009 (EFSA, 2011). Since many cases are not reported, 
these numbers are almost certainly an under-estimate of the disease burden, 
with the underlying figure estimated to be 450,000 in the UK (Strachan and 
Forbes, 2010). Nichols and colleagues (2012) estimated that there are about 
500,000 cases in the UK every year with 80,000 general practitioner (OP) 
consultations. The infection rate increased in older people over 50 in the years 
between 2004 and 2010 probably because of the increased use of drugs which 
makes them more susceptible than other age groups. Reports of Campylobacter 
infecting humans have been increasing all over the world (Frost et al., 2002). It 
was reported that campylobacters result in illness in about I % of the 
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population with about 13,000 hospitalized cases and more than 100 deaths 
yearly in the USA (Anonymous, 2007). Although campy10bacteriosis is known 
to be primarily a sporadic disease (Phillips, 1995) with few affected people 
and the source of infection is not known, (poultry is most likely), outbreaks 
involving large numbers of cases can occur when campylobacters contaminate 
the water supply (Blaser, 1997) or bulk milk containers (Heuvelink et al., 
2009). 
It is believed that humans become infected largely through eating contaminated 
or undercooked poultry (Istre et al., 1984; Kapperud et al., 1992; Evans et al., 
1998; Newell and Fearnley, 2003) or through the cross contamination of other 
foods while preparing poultry (Jacobs-Reitsma, 2000). Studies have indicated 
that the presence of campylobacters in a high percentage of poultry and their 
products is the major cause of Campylobacter infections (Stoyanchev et al., 
2007). When contaminated poultry meat was implicated as the source of 
campylobacteriosis, 20-30 % of the cases resulted from the way these broilers 
were handled, prepared and consumed. Between 50 and 80 % of the MLST 
subtypes from human disease cases are typical of the chicken reservoir as 
whole (EFSA, 2010). 
Campylobacter jejuni was reported to be responsible for more than 12 times 
the number of cases of human campylobacteriosis as that of C. coli in a 
surveillance held in England and Wales (Friedman et al., 2000), but C. coli 
remains a significant cause of such disease. Campylobacter jejuni was reported 
to be responsible for 90 % of human campylobacteriosis (Kramer et al., 2000). 
Tam et at. (2003) reported that C. coli was responsible for over than 25, 000 
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cases of the disease in England and Wales in 2000. Other species have been 
reported to be involved in diarrhoeal illness in humans including; C. 
upsaliensis, C. concisus, C. gracilis, C. hyointestinalis, and C. curvus 
(Lindblom et ai, 1995; Gorkiewicz et al., 2002; Labarca et at., 2002; Lastovica 
and Leroux, 2003; Maher et a/., 2003; Boyanova et al., 2004) and C. lari 
(Griffiths and Park, 1990). A recent study in Ireland revealed that, of 329 
clinical samples confirmed as being Campylobacter species: 66 % were 
C. jejuni, 6.7 % were C. coli, 2.4 % were C. fetus, 1.2 % were C. upsaliensis, 
1.5 % were C. hyointestinalis, 0.6 % were C. lari and 24.4 % were C. 
ureolytjeus (Bullman et at., 2011). 
Campylobacter related disease is generally diagnosed using cultural methods to 
isolate the bacteria. The use of non-cultural techniques such as antigen 
detection or PCR for detection of different pathogens from stool samples is 
increasing (M'ikanatha et al., 2012; Stigi et aI., 2012). Yet replacing cultural 
methods is disadvantageous as no isolates will be available for further testing 
(for example subtyping) making epidemiological studies of outbreaks difficult 
(Jones and Gerner-Smidt, 2012). Culturing samples and forwarding them to 
public health laboratories remains the recommended procedure by the Center 
for Disease Control and Prevention in the USA (Gould et al., 2009). 
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1.1.13 Pathogenesis of Campylobacter jejuni 
Campylobacter has evolved specific mechanisms to survive within host cells 
(Watson and Galan, 2008) but these processes are not well understood 
probably due to the lack of similarities between campylobacters and other 
pathogens (Guerry, 2007). The major pathogenic mechanisms of 
Campylobacter involve flagella proteins, colonization factors, adherence 
proteins, invasion proteins and toxin production (Dasti et al., 2010). 
Studies have demonstrated the role of flagella and motility in invasion and 
pathogenesis (Wassenaar et al., 1991; Golden and Acheson, 2002; Carillo 
et al., 2004), where flagellar mutants that affect motility can completely 
eliminate bacterial internalisation. Motility is required for intestinal 
colonization (Barreto-Tobon and Hendrixson, 2012) of poultry and humans 
(Wosten et a/., 2004). Moreover, it is used in the interaction with and invasion 
of human intestinal epithelial cells (Wassenaar et al., 1991). The flagella of C. 
coli and C. jejuni consist of major (FlaA) and minor (flaB) flagellins (Guerry, 
2007). The FlaA flagellin plays a role in the processes of adherence and 
colonization of the gastrointestinal tract as well as host invasion (Jain et al., 
2008). The gene encoding FlaA is regulated by a cr28 promoter whilst the FlaB 
flagellin gene is regulated by cr54 (Jagannathan and Penn, 2005). Both C. jejuni 
and C. coli have polar flagella (either a single one or one at each end) that are 
composed ofO-linked glycosylated flagellins and this glycosylation is thought 
to playa role in facilitating the approach to the attachment sites on intestinal 
epithelial cells (Dasti, et a!., 2010). Campylobacters use a flagellar based type 
III secretion system that is responsible for secreting and delivering proteins 
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needed for invasion and affecting host cell function, such as the Cia protein 
group (Barreto-Tobon and Hendrixson, 2012). 
Perhaps the best characterized of the C. jejuni adhesins are the 37 kDa outer 
membrane protein termed CadF (Campylobacter adhesion to fibronectin) 
(Konkel et al., 1999), a 42.3 kDa surface exposed lipoprotein termed JlpA (Jin 
et al., 2001) and a 28 kDa periplasmic membrane-associated protein termed 
PEBI (Pei and Blaser, 1993). 
Surface components of the outer membrane paly a role in the interaction 
between campylobacters and their hosts. Examples of these includes the 
surface polysaccharide (lipopolysaccharides and lipooligosaccharides) which 
contribute to internalization indirectly by promoting bacterial attachment to 
host cells (Hu and Kopecko, 2008).In addition to that, lipid rafts, which are 
microdomains within plasma membranes enriched with cholesterol and 
glycolipids, appear to have a role in efficient Campylobacter entry to the host 
cell (Watson and Galan, 2008). 
Campylobacters, while adhering to or invading host cells, secrete proteins, 
toxins and other molecules that adversely affect host cells. These effectors 
stimulate or inhibit host signal transduction pathways, promote cytokine 
production, trigger inflammation, change host cell mitogenesis, cause host cell 
death and water malabsorption (Hu and Kopecko, 2008). Cia proteins are 
required for invasion as evidenced by the inability of mutants to invade or 
survive within eukaryotic cells (Barreto-Tobon and Hendrixson, 2012). 
However, the only verified Campylobacter toxin identified is the cytolethal 
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distending toxin (CDT), which is produced by a number of Campylabaeter 
species including C. jejuni, C. coli, C. fetus, c. lar; and C. upsaliensis (Dasti et 
al., 2010). It is suggested that this toxin is the key factor for 
campylobacteriosis, yet mutated strains that do not express this protein can still 
cause the disease (Abuoun, et al., 2005) but reports suggest the invasion ability 
was decreased lO-fold (Biswas et al., 2000). CDT is composed of three 
subunits; CdtA, CdtC and the active subunit CdtB. The role of CdtA and CdtC 
needs to be investigated (Ceelen et al., 2006) yet they are required for the 
delivery of CdtB to the host cell. CdtB is responsible for binding to the cell 
membrane (Lara-Tejero and Galan, 2001), where its active subunit exhibits 
DNaseI-like activity that causes host cell damage (Ge et al., 2008). 
1.1.14 Antibiotic resistance 
Antibiotics are used in culture media as selective agents. Yet, not all species 
can be isolated by the use of a single medium. A number of antibiotics often 
used in the isolation media were tested on different strains either singly or in 
combination, where differences in their sensitivity and resistance were noted 
between them (Corry et al., 1995b). 
The ~ - l a c t a m m antibiotics, such as cefoperazone, are the most often used 
antimicrobials in Campylabaeter isolation media (Silley, 2003). Resistance to 
this class of antibiotics can be controlled through the intrinsic resistance and 
the production of ~ - l a c t a m a s e e (Li et aT., 2007). Due to cephalothin 
susceptibility, some strains can be missed in the sample (Brooks et al., 1986) 
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such as: C. upsaliensis as antibiotic selection does not support its isolation 
(Warms ley and Karmali, 1989). 
In addition, Campylobacters are resistant to a number of antibiotics including; 
bacitracin, novobiocin, rifampin, streptogramin B, trimethoprim and 
vancomycin (Corry et al., 1995b). Their resistance mechanism is not clear, but 
Zhang and Plummer (2008) reported that it could be related to their low 
permeability to the Campylobacter cell membrane and active efflux that IS 
conferred by the multidrug-efflux transporters. 
Some antibiotics are used III the treatment of campylobacteriosis, which 
include fluoroquilonones (e.g., ciprofloxacin) and macrolides (e.g., 
erythromycin). Development of resistance to antibiotics by campylobacters is 
of concern to human health. 
It was reported that 10-47 % of campylobacters from human sources are 
resistant to ciprofloxacin (Gaudreau and Gilbert, 2003). Resistance to 
fluoroquinolones is mediated by point mutations in quinolone resistance 
determining region in DNA gyrase A (Zhang and Plummer, 2008) as well as 
the efflux pump CmeABC, which works by reducing antibiotics accumulation 
in Campylobacter cells (Luo et al., 2003). 
Resistance to macrolides is associated with target modification and active 
efflux (Cagliero et aI., 2006; Mamelli et aI., 2005). It was reported that in 
Africa, campylobacters from human sources are highly resistant to 
erythromycin, whereas those from food producing animals show low resistance 
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levels (Gibreel and Taylor, 2006). Studies from Asia are rather limited because 
there are few surveillance labs, but by combining limited data from Japan, 
Thailand and Korea, Luangtongkum et af. (2009) estimated that in Asia, 
around 5 % of C. jejuni and 14-62 % C . coli from humans, swine, broilers and 
cattle were resistant to macrolides. 
A number of studies of poultry isolates have been performed to determine their 
contribution to antibiotic resistance. In a study performed in Quebec to 
determine antibiotic resistance in organically raised chickens, it was reported 
that C. jejuni were resistant to tetracycline, erythromycin, azithromycin and 
clindamycin and sensitive to chloroamphenicol, ciprofloxacin, gentamicin, 
nalidixic acid and ampicillin (Thibodeau et al., 2011). In another study 
performed in Japan on the susceptibility of campylobacters from broilers to 
eight antimicrobials, it was reported that campylobacters are sensitive to 
gentamicin, chloroamphenicol and erythromycin but resistant to 
dihydrostreptomycin, amino benzyl penicillin, enrofloxacin, oxytetracycline 
and nalidixic acid (Haruna et al., 2012). 
For food safety and public health, where flouroquinolones are used in 
campylobacteriosis treatments, Camplylobacter resistance to these antibiotics 
results in losing their efficiency and makes the use of them more difficult 
(Luangtongkum et al., 2009). 
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1.1.15 Control of Campylobacters 
In order to reduce the unacceptably high levels of human Campylobacter 
infection, a number of suggestions for reducing the levels of Campylobacter in 
food have been proposed. In selecting an appropriate method consideration 
should be given whether the method would change the organoleptic or 
nutritional value of the food. Also it should be safe, cheap and acceptable to the 
public (Corry et al., 1995a). 
Rosenquist et al. (2003), reported that mathematical models of risk indicated 
that reducing exposure to Campylobacter, reducing their numbers on chicken 
carcasses by 2 logto CFU/g, would reduce the numbers of people who get 
campylobacteriosis by 30-fold. 
Campylobacters are sensitive to drying, low humidity, freezing and freeze thaw 
stress and oxygen. For their control, these points should be considered when 
putting strategies in place (Silva et al., 2011). There are many suggested 
methods for the reduction of Campylobacter numbers in poultry meat, starting 
with prevention of infection of the birds, reduction of contamination during 
processing and treatment of the final meat product. 
Any action that reduces the horizontal transmission (1.1.10.2) of 
Campylobacter is considered to be effective in reducing the chance of 
Campylobacter contamination. The possible ways for poultry meat 
contamination in the slaughter houses are discussed in section 1.1.11. In order 
to reduce or prevent this contamination, it is important to separate the positive 
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from negative flocks in the slaughter house (Wagenaar et ai., 2006). Such 
approach was taken in Denmark by the use of a rapid testing protocol (4h gel 
based PCR technique) for differentiating the positive and the negative flocks 
(Krause et ai., 2006) at slaughter. In addition to that, in Denmark, insect nets 
were used and successfully reduced Campylobacter introduction into broiler 
houses (Hald et al., 2007), yet this type of control has not been investigated in 
other countries (Wassenaar, 2011). 
Campylobacters can survive well on surfaces within slaughter houses, on the 
equipment (Peyrat et ai., 2008) and on cutting boards (Wanyenya et al., 2004). 
Gutierrez-Martin and others (2011) evaluated a number of disinfectants against 
campylobacters using a suspension test which was not used before for 
determining their susceptibility. They found that compounds based on 
quaternary ammonium structures showed the highest levels of reduction (>6 
10glO CFU) for all strains tested under all conditions. The sanitizing agents 
included chloramine-T, povidone-iodine, cetylpiridinium chloride, ethanol, 
isopropanol, chlorhexidine digluconate, formaldehyde and phenol. 
Poor hygiene in the kitchen or cross-contamination from knives, utensils, 
cutting boards to food should be avoided to reduce risk of campylobacteriosis, 
which is thought to be a more common cause than eating undercooked meat 
(Luber, 2009). Chicken livers are excellent reservoir for campylobacters and 
should be cooked properly prior to eating (Whyte et ai., 2006). 
Some studies have pointed out that consumption of certain foods correlates 
with a reduction in the risk of Campylobacter infection. Examples of these 
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foods include: poultry, red meat, vegetables and fruits (Rodrigues et al., 2001; 
Neimann 2001). The reasons for this obvious discrepancy with regard to 
poultry and meat are not known. Also, Kapperud et al. (2003) stated that eating 
mutton and fish are protective factors against Campylobacter infection. These 
studies support the general consensus that eating what are considered to be 
healthy foods, can protect from diseases possibly because some fruits and 
vegetables contain antioxidants and carotenoids which will inhibit bacterial 
growth (Taylor and Engberg, 1999). However, since the consumption of 
chicken is also a risk factor, the frequency of consumption is an important 
consideration as with frequent consumption, the immune system will be 
stimulated and will prevent infection. 
Antimicrobial methods available can be physical, chemical or biological. Trials 
of these methods have produced mixed results (Newell and Wagenaar, 2000) 
without a single treatment being successful. Furthermore some treatments 
might result in the selection of treatment-resistant survivors with increased 
virulence rendering further treatment ineffective; thus, leading to the 
conclusion that a combination of methods should be considered. 
The use of chemicals such as chlorine, trisodium phosphate, ozone and organic 
acids in carcass washing is effective in microbial reduction (James and James, 
1997), however their use is not recommended as chemical residues might 
remain on the meat, consumers do not like foods containing additives and there 
are problems in disposing of the chemicals (James et al., 2007). On the other 
hand, the use of physical methods such as heat and cold cycles has the 
advantage that the likelihood of resistance development is low compared with 
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chemical treatments (organic acids, essential oils) but they may change the 
texture and composition of the food, which would make them less desirable to 
the consumer. James et at. (2007) reported that rapid heating above 70°C 
should be followed by rapid cooling to prevent muscle heating and protein 
denaturation in chicken meat. 
Washing the contaminated surfaces of equipment with hot water and 
hypochlorite was significant in reducing Campylobacter numbers. Dipping or 
spraying poultry carcasses or poultry parts with lactic or citric acid or 
hypochlorite can result in 1.0-1.5 10glO count reduction (EIIebroek et al., 2007). 
Freezing the carcasses was reported to be effective in Campylobacter reduction 
at -20°C (Lee et al., 1998). In addition, James et al. (2007) reported that the 
use of steam or hot water combined with chilling or crust freezing can produce 
greater reduction than using the steam or hot water alone. On the other hand 
some pathogens can survive freezing for long periods (Lund, 2000), and 
therefore combination treatments could provide a greater hurdle causing 
cumulative damage, for example by freezing and thawing and heating in 
combination (Mackey, 2000). In USA, deep or super chilling of chickens at 
temperatures near its freezing (-1 to -2°C) is used (Jul, 1986). 
The use of antibiotics is not acceptable because it results in the development of 
antibiotic resistant strains, which may lead to reduced efficiency of human 
disease treatment (Hariharan et aI., 2004). Competitive exclusion (the Nurmi 
principle) is another strategy that is used to reduce intestinal colonization by 
pathogenic microorganisms. It has proved effective for Salmonella control but 
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not for campylobacters (Mead, 2002) as it does not eliminate them completely, 
(Lin, 2009). 
Biological treatments have been developed for pathogen control. Examples of 
these include the use of phage, (covered in next section) and bacteriocins 
(Sirsat et al., 2009). The application of bacteriocin producing bacteria such as 
Paenibacillus polymyxa or bacteriocins into chicken feed has been shown to be 
effective in controlling campylobacters, but this needs further investigation 
(Stem et al., 2005). Lactobacillus salivarius isolated from a Tunisian chicken 
caecum has shown antimicrobial activity against campylobacters (Kergourlay 
et al., 2012). Plant extracts to control campylobacters were used in a study 
where Chinese leek extracts were shown to inhibit Campylobacter growth (Lee 
et al., 2004). More recently, Castillo et al. (2011) reported the use of extracts 
from edible and medicinal plants for the same purpose. As these are natural 
plant extracts, they can be considered as good candidates for food preservation 
and pathogen control. 
1.2 Bacteriophages 
1.2.1 Introduction 
Bacteriophages, often shortened to 'phages', are viral parasites of bacteria 
which exist universally in the environment. The total number of phages on the 
planet has been estimated to be 1031 phage particles and thus they are the most 
numerous biological entity on earth (Hendrix et al., 1999). They can be found 
in sea water, soil and in the intestines of animals, where they have the ability to 
infect, multiply and kill their host bacteria, including Campylobacter. 
34 
Chapter 1 
1.2.2 Bacteriophage Life Cycles 
There are two types of phage life cycle, lytic and temperate. The lytic phages 
life cycle is simple and has no intermediate form. It starts with adsorption of 
the phage to the surface of the bacterial cell, followed by injection of the 
nucleic acid through the cell wall. After that, phage nucleic acid and protein 
capsids are synthesized using the host cell's biosynthetic apparatus and phage 
particles are assembled. Finally, the bacterial cell envelope ruptures to release 
the phage progeny. Temperate phages have a different life cycle which can 
follow two routes. The ftrst two steps (adsorption and injection) are the same as 
for lytic phages, then the temperate phage will either continue replication and 
lysis in the same way as lytic phages or the nucleic acid will integrate into the 
host chromosome. When excised, the temperate phage may take part of the 
host DNA with it and continue infecting and integrating into a new host where 
it may add the additional excised DNA to the host chromosome (Sulakvelidze 
et at., 200 I). These events may enable the horizontal transfer of genes that can 
include virulence factors or antimicrobial resistance determinants in a process 
known as transduction. In contrast to both lytic and lysogenic phages, the 
ftlamentous phages, for example M13, infect the bacteria without killing the 
host. Instead, they result in continuous excretion of viral particles (Harper and 
Kutter, 2008). 
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1.2.3 The History of Bacteriophages 
In 1896, Ernest Hankin, a British bacteriologist made the first report of phage 
when he found that the water of the Ganges river in India had an antibacterial 
effect against Vibrio cholera (Hankin, 1896; cited in Connerton and Connerton, 
2006). After that Frederick Twort (1915) and Felix d'Herelle (1917) discovered 
that phages are viruses (d'Herelle, 1922; cited in Connerton and Connerton, 
2006). Frederick Twort described a transmissible "glassy transformation" of 
micrococcus culture, which resulted in the degradation of bacteria (Connerton 
and Connerton, 2006). Two years later, microscopic organisms were reported 
by d'Herelle (1917; cited in Connerton and Connerton, 2006). These organisms 
were able to lyse Shigella cultures on plates resulting in a clear zone called a 
plaque. He introduced the term phage within the same year and suggested that 
such phage could be used to reduce or stop bacterial infection. 
In 1917, d'Herelle used phages which were isolated from poultry excreta to 
cure chicken typhus and dysentery in humans (cited in Summers, 2001) which 
are caused by Rickettsia spp. and Shigella spp. respectively. Subsequently, in 
1921, a skin disease caused by Staphylococcus spp. was treated by applying 
phages (Bruynoghe and Maisin, 1921). 
1.2.4 Bacteriophage Structure and Taxonomy 
Phages are composed of capsid proteins that encase nucleic acid (Casjens, 
2005). Phage classification evolved gradually from their first description by 
d'Herelle, who classified them as a single species with many races. Holmes 
(1948; cited in Ackermann, 2003) classified phages as a suborder, with a single 
36 
Chapter 1 
family and a single genus under one order, the Virales. This system was 
premature and was based on the symptoms of the diseases of their hosts, thus it 
was forgotten. Later, Lwoff, Home and Tournier (1962; cited in Ackermann, 
2003) published a system for their classification according to their morphology 
and nucleic acid type. They recognised six types of phages which were tailed 
phages, filamentous phages and cubic phages with single-stranded or double-
stranded DNA (Ackermann, 2003). This system formed the basis for the 
present phage classification. 
Phages are also classified based on the type of the genetic material, whether 
they have single or double stranded DNA or RNA and can be further 
subdivided according to their morphology. The major group of double stranded 
DNA phages are tailed and classified together under one order with three 
families (Proux et al., 2002). According to the International Committee for 
Taxonomy of Viruses (lCTV), viruses are classified into three orders including 
61 families and 241 genera. Among them, phages belong to one order 
(Caudovirales), with 13 families and 30 genera (Ackermann, 2003). 
More than 5100 phages have been examined since 1959. When examined 
under the electron microscope, 96 % of the phages were found to be tailed and 
4 % had polyhedral, pleomorphic or filamentous morphologies (Ackermann, 
2007). Tailed phages were found to contain linear double-stranded DNA 
genomes of different sizes ranging from 18 to 500 kb. These virions are 
composed of a head that is icosahedral in shape containing DNA and a tail 
responsible for binding to the host for the delivery of DNA into the host cells 
(Casjens, 2005). The three families of tailed phages are, the Myoviridae 
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(24.5 % of those examined; Ackermann, 2007) that include phages with 
contractile tails such as T 4 phage, the Siphoviridae (61 % of those examined; 
Ackermann, 2007) that include phages with long non-contractile tails such as A 
phage and the Podoviridae (14 % of those examined; Ackermann, 2007) that 
include phages with short tails such as T7 phage (Ackermann, 2007). Phages in 
the order Caudovirales share some physical properties but it is difficult to 
group them according to their DNA or protein sequences because of the 
diversity caused by horizontal gene transfer, the presence or absence of 
particular genes in all tailed phages that could be used as an indicator for their 
identification (Casjens, 2005) and the mosaic nature of phage genome (Hendrix 
et aI., 1999). Based on morphological observations of the phage reported to 
infect Campylobacter more than 170 belong to the family Myoviridae (Sails et 
al., 1998), two belong to the Siphoviridae family and one to the Podoviridae 
(Connerton et al., 2008). 
Various alternative approaches have been proposed for phage classification. 
Such approaches include; construction of a phage proteomic tree depending on 
the protein sequences (Rohwer and Edwards, 2002). Another approach is the 
use of genomic types, whether they contain single stranded RNA or DNA for 
dividing phages, and further differentiation according to their physical 
characteristics (tailed or filamentous; Lawrence et al., 2002). The current 
system has hierarchical classification where different phage genera and species 
are put under the family. Six genera (A, TI, T5, L5, C2 and lJJM ) were 
accepted by the ICTV for the family Siphoviridae (Proux et al., 2002), six 
genera (T 4, PI, P2, Mu, spa 1 and cPH) for Myoviridae and three genera {T7, 
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P22 and 4>29) for Podoviridae. These genera can be used for the classification 
of other phages. Based on the morphology, DNA-DNA hybridization, nucleic 
acid sequencing and serology, about 250 species are recognised (Ackermann, 
2003). Lastly the use of a modular approach has been adopted to identify 
functional units within the gene content. This approach uses DNA and protein 
sequence similarities to recognise exchangeable functional units (Proux et al., 
2002). Although these modules cover a fraction of all phage genes, phage 
groups can be distinguished by their different combination of modules which 
can be the basis for a higher level of classification. Representing the 
relationship within phage populations will be possible automatically and 
dynamically with the use of this scheme, as it will allow the rapid inclusion of 
newly sequenced phage genomes (Lima-Mendez et aI., 2008). 
1.2.5 Campylobacter Bacteriophage 
1.2.5.1 Campylobacter Bacteriophage Sources and Isolation 
When Campylobacter phages were reported back in the 1960s, they were 
isolated from cattle and pigs where they were reported as lytic against Vibrio 
coli (probably C. coli using present nomenclature) and V. fetus (probably 
C. fetus) (Fletcher and Bertschinger 1964; Firehammer and Border 1968; 
Fletcher 1968; cited in Connerton and Connerton, 2006). Campylobacter jejuni 
phages were recovered in 1980s arising from strains isolated from aborted 
fetuses that were inducible lysogenic phage recovered after treatment with 
mitomycin C (Bryner et al., 1982; cited in Connerton and Connerton, 2006), 
although the source might suggest the bacteria were actually C. fetus. More 
recently, many different Campylobacter phages have been isolated from 
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different sources such as broiler chickens (Connerton et af., 2004), retail 
poultry (Atterbury et af., 2003a), pig manure, sewage and slaughter house out-
flow (Salama et af., 1989). 
To isolate the phages, the collected samples should be centrifuged to remove 
debris followed by filtration to ensure the removal of any remaining bacterial 
cells in the phage suspension (Atterbury et af., 2005). After that, they should be 
applied to an appropriate Campylobacter host strain suspended in a soft agar 
lawn. Plaques become visible after incubation under appropriate conditions. 
However, as a relatively small volume of suspension can be applied to the 
bacterial lawn, phage may be missed if they occur in low numbers. To 
overcome this problem, an enrichment method to increase their numbers was 
devised in which Campylobacter cells were incubated with the sample for 18 h 
prior to detection (Carvalho et al., 201 Ob). 
1.2.5.2 Campylobacter Bacteriophage Classes and Characteristics 
Some Campyfobacter phages have been characterized and found to have 
double stranded DNA genomes that are reported as belonging to the families 
Myoviridae and Siphoviridae (Sails et al., 1998). The phages described by 
Frost et al. (1999) were studied and characterized by Sails et al. (1998), and 
were found to have icosahedral heads and long contractile tails indicating them 
to belong to the family Myoviridae. Phages belonging to the Siphoviridae and 
Podoviridae families were described in Russian Federation reports, but few 
details are available regarding the characteristics ofthese phages (Connerton et 
al., 2008). 
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One of the systems used for characterizing phages utilizes the genomic size 
obtained by the use of pulsed field gel electrophoresis (PFGE). This allowed 
Campylobacter phages used in the scheme of Frost et al. (1999), to be divided 
them into three groups based on their genomic size and head diameter. Group I 
included two phages with head diameter of 140.6 and 143.8 nm and genomic 
size of320 kb. Group II included five phages with average head diameter of99 
nm and average genomic size of 184 kb. Lastly, nine phages were placed in 
group III with an average head size of 100 nm and average genome size of 138 
kb (Sails et al., 1998). 
In our laboratory at the University of Nottingham, all the phages isolated from 
poultry fall in to groups II and III (Atterbury et al., 2003a; Connerton et al., 
2004; El- Shibiny et al., 2005; Loc Carrillo et al., 2005), possibly because 
Group I phages are not common in the UK. Both Group II and III phages are 
lytic phages typical of the Myoviridae family (International Committee on the 
Taxonomy of Viruses, 2004). Lysogenic phages have been reported from 
C. fetus (Ritchie et al., 1983; cited in Connerton and Co nnerton, 2006) and 
from C. jejuni isolated from aborted sheep fetuses (Bryner et al., 1982; cited in 
Connerton and Connerton, 2006), although as noted above the latter source is 
questionable. 
The same sixteen phages of Frost et al. (1999) were classified into four groups 
(A, B, C and D) by Coward et al. (2006) depending on their activities against 
spontaneous transposon and defined mutants of C. jejuni. A correlation was 
shown between the structural grouping 0 f Sails et al. (1998) and the 
phenotyping grouping of Coward et al. (2006). Groups B (<p3, <p8, <pl0, <p14 
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and <p15) and D (<p4, and <p12) which are associated with motility and can be 
flagellotrophic are related to structural groups II and I respectively, whereas 
those that can interact with the capsules; groups A (<p 1, <p2, <p6, <p 11, and <p 16) 
and C (<p5, <p7, <p9 and <p13) are all in structural group III but the important 
bacterial factors in sensitivity to phages in group C are not known (Coward et 
al., 2006). 
1.2.6 Incidence of Campylobacter Bacteriophages in Poultry 
Different studies have been performed worldwide to isolate Campylobacter 
phages from poultry samples. Few have attempted to establish the incidence of 
Campylobacter phage in such samples but amongst those, Atterbury et al. 
(2003a), isolated and characterized Campylobacter phages from chilled and 
frozen retail poultry portions in UK. Such phages were isolated from 11.3 % of 
the chilled samples whereas all the frozen samples tested were negative. Prior 
to freezing the birds are scalded at high temperatures and this together with 
subsequent freezing and thawing cycles may have inactivated the phage. 
Phages were found in samples only when their host strains were also found. 
The phages did not replicate on samples inoculated with them and stored under 
refrigerated retail storage conditions, probably because campylobacters 
themselves do not grow on food samples under such conditions. 
In the year 2005 the incidence of Campylobacter phages in UK poultry was 
studied and determined to be around 20 %, of 205 broiler chicken caeca 
sampled from 22 farms (Atterbury et al., 2005) that were slaughtered between 
22 and 46 days of age. Campylobacters were isolated from 63 % of the samples 
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and all of them were C. jejuni with no C. coli isolated. Campylobacter counts 
were significantly lower in samples with phages than those without phages. 
In another study performed on caeca from organic and free range birds selected 
and slaughtered every three to four days until 73 and 56 days of age 
respectively, the Campylobacter phage incidence was found to be 51 % from 
organic birds whereas their isolation from free range birds was infrequent 
where only one phage was isolated (EI-Shibiny et al., 2005). The 
Campylobacter isolation percentage was high from organic birds (68.5 %) and 
from free range birds (90 %). This high presence could be due to outdoor birds 
having greater exposure to the environment resulting in the presence of more 
types of campylobacters and their phages. Connerton et al. (2004) reported in a 
study performed on a naturally phage-infected broiler chicken barn that phages 
and their hosts could be transferred from one flock to another. 
In Denmark, the isolation rate of Campylobacter phages from broilers and 
ducks (intestines and abattoir sewage) of the Danish poultry production was 
studied and found to be 3 % and 50 %respectively (Hansen et al., 2007). In this 
study, ducks were the major source of phages which indicates that phage 
isolation is influenced more by the type ofpoultry tested (broiler or duck) than 
the sample type (intestine or abattoir sewage). 
A study was performed to isolate phages from the skin and the caecal contents 
of chickens purchased from retail markets in different regions in Korea 
together with sewage and soils from several animal breeding grounds and 
abattoirs. Campylobacter phages were found in 20 % of chicken intestinal 
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samples but the environmental samples were negative when tested (Hwang et 
at., 2009). 
In New Zealand, retail chicken skin samples were tested for the presence of 
campylobacter phages and where found to be negative. In the same study, 
whole chicken rinses from 39 flocks were pooled, tested and 28.2 % were 
found to be phage positive (Tsuei et al., 2007). 
1.2.7 Survival of Campylobacter Bacteriophages 
As with all other phages, Campylobacter phages can survive the same 
environmental conditions as their host, and they can survive with them from 
the chicken intestine to the surface of poultry meat (Atterbury et al., 2003a). 
This means that anyone dealing with uncooked poultry meat is exposed to 
surviving phages. The property of extended survival of phages makes them 
useful therapeutic agents as they can be added to poultry drinking water or feed 
(Carvalho et al., 2010b). 
Phage capcids are made of proteins which are sensitive to acidity (Leverentz et 
al., 2001), for them to survive the gastric barrier and resist the bile in the small 
intestine and colonize it. It was proposed that they should be combined with 
antacids prior to their use (Koo et al., 2001) or by selection of those phages 
which can tolerate low pH. In a study performed by Loc Carrillo et al. (2005), 
Campylobacter phages were mixed with CaC03 before being applied orally to 
chickens. They persisted during the trial period and they were maintained with 
their host in the chicken intestine and their effectiveness was proven. 
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Unlike bacteria, phages are known to be resistant to detergents like SDS, 
sodium deoxycholate and Saponin, whereas chelating agents like citrate and 
EDT A accelerate the inactivation of phages at low salt concentration. 
Chemicals such as glycerine and ethanol when concentrated can cause rapid 
inactivation of phages (Adams, 1959). 
D'Herelle (1926; cited in Adams, 1959) reported that phages can be inactivated 
when heated at 75°C for 30 min. When the temperature was reduced to 70 °C, 
some survived. Thus defining the inactivation temperature will depend on the 
phage characteristics. As mentioned earlier, phages did not survive freezing in 
the study performed by Atterbury et al. (2003a). The inability to isolate phages 
from frozen chicken was suggested to be either because the skin surface 
structure was changed, which prevented phage attachment to it, or because 
phages lost their activity upon freezing. 
1.2.8 Bacteriophage Therapy 
Bacteriophage therapy is defined as the use of phages to treat bacterial 
infection. The development of phage therapy for controlling pathogenic 
bacteria was slow to develop in many countries because the use of antibiotics 
was well established. Another reason for the slower development of phage 
therapy was the lack of evidence of their efficiency (Sulakvelidze et al., 2001), 
which is often due to the lack of understanding of phage biology and their 
replication dynamics as well as bacterial pathogenesis mechanisms and the 
nature of phage interaction with its host (Barrow et aI., 1998). 
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Currently phages are being developed for use as therapeutic agents against 
food pathogens. This is largely due to their wide· distribution in the 
environment and simplicity in their isolation and propagation (Miller and 
Mandrell, 2005). Such therapy is attractive because it may overcome antibiotic 
resistance problems and reduces the use of chemicals in food production 
(Kutter and Sulakvelidze, 2005). For phages to be used in such therapy, a good 
understanding of the phages and their hosts is required (EI-Shibiny et at., 
2005). 
1.2.8.1 Advantages and Disadvantages of Bacteriophage Therapy 
Phages have some properties which give them unique advantages over 
antibiotics. Such properties are that they are self-replicating and have self-
limiting properties, where they replicate only when their hosts are present 
followed by their gradual removal from the environment when their hosts are 
not available (Connerton and Connerton, 2005). Other properties which make 
them of great value as therapeutic agents are their specificity and efficiency in 
killing their target bacteria without affecting the normal flora or their natural 
presence in the environment (Sulakvelidze et at., 2001). Being highly specific, 
they have the ability to infect only specific species or strains of their hosts. 
Exception to this is found with Listeria phage A511 that is effective against the 
entire genus (Zink and Loessner, 1992). As phages are already present in the 
environment, their addition does not constitute the addition of any new 
biologically active entity thus reducing the possibility of the development of 
allergic response (Connerton and Connerton, 2006). In addition, they are 
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generally inexpensive to prepare (Connerton et a/., 2008) and no serious side 
effects have been described upon their use (Sulakvelidze et a/., 2001). 
As with any other treatments, phage may have some negative impacts and 
problems such as development of phage resistance, which won't be a big 
problem because of the phages natural diversity and rapid replication. The 
availability of different phages will give technologists the choice to pick 
another phage that the strain will be sensitive to and as they replicate fast, 
selection for mutation can be done using the resistant strain which will result in 
a change in the host range to overcome many types of resistance (Connerton 
and Connerton, 2006). Another potential problem is the possibility of 
transferring pathogenic traits. This can be avoided by carefully selecting 
virulent phages (Connerton et a/., 2008). Lytic phages are good candidates for 
phage therapy as they infect the host and more phage particles will be produced 
and released upon cell lysis. On the other hand, lysogenic phages are not 
suitable for phage therapy as their DNA is integrated into the host DNA (Boyd 
and Brussow, 2002) and will have the ability to transfer genetic material from 
one bacterium to another. Some lysogenic phages may change the external 
membrane of bacteria that could result in an increase in their pathogenicity or 
resistance to such phages (Canchaya et a/., 2003). Phages themselves can adapt 
and continue to infect these pathogens (Sulakvelidze et a/., 2001). For 
example, a mutated phage tail fiber will allow binding to a mutant bacterial 
receptor or the mutated phage DNA can escape cleavage by mutant bacterial 
endonucleases (Carlton, 1999). Clearly, there is a balance that allows both host 
and predator to proliferate (Connerton et a/., 2004). Moreover, phages may 
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have too narrow a host range. For them to be used as a biocontrol agents, 
therefore their infectivity towards isolates that represent Campylobacter strains 
from broilers and humans should be considered (Hansen et al., 2007). 
Screening bacteria against different phages to ensure that one of these phages 
will be lytic or the use of a combination of phages in a cocktail to lyse most or 
all bacterial types of a specific pathogen could overcome this problem. In 
addition, phages are usually prepared as crude lysates; thus, the presence of 
bacterial debris in such preparations together with endotoxins, even if present 
in low concentrations, could be injurious to patients where the therapy is to be 
used for human treatment. To solve this problem, density centrifugations and 
other methods of purifications (Carlton, 1999) including ion exchange 
chromatography should be performed. Lastly, phages in therapeutic 
preparations should be free from their hosts, thus oxidizing agents could be 
added to kill the host bacteria or sample heating could be done. Such 
applications can denature the protein coat and to ensure phage viability, the 
phage should be re-titrated over time. Other solutions to this problem involve 
the utilization of sterile filtration (Carlton, 1999; Sulakvelidze et al., 2001). 
1.2.8.2 Factors Affecting Bacteriophage Therapy 
Phage replication depends both on their concentration (Levin and Bull 1996; 
Payne and Jansen, 2002; Bull et af., 2002) and their host density. The required 
host density threshold is called 'bacteriophage proliferation threshold' (Payne 
and Jansen, 2002). It is important for all phages to proliferate sufficiently in 
order to cause a crash in the host bacterial population and reduce their 
numbers. Other factors affecting phage therapy include the inoculum size and 
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timing, phage adsorption rate and burst size (Levin and Bull, 1996; Weld et al., 
2004) which is the number of phages produced per cell which is usually in the 
order of 10-100 (Hadas et al., 1997). Moreover, the phage adsorption kinetics 
to bacteria in the intestinal environment can be different from those determined 
experimentally on laboratory media, due to the viscosity of the mucus layer 
(Weld et al., 2004). 
1.2.8.3 Studies in Bacteriophage Therapy 
In addition to the direct application of phages for treatment of bacterial 
infections in humans or animals, they may be used indirectly to prevent food-
borne infection in animals used for food production, for example: their use in 
the reduction of pathogens including Campylobacter, E. coli or Salmonella, or 
they may be used during processing or directly applied to meat. 
In veterinary medicine, phages have been used experimentally to control 
Escherichia coli infections in mice and calves. Smith and Hugins (1982) 
reported that phages that were isolated from sewage works and pig markets 
were successfully used in curing and reducing the number of deaths in mice 
infected with E. coli strains, and they were more effective than antibiotics 
tested in the same study such as ampicillin, chloroamphenicol and 
streptomycin. Moreover, the use of phages in protecting calves, piglets and 
lamb from diarrhoea caused by E. coli was reported in 1983. It was found that 
oral inoculation of phages one to eight hours after E. coli inoculation resulted 
in the protection of calves, piglets and lambs from diarrhoea and death and 
reduced the numbers of E. coli in the alimentary tract (Smith and Hugins, 
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1983). Barrow and others (1998) reported that phages were used in the 
protection of calves from septicaemia caused by E. coli as they delayed the 
bacterial appearance in the blood and lengthened their life span. 
Phages were used in other studies in treating infections caused by bacterial 
strains other than E. coli as cited in Barrow et al. (1998), which includes: 
protection against Salmonella typhi infection in mice (Ward, 1943), the 
survival of mice infected by Shigella dysenteriae (Dubos et at., 1943), wound 
treatments of bum patients caused by Staphylococcus aureus (Lowbury and 
Hood, 1953) and the control of Pseudomonas aeruginosa growth on pig skin 
(Soothill et ai., 1988). 
Respiratory illness due to E. coli in chickens was shown to be reduced after 
treatment with phages (Huff et al., 2003). Such phages were isolated from 
municipal waste treatment facilities and poultry processing plants and injected 
into chicken thighs having E. coli infection in single or multiple treatments, 
and were found to be effective in reducing the mortality rate and curing 
chickens when the disease was in its early stages, with multiple treatments 
being better than a single treatment. Phages were also used against meningitis 
in chickens caused by E. coli. Injecting infected birds with phages led to their 
fast multiplication on bacteria and prevented the massive multiplications of 
bacteria seen in the brains of untreated birds and as a result, the numbers of 
bacteria in the brains of treated birds declined; thus, the percentage of deaths 
was reduced (Barrow et al., 1998). 
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Phages can be used to reduce the number of Campylobacter colonizing poultry. 
Reductions in Campylobacter numbers present in chicken caecal contents of 
between 2 10gIO and 5 10gIO (CFU g-I) have been achieved (Loc Carrillo et al. 
2005; Wagenaar et al., 2005). Treatment of chicken just prior to slaughter 
could significantly decrease the number of campylobacters entering the human 
food chain. Campylobacter phage has been applied under experimental 
conditions to the surface of chicken skin for the same purpose (Goode et al., 
2003). Atterbury et al. (2003b) reported that under refrigerated conditions, 
campylobacters can be infected by phages but without being able to complete 
their replication cycle unless the conditions change to allow the host to increase 
its metabolic activities. 
To find the effective dose of phages, a number of studies were performed using 
phages from group III (Lac Carrillo et al., 2005; Scott et aI., 2007) in which it 
was found that Campylobacter colonization in broiler chickens can be reduced 
with the use of doses between 5 10gIO and 9 10g\O (PFU) with 7 10glO (PFU) to 
be the optimum effective dose. Rabinovitch et al. (2003) reported that phage 
aggregation and non-specific association with digest a or non- host bacteria 
could result in the highest doses being less effective. Their presence in higher 
concentrations will overwhelm the host in part of the intestine making them 
unavailable to continue further replication cycles in other parts of the gut as the 
phages need their host to multiply in order to be effective. 
Group II and III phages have been used to reduce numbers of campylobacters 
in experimentally infected chickens. Both groups of phage succeeded in 
reducing Campylobacter numbers and have the advantage that they have 
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different host ranges (EI-Shibiny et al., 2009). Those from group II were used 
against C. jejuni and C. coli (EI-Shibiny et al., 2009; Carvalho et al., 2010b) 
and those from group III (Loc Carrillo et al., 2005; Scott et aI., 2007) were 
used in therapy against C. jejuni only. 
Phages were used experimentally by Wagenaar and colleagues (2005) with 
broiler chickens, to examine the use of phages as preventive and therapeutic 
agents. In this work, chickens were infected with C. jejuni after four days of 
phage infection in the preventive group. On the other hand, in the therapeutic 
group, they were infected with phages five days after C. jejuni infection. It was 
found that phages do not prevent colonization. Instead, they delayed it in the 
preventative groups. Therapeutically, phages reduced the colonization levels by 
several orders of magnitude, thus they have the potential to be used for the 
control of campylobacteriosis arising from poultry contamination. 
On plant crops, phages have been used to reduce Salmonella contamination 
when experimentally applied to fresh cut apples and melons at 5, 10 and 20°C. 
lt was found that the reduction of Salmonella contamination by phages was 
temperature dependent and the greatest Salmonella reduction, on melon, was 
achieved at temperatures of 5 and 10 °C. The titre of the phage remained stable 
throughout the experiment. In contrast, no reduction in Salmonella numbers or 
recovery of phages was observed in the case of apples, which was probably due 
to their natural acidity (Leverentz, et al., 2001). 
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1.2.8.4 Commercially Available Bacteriophages 
Phages have been used as therapeutic, prophylactic and disinfectant agents 
(Alisky et at., 1998). A few commercial products are available from various 
biotechnology companies. Agriphage, a product supplied by Omnilytics 
company is used to target the bacterial spots on crops as tomatoes and pepper 
specifically for Xanthomonas campestris pv. Vesicatoria or Pseudomonas 
syringae pv. tomato strains. In the food sector, many products are available 
against different bacterial strains including: BioTector which is supplied by 
Cheiljedang Corporation to be applied to animal feed against Salmonella in 
chicken. Moreover, Intralytix Company produces Ecoshield that targets E. coli 
in food and ListShield against Listeria monocytogenes which can also be 
targeted by LISTEX PI 00 which is produced by EBI food safety company 
(Monk et at., 2010). 
1.2.9 Disruption of Biofilms by Bacteriophages 
Bacterial strains of one or several species live as biofilms attached to a surface 
and embedded in an extra-cellular polymeric matrix in their normal habitats, 
which gives them protection against a number of stresses in their environment 
including: desiccation, heating, disinfectants and acidic conditions, increasing 
their chances to survive. Phages have been used to reduce the biofilms of 
different bacterial strains (Hibma et at., 1997; Hughes et at., 1998) including 
Campylobacter biofilms (Siringan et aI., 2011). In addition to that, engineered 
phage enzymes have been used to disperse biofilms by breaking down extra-
cellular polymeric matrix components (Lu and Collins, 2007). Therefore, 
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phages are promising agents in controlling Campyiobacter biofilms and they 
can be used for food safety applications in industry (Connerton et ai., 2011). 
1.3 Bacteriophage Lytic Enzymes (Lysins) 
1.3.1 Introduction 
Lysins are defined as enzymes·produced by phages to break down the bacterial 
cell wall (Jado et ai., 2003; Horgan et ai., 2009) in order to release phage 
progeny (Fischetti, 2008) with the aid of intermediate protein molecules called 
holins (Young, 1992; Sable and Lortal, 1995; Loessner et ai., 1997). 
Lysins have been studied in Gram-positive bacteria, for example: B. subtilis 
(Ward et at., 1982; Garvey et at., 1986) and S. pneumoniae (Garcia et aI., 
1987; Romero et al., 1990) and in Gram-negative bacteria for example: 
Pseudomonas aentginosa PADI (wild type), Pseudomonas aentginosa Br667 
(multidrug resistant burn wound isolate), E. coli XLI-Blue MRF and 
Salmonella enteric Serovar Typhimurium LT2 (Walmagh et al., 2012). The 
main differences between the different types of lysins studied are their 
specificity and whether they attack the thick Gram-positive cell wall or the thin 
peptidoglycan layer of the Gram-negative bacteria, which is protected by an 
outer membrane (Schuch et at., 2009). Lysins are known to be more effective 
at killing Gram-positive bacteria because of lack of the outer membrane and 
the direct contact with the cell wall and the peptidoglycan (Fischetti, 2006), 
whereas in case of Gram-negative bacteria the outer membrane prevents this 
interaction (Fischetti, 2008). 
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1.3.2 Lysin Structure 
Lysins are categorized by their domain structure (Fischetti, 2006). Most of the 
enzymes are composed of two domains; N-terminal and C-terminal domains 
separated by a short linker (Fischetti, 2008). 
The N-terminal domain possesses the catalytic activity of the enzyme which 
breaks down one of the main bonds in the peptidoglycan in the cell wall 
(Young, 1992); which include lysozymes (N-acetylmuramidases), glycosidases 
(N-acetyl-B-D-glucosaminidases) which hydrolyse the P-I-4-glucosidic bond 
in the sugar moiety, endopeptidases (L-alanoyl-D-glutamate) that break down 
the peptide cross-bridge and amidases (N-acetyl-muramoyl-L-alanine amidase) 
that break the amide bond between the sugar and peptide moieties (Fenton et 
al., 2010). Lysins that are specific for Gram-negative strains are composed of a 
single 15-200 kDa catalytic domain, whereas those targeting Gram-positive 
strains are 25-100 kDa in size and may have one or more catalytic domains 
(Schuch et al., 2009). Reported lysins having two catalytic domains from 
Staphylococcus aureus are; LysK, Phill and MV-L (Navarre et al., 1999; 
O'Flaherty et al., 2005; Rashel et al., 2007). The C-terminal cell binding 
domain confers substrate specificity (Fischetti, 2006). It is responsible for the 
enzyme attachment to its carbohydrate substrate in the bacterial cell wall 
through non-covalent binding, and it is needed for the lytic activity of some 
lysins, but this is not always the case (Fenton et aI., 2010). Some lysins such as 
Lys K produce higher lytic activities when their binding domains are removed. 
Horgan et aI., (2009) reported that the C-terminal binding domain may be 
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responsible for limiting the activity of the N-terminal catalytic domain which 
allows it to function only when it is bound to its target in the cell wall. 
Garcia et al. (1990) suggested that lysins with different bacterial and catalytic 
specificities can result when different enzyme domains swap. Examples of this 
can be seen for the Streptococcus pneumoniae phages. The catalytic domains 
of their lytic enzymes could be swapped resulting in a new enzyme. This 
enzyme has the same binding domain for S. pneumoniae but with the ability to 
cleave different peptidoglycan bonds. 
1.3.3 l\1echanism of Action 
The phage lytic system consists of one or more peptidoglycan hydro lases or 
lysins that act on the cell wall and holin protein molecule, both of which are 
essential for the cell lysis. During the late stage of the lytic cycle, lysins 
accumulate in the cytosol and hydrolyse the peptidyglycan in the cell wall 
resulting in the release of mature phage progeny (Fenton et al., 2010). As they 
do not have signal sequences, lysins are not translocated across the cytoplasmic 
membrane. Therefore they need a second phage gene product in the lytic 
system to reach their targets within the peptidoglycan layer. This product is the 
holin (Wang et al., 2000) that acts by forming holes in the membrane to allow 
the passage of endolysins to the cell wall (Payne and Hatfull, 2012). Also, it 
can control the timing of lysis (Wang et al., 2000). Once the lysin reaches the 
cell wall, it breaks down the peptidoglycan layer. The osmotic pressure 
differences between the cells and the surrounding environment cause the 
cytoplasmic membrane to rupture through hypotonic lysis (Fischetti, 2006). 
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For large DNA phages, during phage production, the lysins accumulate in the 
cytoplasm. The cell membrane will be disrupted when holin molecules are 
expressed and inserted into the cytoplasmic membrane. At this stage the lysins 
from the cytoplasm will reach the peptidoglycan layer (Young et al., 2000; 
Bernhardt et al., 2001) and break covalent bonds in the cell wall that are 
responsible for maintaining its structure. This leads to bacterial lysis and 
progeny phage release (Schuch et al., 2009). In contrast, in phages with limited 
coding capacity, the phage-encoded proteins will interfere with the bacterial 
enzymes that are responsible for peptidoglycan synthesis (Young et al., 2000; 
Bernhardt et al., 2001) thus leading to a misassembled cell wall and cell lysis. 
1.3.4 Lysin Specificity 
Lysins are highly specific and will only kill the species (or subspecies) of the 
bacteria from which the phage that encoded them were produced (Loeffler 
et al., 2001) without affecting normal flora. For them to function, the binding 
domain is required to bind to its target within the cell wall, thus offering some 
degree of specificity, as the target will only be found in enzyme-sensitive 
bacteria (Fischetti, 2008). Once the binding is established, the catalytic domain 
can break down the cell wall (Loeffler et al., 2001). 
In some cases, lysins can have a broad lytic activity, as in the enterococcal 
phage lysins. It was reported that they have the ability to kill enterococci as 
well as some other Gram-positive bacteria including Streptococcus pyogenes, 
group B streptococci and Staphylococcus aureus. Such ability makes this group 
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one of the broadest lysins identified, even though the activity on Enterococci is 
higher than on the other genera (Yoong et al., 2004). 
1.3.5 Consideration of Lysin-Based Therapies 
For lysins to be used therapeutically, their properties, including toxicity, 
immuonogenicity, resistance and synergy, should be considered. Lysins are not 
known to be toxic against humans or animals. This was demonstrated using 
lysin treatment in a systemic infection mouse model where no signs of toxicity 
were evident (Nelson et al., 2001; Jado et al., 2003). Similarly, in pre-clinical 
trials in vivo, there were no harmful, abnormal or irritant side effects shown 
(Loessner, 2005). The use of lysins stimulates the immune response which 
leads to reduction in their activities. This was demonstrated when lysin Cpl-l 
from Streptococcus pneumoniae was used against rabbit hyper immune serum. 
Its activity was reduced because of immune system stimulation (Loeffler et al., 
2003). Bacterial resistance to lysins is not expected as phages have evolved 
alongside their hosts and these proteins are absolutely needed for the release of 
the progeny from the host cell and they target peptidoglycan which is essential 
for bacterial viability (Fenton et al., 2010). 
The performance of lysins can be improved when used in combination with 
other lysins in vitro and in vivo. The use of pneumococcal Cpl-l (lysozyme) 
and Pal (amidase) in synergy in a murine sepsis model (Jado et al., 2003), and 
the use of Staphylococcus lysin LysK and lysostaphin together (Becker et al., 
2008) resulted in greater lysis than using them separately (Jado et al., 2003). 
Similarly, lysins can perform better in synergy with antibiotics and this was 
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demonstrated in a number of studies. The activity of Pneumococcal enzymes as 
antimicrobial agent was improved when combined with antibiotics. For 
example CP1-l with penicillin and gentamicin (Djurkovic et at., 2005) and 
LytA with cefotaxime and moxifloxacin (Rodriguez-Cerrato et at., 2007). 
1.3.6 Potential Applications of Lysins 
These enzymes have many potential applications including the control of 
pathogenic bacteria on human mucous membranes (Fischetti, 2006). Examples 
of pathogens that can be treated with lysins include; Streptococcus pneumoniae 
(Loeffler et at., 2001), S. pyogenes (Nelson et at., 2001), Bacillus anthracis 
(Schuch et at., 2002), Staphylococcus aureus (Horgan et al., 2009) and 
Clostridium dijJicile (Mayer et at., 2008). In addition, such lysins could be used 
in the food industry (Fischetti, 2006) against pathogens causing food poisoning 
which will lead to economic loss in poultry production. Clostridium 
perfringens in poultry intestines was controlled by Ply3626 lysin (Zimmer 
et al., 2002). In veterinary medicine, lysins were used against bovine mastitis 
which causes death in dairy cows and contamination of their milk that can be 
used in food production. Ply700 showed lytic activity against mastitis caused 
by Streptococci in raw and pasteurized milk respectively (Celia et at., 2007). 
Plant protection against phytopathogens was achieved using Coliphage T4 
lysins against Erwinia carotovora that cause soft rot in potatoes (Borysowski et 
at., 2006). Lastly, with the increase of antibiotic resistance, lysins can be used 
as alternative antimicrobial agents against infectious diseases (Fenton et al., 
2010). It was reported that Gram positive bacteria repeatedly exposed to low 
concentrations of lysins did not result in the recovery of resistant strains even 
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after 40 cycles in vitro (Fischetti, 2008) regardless of whether they were grown 
in liquids or on agar plates (Nelson et aI., 2001; Schuch, 2009) which is a 
distinct advantage over the use of antibiotics. 
Lysins are currently considered to have great future potential in controlling 
bacterial pathogens, but it is important to remember that there will always be a 
need to find new ways both to prevent and treat pathogen infections (Fischetti, 
2008). 
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Objectives 
• Isolation and characterization of Campylobacter phages and their hosts 
from chicken faeces. 
• Identification of possible lysin genes from CP220 phage that was 
isolated from poultry excreta, followed by their amplification, cloning 
and sub-cloning in expression and non-expression vectors. 
• Molecular characterization of Campylobacter phages including; CPX, 
CP8, CP20, CP30 and CP34 through DNA amplification and 
sequencing of selected genes taking the availability of CP220 and 
CPtlO phages sequences that were published recently by Timms et al. 
(2010) as an advantage. 
• Complete genome Sequencing ofCPX phage that was a originally a co-
isolate of phage CP220 before separation, independent propagation and 
purification using caesium chloride density gradient centrifugation and 
to enable its comparison to CP220 phage and other phages available in 
the data bases. 
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2.1 Culture Media Preparation 
All types of media used were prepared in reverse osmosis water (RO water) 
followed by autoclaving at 121°C, 15 psi for 20 min using the liquid cycle. 
The autoclaved media were cooled to 50 °e before the addition of any 
supplement if required. After cooling, the media were kept at 4 °e until needed. 
2.1.1 Blood Agar (BA) 
Blood Agar base No. 2 (Oxoid, Basingstoke, UK) was prepared according to 
the manufacturer's instructions. After sterilization and cooling to 50 °e, 5 % 
(VN) defibrinated horse blood (TeS Biosciences LTD, Botolph Claydon, UK) 
was added, then the media was mixed thoroughly and poured into Petri dishes. 
2.1.2 Charcol Cefoperazone Deoxycholate Agar (CCDA) 
Campylobacter blood-free selective agar (Oxoid) was prepared according to 
the manufacturer's instructions, sterilized and supplemented with cefoperazone 
(ProLabs Diagnostics, Wirral, UK), which was dissolved in 5 ml of sterile 
water, mixed thoroughly and poured into Petri dishes. 
2.1.3 New Zealand Casamino Acids Yeast Medium (NZCYl\I) 
Basal Agar 
NZCYM broth (Difco, Oxford, UK) was prepared and supplemented to a final 
concentration 1.2 % (WN) with bacteriological agar No.1 (Oxoid) according 
to the manufacturer's instruction, sterilized, mixed thoroughly and poured into 
Petri dishes. 
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2.1.4 NZCYM Overlay Agar 
NZCYM broth (Difco) was prepared according to the manufacturer's 
instruction and supplemented with bacteriological agar No.1 (Oxoid) to a final 
concentration of 0.6 % (WN), sterilized, mixed thoroughly and stored in 200 
ml amounts until required. It was then melted and dispensed into 5 ml amounts 
and cooled to 50 °C and used. 
2.1.5 Luria-Bertani (LB) Agar 
LB (Lennox) broth (Difco), supplemented with bacteriological agar No. I to a 
final concentration of 1.5 % w/v, was prepared according to the manufacturer's 
instructions and sterilized. Selective antibiotics; were added prior pouring in 
Petri dishes. 
2.1.6 Luria-Bertani (LB) Broth 
LB (Lennox) broth (Difco) was prepared according to the manufacturer's 
instructions. Ten millilitre aliquots were dispensed in 30 ml universal bottles 
and sterilized. Selective antibiotics were added before their use. 
2.1.7 Nutrient Broth (NB) 
Nutrient broth No.2 (Oxoid) was prepared according to the manufacturer's 
instructions, sterilized and mixed thoroughly. 
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2.2 Storage Media Preparation 
2.2.1 Campylobacter Storage Medium 
Nutrient broth (NB) No. 2 (Oxoid) was prepared according to the 
manufacturer's instruction, sterilized and supplemented with glycerol (Fisher, 
Loughbrough, UK) to give a final concentration of 15 % glycerol (V N), 
dispensed in 1 ml cryovials and stored at room temperature (20°C) before use. 
2.2.2 Bacteriophage Storage Medium 
NZCYM broth (Difco) was prepared according to the manufacturer's 
instruction, sterilized and supplemented with glycerol (Fisher) to give a final 
concentration of 5 % glycerol (V N), dispensed in 1 ml cryovials and stored at 
room temperature (20°C) before use. 
2.2.3 Clone Storage Medium 
A 10 ml LB broth (Difco) was prepared according to the manufacturer's 
instruction, sterilized and supplemented with glycerol (Fisher) to give a final 
concentration of 50 % glycerol (VN), 250 J.ll aliquots were dispensed in 1 ml 
cryovials and stored at room temperature (20°C) before use. 
2.3 Solutions and Buffers 
2.3.1 Salt Magnesium (S1\1) Buffer 
SM buffer (0.1 M NaCl, 8 mM MgS04.7 H20, 0.002 % gelatin (w/v), 50 mM 
Tris-Cl) was prepared by mixing 5.8 g NaCI (Fisher), 2 g MgS04.7 H20 
(Fisher), 5 ml of 2 % (w/v) gelatin (Sigma-Aldrich, Poole, UK) and 50 ml of 
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1.0 M Tris-HCl (pH 7.5; Sigma-Aldrich). The volume was made up to 1 I with 
RO water after which it was sterilized and stored at room temperature (20 0c). 
2.3.2 Magnesium Sulphate (MgS04) 
AIM solution of MgS04 (Sigma-Aldrich) was prepared by dissolving 12 g 
MgS04 in 100 ml RO water, sterilized and stored at room temperature (20 °C). 
2.3.3 Tris Acetate EDT A Buffer (T AE) pH 8.0 
A 10 X TAE buffer stock solution was prepared by dissolving 48.4 g of Trizma 
base (Sigma-Aldrich); 10 ml of glacial acetic acid (Sigma-Aldrich) and 2.92 g 
of EDT A (Sigma-Aldrich) in 750 ml ofRO water, the pH was adjusted to 8.0 
and the volume was adjusted to 1 1 with RO water. After which it was sterilized 
and diluted 1: lOin RO water when required. 
2.3.4 Tris EDTA Buffer (TE) pH 7.5 
A 10 X TE buffer stock solution (100 mM Tris-HCI, 10 mM EDTA) was 
prepared by dissolving 12.1 g of Trizma base (Sigma-Aldrich) and 3.7 g of 
EDTA (Sigma-Aldrich) in 750 ml ofRO water, the pH was adjusted to 7.5 and 
the volume was adjusted to 1 1 with RO water. Then, it was sterilized and 
diluted 1: lOin RO water when required. 
2.3.5 Tris Borate EDT A Buffer (TBE) pH 8.0 
A 5 X TBE buffer stock solution (445 mM Tris-base, 445 mM boric acid, 10 
mM EDT A) was prepared by dissolving 54.0 g of Trizma base (Sigma-
Aldrich); 27.5 g of boric acid and 2.93 g of EDT A (Sigma-Aldrich) in 750 ml 
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RO water, then the pH was adjusted to 8.0 and the volume was adjusted to I I 
ofRO water. This solution was sterilized and diluted 1:10 in RO water when 
required. 
2.3.6 Phosphate Buffered Saline (PBS) 
Phosphate buffered saline (Oxoid) containing: sodium choloride 0.16 M; 
potassium chloride; 0.003 M; disodium hydrogen phosphate 0.008 M; 
potassium dihydrogen phosphate 0.001 M, was prepared by dissolving I tablet 
per 100 ml RO water according to manufacturer's instructions and sterilized. 
PBS was stored at room temperature (20 0c) until required. 
2.3.7 Ethylenediaminetetraacetic Acid (EDTA) pH 8.0 
A 500 mM stock solution was prepared by dissolving 186.12 g EDTA (Sigma-
Aldrich) in 750 ml RO water, the pH was adjusted to 8.0 and the volume was 
adjusted to I I with RO water. The solution was then sterilized and stored at 
room temperature (20 0c) until required. 
2.3.8 Isopropyl-B-D-Thiogalactoside (IPTG) 
A 100 mM IPTG was prepared by dissolving 0.12 g IPTG (Roche, Welwyn 
Garden City, UK) in 5 ml RO water, sterilized through a 0.2 J..lm membrane 
filters (Sartorius, Epsom, UK) and stored at 4 °C until required. 
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2.3.9 Lysozyme 
Lysozyme from chicken egg white (Sigma-Aldrich) was used to prepare a 
solution at 50 mg mrl, sterilized through 0.2 J.lm membrane filters (Sartorius), 
dispensed in 500 J.lI portions and stored at -20°C until required. 
2.3.10 Calcium Chloride (CaCh) Solution 
This solution was prepared by dissolving 60 ml of 1 M CaCh (Fisher), 
3.0237 g piperazine-N,N'-bis (2-ethanesulfonic acid) (PIPES; Sigma-Aldrich) 
and 150 ml 100 % glycerol (Fisher) in 750 ml RO water. The pH was adjusted 
to 7.0 and the volume was adjusted to 1 I to give final concentrations of60 mM 
CaCh; 100 mM PIPES; 15% glycerol, sterilized and stored at 4 °c until 
required. 
2.3.11 Ammonium Acetate Solution 
Stock solutions of 7.5 M and 100 mM ammonium acetate (Sigma-Aldrich) 
were prepared, sterilized and stored at room temperature (20°C) until required. 
2.3.12 Cells Lysis Solution 
Lysis solution (20 % w/v sucrose, 30 mM Tris-Hel pH 8.0, 1 mM EDT A, 1 
mg mrl lysozyme) was prepared by dissolving 20 g sucrose (Sigma-Aldrich; 
20 % WN); 6 rol of 0.5 M Tris-HCI (Sigma-Aldrich) pH 8.0 (30 mM); 200 l.tI 
of 0.5 mM EDT A (2.3.7; 1 mM) in up to 100 ml RO water, sterilized and 
stored at 4 0c. Prior to its use, lysozyme (2.3.9) was added to a concentration of 
1 mg rol- I . 
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2.3.13 Tris-HCl 
Stock solutions of 1 M, 0.5 M or 100 mM Tris(hydroxymethyl)aminomethane 
(Sigma-Aldrich) were prepared, adjusted to the pH required with concentrated 
HCI (Fisher), made up to the correct volume then sterilized and stored at room 
temperature (20°C). 
2.3.14 Triton-X-I00 
A 1 % Triton-X-100 (Sigma-Aldrich) solution was prepared with RO Water, 
sterilized and stored at room temperature (20°C) until required. 
2.3.15 Tricine Gels Stain Solution 
Stain solution was prepared by dissolving 2.5 g Coomassie Brilliant Blue (0.25 
%; Sigma-Aldrich) in 10 % glacial acetic acid (Fisher), 45 % methanol 
(Fisher). The volume was adjusted to 1 I RO water. The solution was stored at 
room temperature (20°C) until required. 
2.3.16 Tricine Gels Destain Solution 
A destain solution was prepared by mixing 10 % glacial acetic acid (Fisher), 
45 % methanol (Fisher) and adjusted to 1 I with RO water. The solution was 
stored at room temperature (20°C) until required. 
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2.3.17 Ethidium Bromide 
A Stock solution of ethidium bromide (100 mg mr!; Sigma-Aldrich) was 
prepared in RO water, and stored at 4 0c. When required, it was used at 1 Jlg 
mr! final concentration. 
2.4 Antibiotics 
2.4.1 Ampicillin 
A stock solution of ampicillin (100 mg mr!; Sigma-Aldrich) was prepared in 
RO water, sterilized through a 0.2 Jlm membrane filters (Sartorius) and stored 
at 4 °C until required. When required, it was used at 100 Jlg mr! final 
concentration. 
2.4.2 Chloramphenicol 
A stock solution of chloramphenicol (30 mg mr!; Sigma-Aldrich) was 
prepared in 100 % ethanol (Fisher), sterilized through a 0.2 Jlm membrane 
filters (Sartorius) and stored at -20°C until required. When required, it was 
used at 30 Jlg mr! final concentration. 
2.5 Growth of Campylobacters 
2.5.1 Atmosphere Generation 
Microaerobic atmospheres were generated usmg either the evacuation 
replacement method where the jars are evacuated to -20 Hg and replaced with 
anaerobic gas mixture consisting of 85 % nitrogen, 10 % carbon dioxide and 
5 % hydrogen to produce an atmosphere containing 83 % v/v nitrogen, 7 % v/v 
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carbon dioxide, 7 % oxygen and 3 % v/v hydrogen, or through incubation in 
the Modular Atmospheric Controlled System (MACS; Don Whitley Scientific, 
Shiply, UK) which was supplied with a gas mixture of 85 % v/v nitrogen, 10 % 
v/v carbon dioxide and 5 % oxygen. 
2.5.2 Growth and Sub-Culture of Campylobacters 
Campylobacters were routinely sub-cultured on blood agar (2.1.1) and 
incubated at 42°C under microaerobic conditions (2.5.1). The blood agar plate 
cultures were stored for up to 28 d at 4 °C also under microaerobic conditions. 
2.5.3 Gram Stain 
A smear was prepared by mixing an isolated colony with drop of water on 
glass slide, where it was dried and fixed with heat. The slide was immersed in 
crystal violet solution (Prolabs Diagnostics, Gram stain kit) for 1 min, followed 
by Lugol's iodine (Prolabs Diagnostics, Gram stain kit) for 30 s and finally 
decolorized with methylated spirit (Fisher) for 1 min and counter stained in 
carbol fuchsin (Prolabs Diagnostics, Gram stain kit) for 1 min. In between each 
step, excess solution was removed by rinsing with water. Slides were examined 
using light microscopy. 
2.5.4 Isolation of Campylobacter from Chicken Excreta 
Samples taken from the center of the chicken faeces, were directly plated onto 
CCDA plates (2.1.2). All plates were incubated at 42°C under microarobic 
conditions (2.5.1) for 48 h. Colonies were Gram-stained (2.5.3) to check for the 
presence of Campylobacter. Colonies from plates showing positive growth 
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were sub-cultured on to BA (2.1.1) plates and incubated at 42°C under 
micro aerobic conditions (2.5.1) for 48 h. Once pure colonies were obtained, 
they were collected and frozen at -80°C in Campyfobacter storage medium 
(2.2.1). 
2.6 Campylobacter Bacteriophage 
2.6.1 Bacterial Lawn Preparation 
Lawns were prepared using a modified method from Frost et af. (1999). 
Different strains were grown as described in section 2.5.2 on BA (2.1.1) at 42 
°C for 24 h under micro aerobic conditions (2.5.1). Cells were collected using a 
sterile swab into 10 ml of sterile 10 ruM MgS04 freshly prepared from stock 
(2.3.2). Portions of the bacterial suspension (500 JlI) which contained 
approximately 1010 colony forming units (CFU) per ml were transferred into 5 
ml NZCYM overlay agar (2.1.4) which had been melted and kept at 50°C until 
used. The inoculated agar was immediately poured on pre-dried NZCYM base 
agar plates (2.1.3). The plates were rotated gently to produce an even lawn and 
allowed to set at room temperature (20°C). After which, they were dried at 42 
°C for 20 min before use. 
2.6.2 Isolation of Campylobacter Bacteriophage 
This method was modified from Salama et af. (1989). Faeces samples (0.5 g) 
were suspended in 5 ml SM buffer (2.3.1) and allowed to stabilize at 4 °C with 
gentle shaking, overnight. A 1 ml portion was transferred to an Eppendorftube 
and centrifuged at 13,000 g for 10 min, followed by filtering the supernatant 
using 0.2 Jlm pore size membrane filter (Sartorius). A 10 JlI aliquot was 
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dispensed onto a previously prepared bacterial lawn containing the universal 
phage propagation strain C. jejuni PT 14 (2.6.1), and incubated 42°C for 24 h 
under microaerobic conditions (2.5.1). Plates were examined for plaque 
formation. Plaques were collected using a 1 ml Gilson tip and dispersed in 500 
~ l l SM buffer (2.3.1) which was then used for phage propagation. 
2.6.3 Propagation and Concentration of Campylobacter 
Bacteriop hage 
Campylobacter phages were propagated using the modified method from Frost 
et al. (1999). Bacterial lawns were prepared as previously described (2.8.1). 
An aliquot of phage suspension was mixed with 400 ~ 1 1 of bacterial suspension 
(2.6.1) and incubated at 42°C for 20 min. The mixture was added to 5 ml 
NZCYM molten overlay agar (2.1.4) and poured onto NZCYM base agar 
(2.3.1) and allowed to set at room temperature (20°C) for 20 min. Plates were 
inverted and incubated at 42°C for 24 h under microaerobic conditions (2.5.1). 
After plaque formation, the phages were collected by the addition of 5 ml SM 
buffer (2.3.1) to the surface 0 f each plate and the phage allowed to elute into 
the buffer by shaking the plates at 4 °C overnight. The phage suspension was 
collected, filtered using 0.2 ~ m m membrane filters (Sartorius) and concentrated 
as described by Sambrook et at. (1989) where the phage suspension was 
centrifuged at 40,000 g for 2 h at 4 °C using a Beckman JA20 rotor using a 
Beckman 12-21 centrifuge (Beckman, High Wycombe, UK). Pellets were 
dispersed in (500 ~ l ) ) SM buffer (2.3.1) and phage allowed to elute in the buffer 
at 4 °C overnight with gentle shaking. 
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2.6.4 Bacteriophage Titration 
Ten-fold serial dilutions of the propagated phages were prepared in SM buffer 
(up to 10-8)_ A 10 III aliquot of each dilution was dispensed onto the prepared 
lawns (2.6.1) using the Miles and Misra (1938) technique. The liquid was 
allowed to be absorbed and plates were incubated at 42°C for 24 h under 
microaerobic conditions (2.5.1). The number of plaque forming units (PFU) 
per ml in the phage suspension was calculated. 
2.6.5 Bacteriophage Clean-up Using Ammonium Acetate for 
Electron Microscopy 
The propagated phage (2.6.3) was treated with ammonium acetate (2.3.9) as 
described by Ackermann (2005) prior to examination by electron microscopy. 
A 40 ml phage sample in SM buffer was centrifuged using a JA20 rotor in a 
12-21 Beckman centrifuge at 30,000 g, 4°C, 2 h without the brake. Then the 
supernatant was discarded carefully and without disturbing the pellet, 20 ml of 
0.1 M ammonium acetate (2.3.9) was added and the solution was centrifuged at 
25,000 g, 4°C, 1 h without the brake. This step was repeated after which the 
pellet was dispersed in 1 ml SM buffer (2.3.1) and kept on a shaker at 4 °C 
overnight. 
2.6.6 Pulsed Field Gel Electrophoresis (PFGE) to Determine 
Bacteriophage Genome Size 
The method used to prepare DNA for separation by PFGE was modified from 
the standard protocols of Sambrook et al. (1989). Phage suspension (2.6.3; 
50 Ill) was mixed with 10 III of 20 mg mrl proteinase K (Sigma-Aldrich) 
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solution and 50 ~ l l of 1.2 % molten pulsed field certified ultra-pure agarose 
(Bio-Rad, Hemel Hempstead, UK) in TE buffer (2.3.4), mixed well and 
dispensed into moulds and allowed to solidify. Once solidified, blocks were 
removed and placed in Eppendorf tubes containing 1 mllysis solution [1 00 ~ l l
proteinase K of20 mg mr! (Sigma-Aldrich) in 50 mM EDTA pH 8.0 (2.3.7), 
50 mM Tris-HCI (pH 8.0) (Sigma-Aldrich), 1 % sarcosyl (Sigma-Aldrich)] and 
incubated at 55°C for 1 h. The lysis solution was discarded and 1 ml water was 
added. The solution was incubated at 55°C for 15 min, then blocks were 
washed 3 times with washing buffer (20 mM Tris-HCI [pH 8.0] ;Sigma-
Aldrich), 50 mM EDTA pH 8.0 (2.3.7) and incubated at 55°C for 15 min 
between each wash. 
Each block was cut into 3 mm slices, transferred to the wells of a 1 % agarose 
(Bio-Rad) gel prepared in 0.5 X TBE (2.3.5) together with a block of 50-1000 
kb pulse marker (Sigma). The wells were sealed with molten agarose and 
allowed to set, after which they were transferred to the electrophoresis 
apparatus and run in 0.5 X TBE using the following program: 10-30 s over 
17 h using 6.0 v/cm with buffer circulating at 14°C in a BioRad CHEF-DR® II 
system. At the end of the run, the gel was stained with ethidium bromide (1 ~ g g
mr!) solution (2.3.17) for 30 min and the image was recorded usmg a 
ChemiDoc XRS Imager using the Quantity One program (Bio-Rad). 
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2.6.7 Bacteriophage DNA Preparation 
To 200 III of phage (2.6.3) sample containing 108 PFU mrl, 20 III proteinase K 
(10 mg mr!; Sigma-Aldrich) and 200 III detergent solution consisting of 2 % 
sarcosyl (Sigma-Aldrich) , 0.4 % SDS (Sigma-Aldrich), 20 mM Tris-HCL (pH 
8.0; Sigma-Aldrich) and 200 mM EDTA (pH 8.0; Sigma-Aldrich) were added 
and incubated at 55°C for 2 h after which 500 III phenol (Sigma-Aldrich) was 
added, mixed by inversion and centrifuged at 13,000 g for 1 min using a 
Biofuge Pico bench-top centrifuge (Kendro Laboratory Products, Bishops 
Stortford, UK). The supernatant was transferred to a clean eppendorf tube and 
mixed with 500 III chloroform (Sigma-Aldrich), centrifuged under the same 
conditions. This step was repeated. Ammonium acetate (7.5 M) was added in 
amount equal to 1110 of sample volume, and twice of the volume of 100 % 
cold ethanol was also added, mixed gently and kept at -20°C overnight. 
The sample was centrifuged at 13,000 g for 10 min. The supernatant was 
discarded and the pellet was washed with 70 % ethanol followed by 
centrifugation at 13,000 g for 10 min. The supernatant was discarded again and 
the pellet was dried at 37°C for 15 min after which the pellet was dispersed in 
50 11lt X TE (2.3.4) buffer. The concentration of prepared DNA was measured 
using an ND-1000 spectrophotometer 'Nanodrop' (Labtech, Ringmer, UK) at A. 
260 and stored at 4 °C until needed. 
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2.6.8 Whole Genome Amplification Using REPLI-g Kit 
The prepared DNA (2.6.8) was pre-amplified using REPLI-g mini prep kit 
(Qiagen, Crawley, UK) following their instructions. Briefly, to 5 ~ 1 1 of DNA 5 
~ 1 1 buffer DI (9 ~ 1 1 buffer DLB and 32 ~ 1 1 nuclease free water) was added, mixed 
by vortexing, centrifuged briefly and incubated at room temperature (20 0c) for 
3 min. To this, a 10 ~ 1 1 buffer NI (12 ~ 1 1 stop solution and 68 ~ l l nuclease free 
water) was added, mixed by vortexing and centrifuged briefly. Then 30 ~ 1 1
master mix (29 ~ l l REPLI-g mini reaction buffer and 1 ~ 1 1 REPLI-g mini DNA 
polymerase) was added and incubated at 30 °C for 10-16 h. The DNA 
polymerase was deactivated at 65 °C for 3 min and the samples were stored at 
-20 °C until required. 
2.6.9 Polymerase Chain Reaction (PCR) 
Phage DNA was prepared (2.6.7) and amplified. The reaction mixture was 
prepared as follows: 
Reagent Stock Final Volume 
Concentration Concentration Used 
PCR bJffer (AB gere, Smy, UK) lOX IX 5f.ll 
MgCb (AB gere) 25mM 2.25mM 4.5f.ll 
dNTPS ( P r o ~ ~ SoutlErrpton, UK) 25mMeach 2.5 mM each 5f.ll 
DNA 50ngllrl I n g ~ r l l If.ll 
Forward PIirn2" (fuofms MWG) 100 ptrnl Ilfl 2ptrn1llfl l ~ ~
~ ~Prirrer (Eurofin<; MWG) 100 ptrnl Ilfl 2 ptrnl Ilfl l ~ ~
Taq PolyIrernse (Fw) l U ~ r l l 0.02 U Ilrl If.ll 
Steri£ Distilled Water - - 31.5 f.ll 
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At the end of the run, the products were stored at -20°C for further analysis. 
The primers (Eurofins MWG, Ebersberg, Germany) were designed and used 
for amplification of each gene sequence. 
2.6.10 Agarose Gel Electrophoresis 
Agarose (Biogene, Cambridge, UK) was dissolved in T AE buffer (2.3.3) and 
heated to prepare gels of different concentrations (0.8, 1 and 1.5 %). The 
mixture was cooled to approximately 50°C and ethidium bromide to a final 
concentration of 1 Ilg mr) was added. This was followed by pouring the gel 
into a minigel cast (Anachem, Luton, UK) with 1.5 mm well combs and 
allowed to set. The well combs were removed and the gel transferred to an 
electrophoresis chamber filled with TAE buffer (2.3.3). 
The peR (2.6.10) products (20 %) were mixed with 6 X loading dye 
(Promega) and loaded in the gel wells together with DNA markers (Promega) 
and run at 85 V (70 V for low melting gels) for 30-45 min based on the 
migration rate. 
2.6.11 peR Product Purification using Gel Extraction Kit 
peR products (2.6.10) were run on a 0.8 % low melting point agarose (Melford 
Laboratories Ltd, Ipswich, UK) gel containing lllg mr) ethidium bromide 
(2.3.17) in 1 X T AE (2.3.3) followed by its purification if required using 
QIAquick gel extraction kit (Qiagen) according to the manufacturer's 
instructions. Briefly, the regions of gel containing the product were excised 
using a clean, sharp scalpel and any extra agarose removed. To 1 volume of the 
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gel, 3 volumes of QG buffer were added and incubated at 50°C for 10 min, 
after which 1 volume of isopropanol (Sigma-Aldrich) was added to the sample 
and mixed. The sample was applied to a QIAquick column and centrifuged at 
13,000 g for 1 min. The flow-through was discarded and 0.5 ml QG buffer was 
added to the column and centrifuged under the same conditions. For washing 
purpose, 0.75 ml PE buffer was added to the column and centrifuged under the 
same conditions. The flow-through was discarded again and re-centrifuged 
under same conditions. To elute DNA, the column was placed onto a new 
Eppendorf tube and 30 JlI TE buffer (2.3.4) was added to the column, left to 
stand for 1 min and centrifuged under the same conditions. The DNA 
concentration was measured using an ND-1000 spectrophotometer 'Nanodrop' 
(Labtech) at A 260 nm. 
2.6.12 PCR Product Purification using PCR Purification Kit 
PCR products (2.6.10) were purified when required using QIAquick PCR 
purification kit (Qiagen). Breifly, PCR product was mixed with buffer PB in a 
ration of (l:5 VN), applied to the QIAquick column and centrifuged at 13,000 
g for 1 min. The flow through was discarded and the column was placed back 
in the same tube. To wash, 0.75 ml Buffer PE was added to the QIAquick 
column and centrifuged under the same conditions. After that, the flow-through 
was discarded and the column was placed back in the same tube and 
centrifuged for additional 1 min under the same conditions. To elute the DNA, 
the column was placed into clean Eppendorftube, 30 JlI TE (2.3.4) was added. 
The column was left to stand for 1 min and centrifuged under the same 
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conditions. The DNA concentration was measured usmg an NO-IOOO 
spectrophotometer 'Nanodrop' (Labtech) at A. 260 nm. 
2.6.13 Bacteriophage Purification using Caesium Chloride 
Selected phage was purified using caesium chloride density gradient as 
described by Sambrook et at., in 1989. A suspension of the phage containing 
lOll PFU was mixed with caesium chloride (Sigma-Aldrich) to a final 
concentration of 0.75 g mrl, loaded into a Beckman centrifuge tube (Poly 
allomer tube: quick-seal bell top tubes: 3.5 mt) using a 25 gauge needle and 
sealed using heat. The tubes were centrifuged at 264,000 g, at 4°C, for 24 h 
using TLA 100.3 rotor in a Beckman TL-I00 Ultra centrifuge. The 
concentrated phage was indicated by a blue band which was collected by 
piercing the tube with 23-0 hypodermic needle just below the band and 
withdrawing the solution. 
Excess caesium chloride was removed by ultrafiltration using a Microcon 
30,000 Oa molecular weight cut off column (Millipore, Watford, UK) 
centrifuged at 6,500 g for 10 min in a Biofuge Pico bench-top centrifuge 
(Kendro Laboratory Products). Followed by washing the pellet twice with 100 
III SM buffer (2.3.1) by centrifugation under the same conditions. The column 
was then inverted and the phage was eluted in 100 III SM buffer (2.3.1) by 
centrifugation under the same conditions and stored at 4 °C until required. 
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2.7 The Effect of Phage Infection on Campylohacter 
Growth 
Fifty ml of NB (2.1.7) was inoculated with an overnight culture of C. jejuni 
PT14 grown on BA (2.1.1) under micoaerobic (2.5.1) conditions at 42°C that 
was suspended into 10 ml PBS buffer using a sterile swab. 
This experiment was run in three independent replicates and three NB flasks 
were used as controls. A 1 ml fraction was collected from each flask, diluted 
lO-fold in PBS (2.3.6) and dispensed using the Miles and Misra technique onto 
CCDA plates (2.1.2) and incubated at 42°C for 48 h under microaerobic 
(2.5.1) conditions. 
The cultures were incubated with shaking under microaerobic (2.5.1) 
conditions for 2 h at 42°C, 100 rpm, followed by their inoculation with 
selected phage at a multiplicity of infection (MOl) of one. Samples were 
collected for bacterial counting on CCDA (2.1.2) plates and phage growth. The 
incubation was continued for 10 h and samples were collected hourly. Phage 
counts were performed after storing the samples at 4 °C for 24 h. This was 
done as described in (2.6.4) on NZCYM (2.1.3) plates. 
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2.8 Cloning and Expression of Bacteriophage Genes 
2.8.1 Competent Cell Preparation using Calcium Chloride 
(CaCh) Solution 
From overnight cultures incubated at 37°C of selected Escherichia coli strains 
in LB (2.1.6) containing chloroamphenicol (2.4.2), 4 ml was inoculated in to 
400 ml fresh media. All LB incubation was done at 37°C, shaking at 200 rpm 
unless otherwise stated. Once the OD at 590 nm reached 0.375, the culture was 
transferred to ice for 10-15 min. The OD was measured using an Ultra Spec 
2000 (UVNisible) spectrophotometer (GE Health Care, Little Chalfont, UK). 
The culture then was centrifuged using 1A-I0 rotor in a 12-21 Beckman 
centrifuge at 1600 g for 10 min at 4 °C without the brake. The pellet was 
re-suspended in 80 ml of ice cold CaCh solution (2.3.10) and kept on ice for 10 
min followed by centrifugation 1000 g for 5 min at 4 °C without the brake. The 
pellet was re-suspended in 80 ml ice cold CaCh solution (2.3.10) and kept on 
ice for 30 min. The solution was centrifuged at 1000 g for 5 min at 4 °C 
without the brake. The pellet was resuspended in 8 ml ice cold CaCh (2.3.10), 
dispensed in 100 JlI volumes in pre chilled 1.5 ml Eppendorf tubes, frozen 
using liquid nitrogen and stored at -80°C until required. 
2.8.2 TOPO-Cloning of Bacteriophage CP220 Selected Genes 
Selected PCR products (2.6.9) were cloned in pCR 2.t-TOPO using TOPO-
Cloning Kit with E. coli TOP 10 cells (Invitrogen, Paisley, UK) following the 
manufacturer description. 
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The TOPO cloning reaction was set up as follows: 
Reagent Stock Concentration Fmal Concentration Volume Used 
PCRProduct Appux. 02 Ilg Ilrl 66ngllrl 2,.u 
Sahsolufun 12MNaCl 02MNaCl 1,.u 
0.6MMgCL O.lMMgCl 
TOPOvector lOngllrl 1.67ngllrl 1,.u 
Water - - 2,.u 
The reaction mixture was incubated at room temperature (20 °C) for 5 min, 
then transferred to ice. From the TOPO cloning reaction, 2 III was taken and 
added to a vial of chemically competent E. coli cells (lnvitogen). 
2.8.3 Transformation into Chemically Competent Cells 
The cloned PCR products (2.8.2) were transferred into a vial of E. coli TOPIO 
chemically competent cells, mixed gently and incubated on ice for 30 min 
followed by heating shock in a 42 °c water bath for 30 s and then placing back 
on ice for 2 min. Two hundred and fifty III ofS.O.C medium that had been kept 
at room temperature was added and transferred to a 15 ml snap-cap tube and 
shaken at 200 rpm in a 37 °C incubator for I h. Aliquots of 20 III and 10 III 
were spread on LB agar plates (2.1.5) containing the appropriate antibiotics. 
Prior to use if required, these plates were spread with 15 III of 100 mg ml -I x-
Gal (Melford Laboratories Ltd). The plates were incubated at 37 °c for 24 h. 
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2.8.4 Plasmid Mini Preparation (Using QIA Prep Spin Kit) 
From selected overnight cultures of plasmid containing E. coli incubated in 10 
ml LB containing the appropriate antibiotics at 37°C for 24 h, aliquots of the 
cultures obtained were stored in 12.5 % glycerol (2.2.3) at -80°C and the rest 
was used for plasmid mini preparation using a QIA prep spin kit (Qiagen) 
according to the manufacturer's instructions. Briefly, from the culture, 1.5-3 
ml was pelleted by centrifugation 13,000 g for 1 min using a Biofuge Pico 
bench-top centrifuge (Kendro Laboratory Products). The pellet was 
resuspended in 250 III buffer PI (50 mM Tris-HCL [pH 8]; 10 mM EDTA; 100 
Ilg mr' RNase A) followed by the addition of 250 III buffer P2 (200 mM 
NaOH; 1 % WN Sodium dodecyl sulphate). The solution was mixed 
thoroughly by inverting, after which 350 III buffer N3 (3 M potassium acetate 
[pH 5.5]) was added and mixed by inverting. The mixture was centrifuged at 
13,000 g for 10 min after which the supernatant was applied to the QIA prep 
spin column and centrifuged at 13,000 g for 1 min. The column was washed by 
adding 0.5 ml buffer BP and centrifuged under the same conditions. The 
column was washed by adding 0.75 ml buffer PE and centrifuged under the 
same conditions. The flow through was discarded, and additional 
centrifugation for one minute was performed before eluting plasmid DNA with 
30 III of TE buffer (2.3.4). Plasmid concentration was measured using ND-
1000 spectrophotometer 'Nanodrop' (Labtech) at A. 260 nm and stored at -20 
°C for before analysis. 
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2.8.5 Restriction Digest of the Plasmids in TOPO Vector 
Prepared plasmids were digested using EcoRI restriction enzyme (Promega) to 
detect the presence of the inserts. 
The reaction mixtures were prepared as follows; 
Reagent Stock Final Volume 
Concentration Concentration Used 
Buffer (Prorrega) lOX IX 2 ~ ~
EcoRI (Promega) IOUJ..lrl 025UJ..lrl 0 . 5 ~ ~
Phsmid 1 J..lgmfl 50ng l ~ ~
Sterile, dei>nized water - - 1 6 . 5 ~ ~
Following incubation at 37°C for 1 h, the reaction products were analyzed by 
agarose gel electrophoresis (2.6.10). 
2.8.6 Gene Expression in pET System 
The selected vectors and inserts were prepared as follows: 
2.8.6.1 Restriction Digest 
Samples were grown in LB (2.1.6) containing ampicillin (2.4.1). A portion of 
the culture was stored in 12.5 % glycerol at-80 °C (2.2.3). The rest was used 
for plasmid mini preparation (2.8.4). 
The restriction digests were performed using NdeI (Promega) and BamHI 
(Promega) as follows: 
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Reagent Stock F1nal Volume 
Concentration Concentration Used 
Buffer D ( P r o ~ ) ) lOX IX 2.DJ.tl 
Ndel (Promega) IOUJirl 0.25 U Jlrl 0.5 J.tl 
BamHI (Promega) IOUJirl O.25UJlrl 0.5 J.tl 
Pbsmid 1 Jlgni 50ng 1.0J.tl 
Sterik, deionized water 16.0 J.tl 
After incubation at 37°C for I h, followed by enzyme inactivation at 65°C for 
15 min, the products were examined using a I % agarose (Biogene) gel 
(2.6.10) to establish complete digestion. 
2.8.6.2 Vector Dephosphorylation 
The digested vector was dephosphorylated using Antractic phosphatase 
(NewEngland BioLabs LTD, Hitchin, UK) as follows: 
Reagent Concentration Used Volume Used 
Antracti: ~ ~ 00fIer lOX IX 2.0j.il 
l)ibTtNed vector ApJrox. (1-5 Jig) 17.0J.tl 
Antractic phosphatase 5 units 1.0 J.tl 
The mixture was then incubated at 37°C for 15 min, followed by enzyme 
inactivation at 65°C for 5 min. 
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2.8.6.3 Vector and Insert Purification 
To purify the dephosphorylated vector and the insert, the samples were run on 
0.8 % low melting point agarose (Melford Laboratories LTD, Ipswich, UK) gel 
(2.6.10) followed by its purification using QIAquick gel extraction kit (Qiagen; 
2.6.11 ). 
2.8.6.4 Ligation 
The purified insert (2.8.6.3) was ligated with the purified vector (2.8.6.3) using 
T4 DNA Ligase (Promega) using a 3:1 molar ratio insert:vector. The reaction 
mixture was prepared as follows and was then incubated at 16°C or 16 h. 
Reagent Amount 
Vector 100 ng 
Irnert "A" ng 
Ligase buffer (10 X) (Promega) 1.0 J.tl 
T4 DNA ligase (Protrega) OJ-LOU 
Nuchl<;e free water Upto 1O.0J.tl 
The molar ratio can be calculated using the following formula: [(100 ng vector 
* kb insert) / kb vector) * (3/1)] = "A" ng insert 
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2.8.6.5 Transformation into a non-Expression Host 
The ligated mix was first dialyzed for 20 min using 0.025 Ilm VSWP Millipore 
filters, and then it was transformed into a non expression host TOP 10 
chemically competent E. coli cells (Invitrogen) as described in 2.8.3. 
2.8.6.6 Transformation into Expression Host 
Plasmids from confirmed positive clones were transformed into E. coli 
expression hosts that were prepared (2.8.1) to allow protein expression as 
described in 2.8.7. 
2.8.7 Test Protein Expression using the pET System 
Colonies obtained from (2.8.6.6) were inoculated into 10 ml LB (2.1.6) 
containing ampicillin (2.4.1) and chloroamphenicol (2.4.2). Part of the culture 
was stored in 12.5 % glycerol (2.2.3) and the rest was used in the experiment. 
To 20 ml of fresh media, 1 ml culture was added and incubated at 37°C, 
shaking at 200 rpm until the OD 600 nm reached 0.3-0.4. After this time a 1 ml 
sample was taken as "pre-induced" sample for total cell extraction and the rest 
of the sample was induced with 0.1 mM IPTG (2.3.8), and incubated. After 4 h, 
a sample (1 ml) was taken, from which the OD 600 was measured using an 
Ultra spec 2000 (UVNisible) spectrophotometer (GE Health Care) and a total 
cell protein extract prepared as follows. 
The sample was centrifuged at 13,000 g for 1 min in Biofuge Pico bench-top 
centrifuge (Kendro Laboratory Products). The supernatant was discarded and 
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the pellet was resuspended in nuclease free water, for which the volume was 
calculated as follows: Water Volume = OD600 * 100. 
The extracted fractions were stored at -20 °C for analysis. 
2.8.8 Isolation of Material from Cell Fractions 
From an overnight culture of the sample expressing the protein, 1 ml was 
transferred to 20 ml LB (2.1.6) containing ampicillin (2.4.1) and 
chloroamphenicol (2.4.2), and incubated until the OD 600 reached 0.3-0.4 
(measured using Ultra spec 2000 [UVNisible] spectrophotometer [GE Health 
Care]). After which a 1 ml sample was taken as a "pre-induced" sample and 
the rest of the sample was induced with 0.1 mM IPTG (2.1. 8), incubated for 4 
h and another 1 ml sample was taken as the "post-induced" sample. 
Fractions were prepared as follows: The sample was centrifuged at 13,000 g 
for 1 min in Biofuge Pico bench-top centrifuge (Kendro Laboratory Products). 
The supernatant was discarded and the pellet was re-suspended in cell lysis 
solution (2.3.12) containing 1 mg mrl lysozyme (2.3.9), and incubated on ice 
for 10 min, followed by its centrifugation at 13,000 g for 1 min. The 
supernatant was collected as the "periplasmic" fraction. The pellet was re-
suspended in 1 00 mM Tris-CI (2.3.13), frozen in liquid nitrogen and thawed in 
37 °C water bath. This step was repeated twice, before the samples were 
centrifuged at 13,000 g for 5 min. The supernatant was collected as the 
"cytoplasm" fraction and the pellet was re-suspended in 1 % triton-X-I00 
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(2.3.14), kept at 4 °C for 10 min and retained as "membrane proteins and 
inclusion bodies" fraction. 
For the pre-induced samples, 100 III aliquots were used whereas for the post 
induced samples 200 III aliquots were used for protein analysis. 
The extracted fractions were stored at -20°C before analysis. 
2.8.9 Effect of Induction with IPTG on Cell Growth 
From an overnight culture of protein expressing E. coli (2.8.6.6) a 1 ml sample 
was transferred to a 20 ml LB (2.1.6) containing ampicillin (2.4.1) and 
chloroamphenicol (2.4.2) and incubated for a further 12 h. The OD 600 was 
measured hourly using Ultra spec 2000 (UVNisible) spectrophotometer (GE 
Health Care). When the OD 600 nm reached 0.3-0.4, the samples were induced 
with 0.1 ruM IPTG (2.3.8) and their incubation continued for 12 h. 
2.S.10 Electrophoresis Using Tricine Gels 
The protein profiles of recombinant E. coli extracts (2.8.7, 2.8.8) were 
visualized by electrophoresis on 10-20 % Novex tricine gels using a 
propriatary XCell sureLock mini cell system (Invitrogen). The sample to be run 
was prepared by mixing the protein extracts (5 Jll) with 2 X Novex Tricine 
SDS sample buffer (Invitrogen; final concentration 50 % v/v); lOX NuPAGE 
reducing agent (Invitrogen; final concentration 10 % v/v) and made up with 
nuclease free water to give a final volume of 20 Ill. Followed by heating the 
samples at 85°C for 2 min, and then centrifuged at 13,000 g for 1 min. The 
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samples were loaded on the gel with a See Blue Plus 2 pre-stained standard 
(Invitrogen) and the gels electrophoresed using 1 X running buffer (Invitrogen) 
for 90 min at a constant 125 V. At the end of the run, the gels were stained 
(2.3.15) for 30 min and de-stained (2.3.16) for 1 h. 
2.9 Mass Spectrometry 
Mass spectrometry (MS) work was performed as a service by R. Susan Liddle 
at the University of Nottingham using the following procedures. 
2.9.1 Gel Piece Processing and Tryptic Digest 
Samples to be digested were prepared on 10-20 % Tricine gels (2.8.10) after 
which they were stained using colloidal coomassie blue (Fisher) and de-stained 
in water. The target samples were excised from gels using a sterile scalpel 
followed by their processing in gel pieces using the ProteomeWorks 
MassPREP robotic liquid handling station (Waters, Elstree, UK). Such samples 
were incubated in 100 J.lI of de-stain solution (50 mM ammonium bicarbonate, 
50 % acetonitrile) for 10 min at room temperature and which was repeated 
three times. The final aliquot was dehydrated by incubation in 50 J.lI of 
acetonitrile for 5 min at room temperature. Then, the acetonitrile was removed 
and the gel plugs were for 10 min to allow evaporation. The sample was then 
incubated for 30 min in 50 J.lI of reducing solution (10 mM dithiothreitol, 100 
mM ammonium bicarbonate) which was removed at the end of the incubation 
period. The samples were incubated for 20 min in 50 J.lI of alkylation solution 
(55 mM iodoacetamide, 100 mM ammonium bicarbonate) at room 
temperature. Gel slices washing was carried out at room temperature in the 
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following solution; 50 III of 100 mM ammonium bicarbonate for 10 min, 50 III 
of acetonitrile for 5 min and dehydrated by double room temperature washes in 
50 III of acetonitrile for 5 min and evaporation for 5 min. The microtitre plate 
containing the gel plugs was cooled to 6 °C for 10 min before the addition of 
25 III per well of trypsin gold (Promega) and diluted to 10 ng Ilrl in trypsin 
digestion buffer (50 mM ammonium bicarbonate). Trypsin entry into the gel 
plugs was allowed with minimal autocatalysis by incubating the plate at 6 °C 
for 20 min and at 40°C for 4 h. Samples were stored at 4 °C until MS 
analysis. 
2.9.2 Mass Spectrometry Analysis of Samples 
Samples analysis was carried out by LC-ESI-tandemMS on a Q-TOFII mass 
spectrometer fitted with a nanoflow ESI (electro spray ionization) source 
(Waters Ltd). Peptides were separated on a PepMap CI8 reverse phase, 75 Ilm 
i.d., IS-cm column (LC Packings) and delivered on-line to the MS via a CapLC 
HPLC system. The mass spectrometer was operated with a capillary voltage of 
3000 V in positive ion mode. Argon was used as the collision gas. Acquiring 
the tandem MS data was achieved using automated data-dependent switching 
between MS and MS/MS scanning which depends on the ion intensity, mass 
and charge state (data directed analysis (DDA™). For such experiments the 
methods were created in the MassLynx 4.0 software where the charge state 
recognition was used to select doubly, triply and quadruply charged precursor 
peptide ions for fragmentation. For the tandem MS acquisition, one precursor 
mass was selected at a time. The collision energy was selected automatically 
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according to the charge and mass of each precursor and varied from 15 to 
55 eV. 
2.9.3 De novo Sequence Interpretation of Tryptic Peptides 
A de novo sequence interpretation for individual peptides was performed using 
the PepSeq tool of the MassLynx™ 4.0 software package (Waters). 
TandemMS spectra from the DDA LC-tandemMS runs were processed into 
singly charged, mono-isotopic masses using MaxEnt 3 maximum entropy 
software (Waters). The resulting spectra were opened in the PepSeq window, 
and combinations of automated and manual direction of the tools were used to 
elucidate each peptide sequence. 
The de novo peptide sequences were used to perform database searches using 
BLASTP (at http://www.ncbi.nih.gov) using parameters for "short, nearly 
exact matches". 
2.10 His Tag Addition to the Expressed Protein 
Oligonucleotides were designed to insert at the 5'-end of the gene to create an 
N-terminal fusion with the expressed protein. The oligonucleotides were 
purchased from MWG (Germany) and kinased using T4 polynucleotide kinase 
(Promega) following the manufacturer's recommendations. 
Briefly, the reaction mix was prepared as indicated below and incubated at 
37°C for 30 min. 
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Reagent Stock HnaI Volume 
Concentration Concentration Used 
Oligonucleotides 100 pmol 2.5 pmol 1 ~ l l
Kinase buffer 10 X IX 4 ~ l l
ATP 10mM ImM 4 ~ l l
T4 Polynucleotide Kinase 10 U ~ r l l 0.375 U ~ r l l 1.5 ~ l l
Water - - 29.5 ~ l l
The reaction was stopped by the addition of 2 JlI 0.5 M EDT A (2.3.7) and 1 
volume of phenol:chloroform:isoamylalcohol (25:24:1; Sigma), before 
vortexing for 1 min and centrifugation in a bench top centrifuge operating at 
13,000 g for 2 min. The upper aqueous layer was collected and 1 volume of 
chloroform:isoamylalcohol (24:1; Sigma) was added, vortexed and centrifuged 
as described earlier. Following centrifugation, the upper layer was collected 
and transferred to clean Eppendorfand 0.5 volume of7.5 M ammonium acetate 
(2.3.11), 2 volumes 100 % ethanol (Fisher) added and mixed. The sample was 
left at -80°C for 30 min, and then centrifuged for 5 min. Finally, the 
supernatant was discarded and the pellet resuspended in 20 ~ l l TE (2.3.4). 
The kinased forward and reverse oligonucleotides were mixed together and 
heated at 90°C for 3 min. The Eppendorf tube containing the mix was left in 
the boiling water in a double ice box and allowed to cool slowly over night. 
Followed by their self-ligation using T4 DNA ligase (Promaga) prepared by 
mixing and incubating the annealed oligonucleotides at 25°C for 3 h, followed 
by heat deactivation at 65°C for 15 min. 
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Reagent Stock Final Vohune 
Concentration Concentration Used 
Oligonucleotides - - 12 III 
Ligase buffer lOX IX 1.5 III 
T4 DNA Ligase (Promega) 10 U Ilr1 1 U Ilrl 1.5 III 
The ligation was first dialyzed for 20 min using 0.025 Ilm VSWP Millipore 
filters, and then digested using NdeI at 37°C for 1 h before deactivation at 65 
°C for 15 min. The pET3a vector containing the gene to which the His-tag was 
to be appended was digested with NdeI and dephosphorylated (2.8.6.2). 
Reagent Stock Final Amount 
Concentration Concentration 
Sample - - 15 III 
Buffer D (lOX) lOX IX 2.0 III 
Nde I (Promega) 10 U Ilrl 0.67 U Ilr1 2 III 
Water 
- - 11 III 
The His tag oligonucleotides were ligated into the vector using T4 DNA ligase 
(Promega) as described in 2.8.6.4, followed by transformation into E.coli 
TOPlO chemically competent cells (2.8.3). 
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2.11 Lytic Activity of Expressed Proteins 
Bacterial lawns of various bacterial strains were prepared as described in 2.6.1, 
to which protein samples were applied to the lawns as replicate 10 fll droplets. 
The droplets were allowed to absorb into the agar and all the plates were either 
incubated at 42°C under microaerobic conditions (2.5.1) or aerobically at 37 
°C for 24 h. 
2.12 Trichloroacetic Acid (TeA) Precipitation 
Purified phage preparations were subject to TCA precipitation prior 
electrophoresis on 10-20 % Novex Tricine gels (2.8.10) for MS analysis. 
Briefly, to CsCI density gradient purified phage CPX, a one tenth volume of 
0.15 % deoxycholate (Sigma-Aldrich) was added, vortexed and incubated for 
10 min, after which a one tenth volume of72 % TCA was added and incubated 
for a further 5 min at room temperature. The solution then was centrifuged at 
13,000 g in a Pico bench-top centrifuge (Kendro Laboratory Products) for 8 
min. The supernatant was removed using a needle and syringe and the pellet 
was resuspended in 20 fll SM buffer (2.3.1). 
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CHAPTER THREE 
ISOLATION OF CAMPYLOBACTERS AND 
BACTERIOPHAGES 
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3.1 Introduction 
Campylobacter jejuni is considered the most important cause of bacterial 
foodbome gastroenteritis worldwide (Reid et aI., 2008). Campylobacters are 
ubiquitous in nature with a large environmental reservoir residing in poultry, 
where they form part of the commensal micro flora (Beery et al., 1988; Newell 
and Feamley 2003). Organic and free-range farming practices have been 
shown to produce birds with a higher incidence of Campylobacter colonisation 
(Heuer et al., 2001; EI-Shibiny et aI., 2005). In one study on raw chicken meat 
sold in the UK, 80% was contaminated with Campylobacter (J0rgensen et al., 
2002) with 98% of isolates speciated as C. jejuni and 2% C. coli. The 
probability of isolating phages is increased where their hosts thrive, so poultry, 
in particular free range chickens, are a likely source of phages (Atterbury et al., 
2003a). The work in this chapter describes the isolation of Campylobacter and 
their phages from free-range layer chickens exposed to the environment. This 
was carried out to extend the availability of characterised phages for use in 
phage therapy against campylobacters in domestic poultry (Loc Carrillo et aI., 
2005). 
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3.2 Results 
3.2.1 Campylobacter and Bacteriophage Isolation, Propagation, 
Concentration and Titration 
Fresh chicken faeces collected from free range chickens from three different 
farms in Leicestershire were transported to the laboratory in cool boxes within 
30 minutes of collection and screened immediately for the presence of 
campylobacters and phages. The results are listed in Table 3.1. Campylobacter 
isolation was performed by direct plating on CCDA plates (see section 2.5.4) 
and confirmed by Gram stain (see section 2.5.3) to be Gram-negative. 
Campylobacter isolates were stored in Campylobacter storage medium (2.2.1). 
Campylobacters were isolated from 51 % of the total number of samples (35). 
Of the samples collected from Heath Farm, 57 % were Campylobacter positive 
(8/14), and from Calcutt Heights, 50 % of the samples were positive (10/20). 
Lastly, the sample obtained from Minster veterinary practice was negative. 
All the phages were isolated and propagated from the samples according to the 
method described previously in sections 2.6.2 and 2.6.3. Phages were 
successfully isolated from Heath Farm and Calcutt Heights Farm (Table 3.1), 
and these coincided with the Campylobacter-positive samples at the respective 
frequencies of 14 % (2/14) and 5 % (1120). The phages were numbered 3b, 4a 
(Heath Farm) and 18b (Calcutt Heights Farm). Phage 3b proved to be difficult 
to propagate in the laboratory. However, the remaining two phages were 
plaque purified, concentrated (see section 2.6.3) and titrated (see section 2.6.4) 
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on C. jejuni PTI4. Their titre was found to be was 109 PFU mr) for each of 
them. 
Table 3.1 Isolation ofCampylobacters and bacteriophages 
------------
Farm Name 
Heath Calcutt Minster Total 
Farm Heights 
Number of Samples 14 20 1 35 
Samples Positive for 8 10 0 18 
Campylohacter 
Samples Positive for phages 2 1 0 3 
3.2.2 Susceptibility of Campylobacters to Bacteriophages 
The ability of the three phages isolated in the previous section to produce 
plaques on range of campylobacters was examined. This analysis was extended 
to include some previously characterized and uncharacterized phage in order to 
compare their lytic profiles. The uncharacterized phages were recovered from 
retail chicken and were of interest because they had been demonstrated to 
possess larger DNA genomes (W phages; Atterbury et at., 2003a) on the basis 
of estimates from pulsed fields gel electrophoresis. The lytic profiles of all the 
phages were compared using a number of Campylobacter strains from different 
sources; broiler, human and reference sources including strains previously 
found to be resistant to phage attack. 
Campylobacter strains were obtained from various different sources: Health 
Protection Agency, Queens Medical Centre and the Laboratory collection from 
broiler and layer chickens are listed in Table 3.2. Bacterial lawns were 
prepared from each strain as described in section 2.6.1. Filtrates recovered 
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from environmental suspensions (4a and 18b) as described previously in 
section 2.6.2, and a set of laboratory phage isolates (Table 3.3) initially 
recovered from retail chicken; (W2, W3, W5, W7, W8; Atterbury et al., 
2003a), were applied to bacterial lawns prepared (see section 2.6.1) as 10 III 
aliquots containing 106 or 109 PFU mrl to examine their lytic effects on these 
strains. Table 3.4 presents the results of susceptibility testing of Campylobacter 
strains against various phages. 
Bacterial lawns were tested with 109 PFU phages to intentionally overload 
them in order to look for minority populations of mutant phage with different 
host ranges to the majority of the population. However, if the strain was 
sensitive to the majority of the phage, the results were generally not different 
except in the case ofHPC5 and OCIIClO, which produced better defined zones 
of lysis on the host bacterial lawns compared to the routine test dilution of 106 
PFU that resulted in .no lysis of OCIICIO or semi-confluent lysis for HPC5 
with phage 4a only. 
All the phages tested had the same lytic effect on C. jejuni PT5 and PT33 
resulting in complete lysis of the lawn. None of the phages were virulent 
against NCTC PTl, PT2, PT35, 12668 (Health Protection Agency); 163,166 
(QMC); MPVC1, TlVC9, GIlC8, OR12 and OCmC2 (Laboratory stocks) with 
no plaques formed even on the overloaded spots. Phage l8b was the only 
phage found to lyse Campylobacter human strains 162 and 164. 
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Table 3.2 Details of Campylobacter strains used in this chapter 
All strains are C.jejuni except: NCTC 12668, OR12 and PT44 are C. coli 
Strain Source Isolated from Year obtained 
PTl4 HP A Colindale Human faeces 2000 
PTl HP A Colindale Human faeces 2003 
PT2 HP A Colindale Human faeces 2003 
PIS HPA Colindale Human faeces 2003 
PTl6 HPA Colindale Human faeces 2003 
PTl9 HPA Colindale Human faeces 2003 
PT33 HPA Colindale Human faeces 2003 
PT35 HP A Colin dale Human faeces 2003 
PT44 HP A Colindale Human faeces 2003 
11168 NCTC Human faeces 2000 
12668 NCTC Human faeces 2000 
161 Queen Medical Centre Human faeces 2005 
162 Queen Medical Centre Human faeces 2005 
163 Queen Medical Centre Human faeces 2005 
164 Queen Medical Centre Human faeces 2005 
165 Queen Medical Centre Human faeces 2005 
166 Queen Medical Centre Human faeces 2005 
MPVCl Laboratory stock Broiler chicken cloacal swab 2001 
TlVC9 Laboratory stock Broiler chicken cloacal swab 2001 
GnC8 Laboratory stock Broiler chicken cloacal swab 2001 
OR12 Laboratory stock Free range chicken excreta 2007 
HPC5 Laboratory stock Broiler chicken cloacal swab 2001 
FDC3 Laboratory stock Broiler chicken cloacal swab 2001 
DVIFS Laboratory stock Broiler chicken cloacal swab 2001 
OCIIIC2 Laboratory stock Broiler chicken cloacal swab 2001 
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Table 3.2 cont. Details of Campylobacter strains used in this chapter 
All strains are C.jejuni except: NCTC 12668, ORI2 and PT44 are C. coli 
Strain Source Isolated from Year 
obtained 
OCIICIO Laboratory stock Broiler chicken cloacal swab 2001 
HP I CIO Laboratory stock Broiler chicken cloacal swab 2001 
OK VIII C3 Laboratory stock Broiler chicken cloacal swab 2001 
HP IF9 Laboratory stock Broiler chicken excreta 2001 
BIll C7 Laboratory stock Broiler chicken cloacal swab 2001 
OC I F3 Laboratory stock Broiler chicken excreta 2001 
a III F2 Laboratory stock Broiler chicken excreta 2001 
TIIIC9 Laboratory stock Broiler chicken cloacal swab 2001 
CIIC3 Laboratory stock Broiler chicken cloacal swab 2001 
TIF2 Laboratory stock Broiler chicken excreta 2001 
FDIC2 Laboratory stock Broiler chicken cloacal swab 2001 
OKIX C3 Laboratory stock Broiler chicken cloacal swab 2001 
OKXC2 Laboratory stock Broiler chicken cloacal swab 2001 
ES I Laboratory stock Free range chicken excreta 2001 
aHlI F7 Laboratory stock Broiler chicken excreta 2001 
C IC4 Laboratory stock Broiler chicken cloacal swab 2001 
DVIV CI Laboratory stock Broiler chicken cloacal swab 2001 
DV IVC8 Laboratory stock Broiler chicken cloacal swab 2001 
aHlClO Laboratory stock Broiler chicken cloacal swab 2001 
MPVCI Laboratory stock Broiler chicken cloacal swab 2001 
BI03032A The University of Bristol Broiler chicken house doors 2008 
(swab) 
BI03066A The University of Bristol Broiler chicken house excreta 2008 
BI0309B The University of Bristol Broiler chicken house overshoes 2008 
BI03037A The University of Bristol Broiler chicken house anteroom 2008 
overshoes 
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Table 3.2 cont. Details of Campylobacter strains used in this chapter 
All strains are C.jejuni except: NCTC 12668, OR12 and PT44 are C. coli 
Strain Source Isolated from Year 
obtained 
B103025A The University of Bristol Broiler chicken house overshoes 2008 
BI0269 The University of Bristol Broiler chicken house overshoes 2008 
BI02632B The University of Bristol Broiler chicken house (swab back 2008 
double doors) 
BI02635C The University of Bristol Broiler chicken house (swab 2008 
anteroom door) 
BlOC61B The University of Bristol Broiler chicken house excreta 2008 
C1235100B The University of Bristol Broiler chicken caecal contents 2008 
C124136C The University of Bristol Broiler chicken house (swab 2008 
anteroom equip.) 
C123566c The University of Bristol Broiler chicken house excreta 2008 
Cl241103B The University of Bristol Broiler chicken caecal contents 2008 
Cl22514B The University of Bristol Broiler chicken house (swab 2008 
outside grass) 
Cl235105A The University of Bristol Broiler chicken caecal contents 2008 
Dl5C9C The University of Bristol Broiler house (swab concrete 2008 
outside) 
DI5C83B The University of Bristol Broiler house swab 2008 
D15C18C The University of Bristol Broiler chicken house (swab 2008 
outside grass) 
Dl5CI0B The University of Bristol Broiler house (swab concrete 2008 
outside) 
Dl5C82A The University of Bristol Broiler house swab caecal 2008 
contents 
Dl5C46B The University of Bristol Broiler chicken house (outside 2008 
puddle) 
Dl5C17B The University of Bristol Broiler chicken house (swab 2008 
outside grass) 
Dl5C2 The University of Bristol Broiler chicken house (swab 2008 
outside grass) 
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Table 3.3 Details of bacteriophages used in this chapter 
Phage Campy[obacter Source Isolated from Year 
propagation 
strain 
CP8 PTl4 Laboratory Free Range 2001 
stock chicken excreta 
CP20 FDC3 Laboratory Broiler chicken 2001 
stock excreta 
CP30 PTl4 Laboratory Broiler chicken 2001 
stock excreta 
CP34 PTl4 Laboratory Broiler chicken 2001 
stock excreta 
CP220 PTl4 Laboratory Broiler chicken 2003 
stock carcass 
CPX PTl4 Laboratory Broiler chicken 2007 
stock carcass 
W2 PTl4 Laboratory Poultry meat 2001 
stock 
W3 PTl4 Laboratory Poultry meat 2001 
stock 
W5 PTl4 Laboratory Poultry meat 2001 
stock 
W7 PTl4 Laboratory Poultry meat 2001 
stock 
W8 PTl4 Laboratory Poultry meat 2001 
stock 
3b PTl4 This thesis Free range 2007 
chicken excreta 
4a PTl4 This thesis Free range 2007 
chicken excreta 
18b PTl4 This thesis Free range 2007 
chicken excreta 
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Table 3.4 Susceptibility of Campylobacter strains to bacteriophages 
Campylobacter strains from 1-11 were obtained from HP A Colindale, strains 12-17 were 
human isolates obtained from QMC; strains 18-26, were from laboratory stocks. CL, confluent 
lysis; SCL, semi-confluent lysis; -, no plaques were formed. 
Results were obtained using 106 and 109 PFU for all strains. Whcre there was no difference 
between the two different concentrations, only the 106 PFU phage concentration is presented. 
Where there was a difference between the two concentrations both results are presented. 
Campylobacter Bacteriophages 
Strains W2 W3 W5 W7 W8 4a 18b 
1 PTl4 CL CL CL SCL CL SCL CL 
2 PTl - - - - - - -
3 PT2 - - - - - - -
4 PT5 CL CL CL CL CL CL CL 
5 PTl6 - SCL - CL - - SCL 
6 PTl9 - CL - - CL SCL -
7 PT33 CL CL CL CL CL CL CL 
8 PT35 - - - - - - -
9 PT44 - - - - - SCL -
10 11168 SCL - - - - - SCL 
11 12668 - - - - - - -
12 161 SCL - - SCL - SCL SCL 
13 162 - - - - - - SCL 
14 163 
- - - - - - -
15 164 - - - - - - SCL 
16 165 SCL - - SCL - - SCL 
17 166 - - - - - - -
18 MPVCl - - - - - - -
19 TlVC9 - - - - - - -
20 GIIC8 - - - - - - -
21 OR12 - - - - - - -
22 FDC3 SCL CL - CL CL SCL SCL 
23 DVIFS - - SCL - - - -
24 OCmC2 - - - - - - -
25 HPC5 with 100 PFU - - - - - SCL -
with 109 PFU - CL CL - CL CL -
26 OCIICI0 
with 106 PFU - - - - - - -
with 109 PFU CL CL CL 
-
CL 
- -
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To extend this comparison a further set of Campylobacter strains were tested 
(Table 3.2) using laboratory stock phages: CP8, CP20, CP30, CP34, CP220 
(Loc Carrillo et aI., 2005; Scott et ai., 2007; EI Shibiny et ai., 2009) and CPX, 
which was co-isolated with CP220 (listed in Table 3.3). The bacterial lawns 
were prepared from each strain as described in section 2.6.1, and the phages 
propagated and titrated according to the methods described in sections 2.6.3 
and 2.6.4. The phages were then applied to the lawns as 10 l.tI spots containing 
with 106 PFU to examine their lytic effects on these strains to enable 
comparison with the fIrst set of strains. The phage lytic profIles are shown in 
Table 3.5. 
All phages could be discriminated on the basis of their lytic profiles. None of 
the tested phages were virulent against the following strains; PT!, OR12, 
GHIIF7, CIC4, DVIVC1, DVIVC8, GHICIO, MPVCl, B10269, C124136C, 
C1241103B and C122514B. PT2 was lysed only by phage CP220, FDIC2 by 
CPX and OKIXC3, OKXC2 and ES 1 only by CP20. Campylobacter strains 
HPC5, HPICIO, Dl5C9C and Dl5C17B were lysed by all tested phages. 
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Table 3.5 Susceptibility of Campylobacter strains to bacteriophages (106 PFU) 
CL, confluent lysis; SCL, semi-confluent lysis; OL, opaque lysis -, no plaques were formed. 
r---
Campylobacter 8acteriophages 
Strains CP8 CPX CP20 CP30 CP34 CP220 
1 PTl - - - - - -
2 PT2 
- - - - -
OL 
3 PT44 CL CL CL 
- -
CL 
4 OR12 - - - - - -
5 TIVC9 - - CL CL - -
6 HPC5 CL CL CL CL CL SCL 
7 OCmC2 - - - - - -
8 12668 - - CL - - CL 
9 HP I CI0 CL SCL CL CL CL CL 
10 OK VIII C3 SCL - SCL CL CL 
-
11 HPIF9 CL - CL CL CL OL 
12 8I1I C7 - - - CL CL -
13 OCI F3 
- -
OL CL SCL 
-
14 GIll F2 - - OL OL OL -
15 TIIIC9 
- - -
CL CL 
-
16 CIIC3 - CL CL - - -
17 TIF2 - - CL - - OL 
18 FDIC2 - SCL - - - -
19 OKIXC3 - - CL - - -
20 OKXC2 - - CL - - -
21 ESI - - OL - - -
22 GHIIF7 - - - - - -
23 CIC4 - - - - - -
24 DVIVCl - - - - - -
25 DVIVC8 - - - - - -
26 GHlCI0 - - - - - -
27 MPVCl - - - - - -
28 8103032A 
- - -
SCL SCL 
-
29 8103066A - - - CL SCL -
30 8103098 - - - OL - -
31 8103037A - - - CL CL -
32 8103025A 
- -
CL - - CL 
33 810269 
- - - - - -
34 81026328 - - - CL CL -
35 8102635C - - - CL CL -
36 810C618 
- -
CL 
- -
CL 
37 CI2351008 
- - -
CL CL 
-
38 C124136C 
- - - - - -
39 C123566c 
- -
CL CL CL CL 
40 C12411038 - - - - - -
41 C1225148 - - - - - -
42 C1235105A - - - CL CL -
43 D15C9C CL CL CL CL CL CL 
44 D15C838 - - CL - - SCL 
45 D15C18C - - CL OL OL -
46 D15CI08 OL - CL CL CL OL 
47 D15C82A - - CL - - CL 
48 D15C468 CL 
-
CL CL CL CL 
49 Dt5CI78 CL CL CL CL CL CL 
50 Dt5C2 
- -
CL OL 
- -
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3.2.3 Pulsed Field Gel Electrophoresis (PFGE) 
To estimate the genomic DNA sizes of the newly isolated phages 3b, 4a, 18b, 
and other phages from the laboratory stocks including: W2, W3, W5 and W7, 
samples were prepared in agarose blocks for PFGE as described in section 
2.6.7, and following electrophoresis the gels were stained with ethidium 
bromide and the images captured with a ChemiDoc XRS Imager using the 
Quantity one program (Bio-Rad). 
Gels revealed that phage preparations of 3b, 4a, 18b, W2, W3, and W7 
contained a discreet a single DNA band corresponding to the genomes of these 
phages. The sizes 0 f the newly isolated phages; 3 b, 4a and 18b were estimated 
at 145 kb whilst the W2, W3 and W7 phages sizes were estimated to be 180, 
194 and 195 kb respectively. In contrast two bands were obtained from W5, a 
major band of estimated size 130 kb and a minor band of 195 kb (Figure 3.1). 
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Figure 3.1 PFGE showing genomic DNA of selected bacteriophages 
In order to determine the genomic size of different phages, samples were 
prepared and run using PFGE. Lanes represented are as follows; 
A) Lane I ; PFGE DNA marker, Lane 2; phage 4a, Lane 3; phage 3b, Lane 4; 
phage I8b 
B) Lane I; phage W2, Lane 2; phage W3, Lane 3; phage W5, Lane 4; phage 
W7, Lane 5; PFGE DNA marker 
3.2.4 Separation of W5 bands Obtained from PFGE 
The phage W5 was found to have two different sized DNA bands by PFGE 
(Figure 3.1). In order to fmd whether these DNAs represented two forms of the 
same phage or two different phages in the same sample, attempts were made to 
separate them by plaque purification. 
Ten-fold serial dilutions of phage W5 at 108 PFU mr' were prepared and the 
10-5, 10-6, 10-7 dilutions were mixed with 500 III C. jejuni PTl4 (Universal 
propagation strain) suspension that was prepared by collecting the PTI4 
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growth from blood plate using a swab and suspending it in 10 mM MgS04 
(described in section 2.3.2). The selected dilutions were propagated as 
described in section 2.6.3. After plaque formation, lOwell-isolated plaques 
from the 10-7 dilution, were picked using 1000 III Gilson tips and transferred to 
Eppendorftubes containing 500 III SM buffer (described in section 2.3.1), and 
each left overnight at 4 °C under shaking conditions. Propagation of the phage 
was repeated using 200 III of these suspensions (undiluted) under similar 
conditions but this time each plaque was propagated on five plates. After 
incubation, 5 ml of SM buffer (described in section 2.3.1) was added to each 
plate and kept at 4°C overnight with gentle shaking. The phage suspension was 
then collected, concentrated and titrated as described earlier in sections 2.6.3 
and 2.6.4. PFGE blocks were then prepared to liberate genomic DNAs and a 
PFGE gel was prepared and run as described in section 2.6.7. 
The PFGE image is shown in Figure 3.2. One sample (lane 6) did not show any 
visible DNA bands. Two samples (lanes 3 and 9) appeared as a smear and the 
rest of the samples revealed a DNA bands of equivalent size to the smaller 
genomic DNA band (130 kb) observed in the preparation from the original 
plaque isolate. 
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Figure 3.2 PFGE of genomic DNA of different plaques from W5 phage 
PFGE of phage W5 revealed two DNA bands of different sizes. In order to 
determine whether these fragments belonged to the same phage, attempts were 
made to plaque purify them, from which samples were prepared for separation 
of the genomic DNAs by PFGE. Lanes represented as follows; 
Lanes I to 10; genomic ON A from 10 different plaques of W5 phage, Lane II; 
PFGE DNA marker 
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3.3 Discussion 
Campylobacters were isolated from 51 % of the chicken faecal samples 
examined in this chapter with around 8 % also containing Campylobacter 
phages. A high prevalence of Campylobacter in free-range chicken has been 
reported previously (Rivoal et al., 2005). All the phages tested could be 
distinguished from each other based on their lysis profiles with host 
Campylobacter strains. The phage diversity encountered could arise from the 
acquisition ofphage from multiple environmental sources, or alternatively once 
acquired, the phage could adapt within the chicken intestinal tract to maximize 
the use of the host campylobacters available to them. Samples which were 
negative for campylobacters were negative for phages as well. This correlates 
with the finding that phages are present only when their hosts are present. 
Since poultry in UK are frequently colonized by campylobacters, the high 
percentage of their isolation was expected (Corry and Atabay, 2001). 
Phages were isolated from the samples analysed at a frequency of 8 %, which 
was somewhat lower than the frequency observed by Atterbury et al. (2005) of 
approximately 45 %, but from the data presented by Connerton et al. (2004), 
the frequency of isolation is variable, depending on whether a suitable sensitive 
host is available. The isolated phages were plaque purified, and propagated in 
order to determine their genomic sizes. PFGE can be used to separate large 
DNA fragments efficiently (McCelland et al., 1987), and it has been used for 
genomic investigations of different strains of bacteria and phages (Prevots et 
al., 1990; Loc Carillo et ai, 2007). Genomic DNAs of the isolated phages 3b, 
4a and 18b were estimated at 145 kb in size, which places them in group III 
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according to the classification system of Sails et al. (1998), who classified 
phages into three classes based on their average size into groups I, II and III 
with average sizes of 320, 184 and 138 kb, respectively. According to the 
genomic size estimates of the W phage series obtained from PFGE, they can be 
placed into group II based on Sails et al. (1998). 
Phage preparations of W5 produced two DNA fragments on the PFGE gel 
indicating that two different phages might be present. Obviously, when 
characterizing a phage isolate it is important that it is a pure culture, so 
experiments were performed in order try to separate them. However, these 
efforts only resulted in the isolation of the smaller phage at the expense of the 
larger phage or in one case, another example of the two genome sizes 
remaining together. The smaller phage was of a genome DNA size typical of 
group III phages, and was probably recovered more frequently because the 
population of this phage in the sample was greater than the larger one. It was 
apparent from the original PFGE gel (Figure 3.1) that the genome 
concentration was lower for the larger sized phage. To be able to investigate 
whether the two DNA bands on the PFGE gel resulted from the same phage 
with two variations in size or two completely different phages, more work 
would need to be done using larger scale preparations in conjunction with 
DNA sequencing. The observations regarding W5 were similar to those 
regarding CP220 (see Chapter 5), in that in some preparations two DNA bands 
were visible. In the latter case it was possible to separate the preparation into 
two phages with different sized genomes, CP220 and cpx. As the sequence of 
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CP220 and was available, efforts were concentrated on obtaining the sequence 
of its co-isolate CPX (Chapter 5) rather than W5. 
All the phages isolated in our laboratory could be classified into groups II and 
III (Atterbury et al., 2003a; Connerton et al., 2004). Group I phages were not 
isolated, which is likely to be because Group I phages are either not common in 
the UK or in the Campylobacter sources sampled (chickens and humans). 
The lytic profiles of all the phages studied in this chapter were distinguishable 
from each other using a diverse set of Campylobacter strains, which highlights 
the diversity in Campylobacter phage specificity. None of the phages lysed the 
laboratory strains MPVCl, Tl VC91, GIIC8, ORI2, OCIIIC2, GHIIF7, CIC4, 
DVIVC1, DVIVC8 and GHICIO that had been specifically selected as being 
more resistant to phage attack on the basis of previous screening with different 
phage sets (Dr. P. Connerton, University of Nottingham, pers. Comm.), and 
highlights that more work needs to be done in order to find suitable phages 
that might be used to treat such strains in phage therapy. 
Bacterial strains can be resistant to phage treatments. One possible reason for 
such resistance is the interaction between the phages and host receptors and co-
receptors. Phage attachment to its host is the first step in phage infection and 
any change in the surface profile either by regulated expression or mutation in 
the receptors will lead to phage insensitivity. For that reason, understanding 
phage receptors is required to optimize phage cocktails that can be used for 
bacterial control and food spoilage prevention (Shin et al., 2012). In addition to 
that, infection level can be reduced in cells having DNA restriction 
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modification systems by destroying foreign DNA and host cell genes leading to 
phage replication block (Rees and Loessner, 2009). 
It was hoped that by testing a concentration of the phages (109 PFU mrl), that 
contained a much higher number of phage than would normally be required for 
lytic profiling, that variants within the phage population e f f e c t i v ~ ~ against these 
problematic strains might be detected. However, in this instance no variants 
were detected. The standard dose used for lytic profiling (106 PFU mrl) 
allowed the host ranges of the different phage to be ascertained and the results 
were generally easier to read than those in which excess phage titres were 
added. These strains remain insensitive to the bacteriophage but it is unclear at 
this time whether this is because they do not bind or are prevented from 
completing their life cycle. 
116 
Chapter 4 
CHAPTER FOUR 
MOLECULAR CHARACTERIZATION OF 
CP220 BACTERIOPHAGE AND RELATED 
BACTERIOPHAGES 
117 
Chapter 4 
4.1 Introduction 
The complete genome sequence ofphage CP220 was determined by workers at 
the University of Nottingham and the Sanger Centre (Timms et al., 2010). The 
availability of this data allowed the phage CP220 sequence to be used as the 
template on which primers could be designed for DNA amplification for the 
characterization and analysis of other phages. Some regions of particular 
interest included the putative lysin genes (CPT 0075, 120 and 142), because of 
their potential antimicrobial action. The lysin genes were the first selected for 
characterization, followed by a gene with a possible transposase function (CPT 
0035c) together with structural genes (CPT 0034c, 0052, 0053, 0045, 0058, 
0175). 
CPtl0 is another phage in the same class as CP220, the genomic sequence of 
which was published together with that ofCP220. The two sequences exhibit a 
great deal of similarity. In order to investigate the relationships between these 
phages and those from other classes, a number of genes were selected within 
the CPtlO genome sequence for amplification. These included a lipoprotein 
gene (CPtlO_ 0771), a head completion protein (CPt 10_0591), a methyl 
transferase gene (CPtlO_1471) and a transposase gene (CPtlO_1761). PCR 
would then be used to find out if they were present in CP220 and other phages. 
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4.2 Results 
4.2.1 Propagation and Concentration of Bacteriophages 
A number of phages were selected for this study including CP220, CPS, CPX, 
CP20, CP30 and CP34. The phages were propagated (see section 2.6.3) and 
titrated (see section 2.6.4) using the C. jejuni host strain PT14 with the 
exception with CP20, which was titrated on C. jejuni HPC5. The number of 
plaque forming units (PFU) was calculated and found to be 109 for each phage 
preparation. 
4.2.2 DNA preparation and Pre-amplification of 
Bacteriop hages 
Genomic DNA from phages: CP220, CPX, CPS, CP20, CP30 and CP34 were 
prepared according to the method described in section 2.6.S. The concentration 
of the prepared DNA was insufficient to perform all the molecular 
charactization experiments. Thus, DNA of all phages was pre-amplified using 
whole genome amplification REPLI-g kit as described in section 2.6.9, which 
resulted in samples with higher DNA concentrations for their use in subsequent 
experiments. 
4.2.3 Gradient Polymerase Chain Reaction Amplification of 
Genes from Bacteriophage CP220 
Three genes from CP220 phage were selected (CPT 0075, 120 and 142) for 
PCR amplification. Primers (Eurofins MWG Operon, Ebersberg, Germany) 
were designed and used for amplification of each gene. The primer sequences 
are listed in Table 4.1 
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Table 4.1 Primer sequences of bacteriophage CP220 potential lysin genes 
CP220 Position Sequence 
Gene 
CPf0075 68295 .•. 68588 F: s-TICATA TGCCTCCITTAACfAGAGTTGGTG-3' 
R S-TIGGATCCfTATcrACAAATAACA TTICCAGATCC-3' 
CPT 120 107127 ... F: S-AACATA TGAATT ACGATAAAClGAATAAAA TGGG-3' 
IOMll R 5'-AAG GAT CCD TATTAA GAGTTI AGTTTA TTA AAT TIT 
GAC-3' 
CPfl42 1 ~ 9 9 ... F: S-TICATA lGAATAATICfGGAGTTIGITCATTIC-3' 
127019 R5'-TIGGATCCCTATGITTTIGCAAGACAAGAAACCC-3' 
In order to determine the optimum annealing temperature for DNA 
amplification, gradient amplification using a range of temperatures was carried 
out for the selected genes from phage CP220 in CI000tm thermal cycler 
(Biorad), using the reaction mixture described in methods section 2.6.10 using 
the following cycles. 
CPf0075,CPT 120 andCPT 142 
IC)de 96't:: 3 min 
35C)Cb; 96't:: 1 min 
55-65't:: 1 min 
72't:: 1 min 
1 C)de 72't:: 7 min 
At the end of the program cycle, a 1 % agarose gel (see methods section 
2.6.11) was run using 20 % of the PCR products together with 1 kb DNA 
markers (Promega), and the gels examined and the image recorded with a 
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ChemiDoc XRS Imager using the Quantity one program (Bio-Rad). Figure 4.1 
presents the agarose gel of the gradient PCR amplification products. 
The annealing temperatures tested were: 55 .8, 57.4, 59, 60.6 and 62.2 °c The 
optimum annealing temperature for CP220 CPT 120 was established to be 
between 60.6 and 62.2 °c (Figure 4.1 A), which wa the same for CP220 
CPT0075 and 142 (Figure 4.1B). By analyzing the e results, 61 °C was chosen 
as the annealing temperature for further PCR amplification regimes. 
Figure 4.1 Gradient PCR amplification of phage CP220 selected genes 
In order to determine the optimum annealing temperature for phage CP220 
DNA amplification, gradient PCRs were run using primers designed for the 
amplification of the selected genes. PCR products were examined using 1 % 
agarose gel electrophoresis. Lanes are represented as follows: 
Aj CPT 120 
Lane 1; 1 kb DNA marker, Lanes 2-6; PCR product at temperatures 55.8, 
57.4, 59,60.6 and 62.2 °c 
Bj CPT 142 and 0075 
Lane 1; I kb DNA marker, Lanes 2-6; PCR product at temperatures 55.8, 
57.4, 59, 60.6 and 62.2 °C for CPT 142, Lanes 7-11 ; PCR product at 
temperatures 55.8, 57.4, 59, 60.6 and 62.2 °c for CPT 0075 
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The annealing temperature for PCR amplification was selected to be 61 °C. 
Primers (Table 4.1) were designed to amplify the potential lysin genes CPT 
0075, 142 and 120 from phage CP220 DNA (accession number: FN667788). 
Phage CP220 DNA, prepared as described in methods section 2.6.8, was 
amplified using the reaction mixture as described in section 2.6.10 using a TC-
312 thermal cycler (Scientific Laboratory Supplies) programmed with the 
following cycles: 
lC)de 96'C 3 min 
35C)dcs 96'C 1 min 
61'C 1 min 
72'C I min 
1 C)Cic 72'C 7 min 
The PCR products were examined using 1 % agarose gel electrophoresis (see 
section 2.6.11) together with a 100 bp DNA marker (Promega). The gel image 
was recorded with a ChemiDoc XRS Imager using the Quantity one program 
(Bio-Rad), and is shown in Figure 4.2. The DNA fragment sizes were 
estimated as follows: CPT 120 fragment was 664 bp whereas the fragment 
sizes of CPT 142 and CPT 0075 were 204 and 302 bp, respectively. 
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Figure 4.2 PCR amplification of phage CP220 potential lysin genes 
Phage CP220 DNA was amplified using primers de igned for the potential 
lysin genes. The PCR products were examined by 1 % agarose gel 
electrophoresis and the fragment sizes estimated to be 664, 204 and 302 bp for 
CPT 120, CPT 142 and CPT 0075, respectively. Lanes representing 20 % of 
the PCR amplification products are as follows: Lane 1; CPT 120, lane 2; 100 
bp DNA marker, lane 3; CPTI42, lane 4; CPT 0075. 
4.2.5 Class II Campylobacter Bacteriophage Genes in Other 
Bacteriophages 
In order to compare any relationship between different phages, DNA from 
selected phages (CPX, CPS, CP20, CP30, CP34 and CP220) isolated 
previously from chicken sources were prepared (see methods ection 2.6.S). 
The phage DNA were used as template for PCR amplification (see methods 
ection 2.6.10) with primers (Eurofins MWG Operon) specifically designed 
upon selected genes from the Class II bacteriophage genomes of CP220 and 
CPtlO available in the database (Tables 4.1 and 4.2). The gene selection was 
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based on their potential function (for instance lysins, transposases, 
lipoproteins) or because their presence had been examined in phages of the UK 
Campylobacter typing scheme as part of another study performed by Timms 
et al. (2010), in this case the GP 18 and GP 19 structural genes 
The amplification was carried out using reaction mixture in detailed in section 
2.6.10 using TC-312 thermal cycler (Scientific Laboratory Supplies) using the 
following cycles: 
IC)de 96'C 3 min 
35C)C1a> 96'C 1 min 
61'C 1 min 
72'C 1 min 
1 C)C\e 72'C 7 min 
The PCR products were examined using a 1 or 1.5 % agarose gels loaded with 
1 kb and/or 100 bp DNA markers (Promega). The gel image was recorded with 
a ChemiDoc XRS Imager using the Quantity one program (Bio-Rad). The 
DNA fragments were extracted and purified from agarose gel slices as 
described in section 2.6.13 and DNA sequenced using the Euorofins MWG 
Operon value one service. The DNA sequences obtained were analyzed using 
the BioEdit program. The nucleotide sequence similarities and differences 
between the amplified DNAs and the class II bacteriophage genes are listed in 
Appendices 1 and 2. 
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Table 4.2 Primer sequences of selected Class II bacteriophages genes 
CP220 phage genes 
Genes Position Sequmce 
CPrOO35c C*27555 ... 'lKm F: 5'- GGT GGA TCA AAA GCA ACA GG -3' 
R 5'-AGAGGAAAGATITGCGACO\-3' 
GP18 C*25935 ... 27485 F: 5'- GGG TAT GCA AGT TIG CCA AG -3' 
CPfOO34c R: 5'- AAG CAC AAC AAT CAC CAC GA -3' 
GP18 48293 ... 49Xl9 F: 5'- AGA TCC AAG CCA AGC AAG TG -3' 
CPr 0052 R: 5'- TGG CCT TGA ACC TTC TIT TG -3' 
GP18 49913 ... 51M9 F: 5'- CGA TCG CGT AAA CGT TGT T A -3' 
CPr 0053 R: 5'- T AC GCT TOC TGG ATT GTI TG -3' 
GP19 41505 .. .42263 F: 5'- CAA GTI TTC CGG GAT TGA CT -3' 
CPf0045 R: 5'- TCC TCA AAT TGA TGT GCT TGA -3' 
GP19 56719 ... 5rrf) F: 5'- ACC CAG GGG GCT TAT TI A CA -3' 
CPr 0058 R: 5'- GCC GAT TT A CCA TCT TGT GG -3' 
GP19 157455 ... 158:m F: 5'- AAG ATG CGA GGT GAA ACA GA -3' 
CPf175 R: 5'- CCG CTT TCA AAG TIC CGT T A -3' 
CPtlO phage gmes 
Genes Position Sequmce 
CPtlO 0591 5<Xm ... 60181 F: 5'- AGC CGA GCT GCT AAA CTG AG -3' 
R: 5'- GAA AAG CGT TGC CCT TGT AT -3' 
CPtlo_am 68741 ... ffJm F: 5'- TIC TIG GAA TGT TGG AAA TGT T -3' 
R: 5'- AGC TTT GAA TGG GTT TGC TG -3' 
CPtIO 1471 123774 ... 124439 F: 5'- TCC AAA TCG TGT TIT GTI ATG G -3' 
R: 5'- TTI TIG TGT TGG GTG AAC GA -3' 
CPtlO 1761 147008 ... 148342 F: 5'- GAT CAA AAG CAA CAG GCT T AC A -3' 
R: 5'- TCT CCT CCG TCT TAG AGG AAA -3' 
* C used to indicate that this gene is located on the complementary strand 
Primers sequences obtained from Timms and others (2010) 
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4.2.5.1 Comparison to CP220 Bacteriophage 
The CP220 phage genes included a number of potential lysin genes (CPT 0075, 
120 and 142), a gene with possible transposase function (CPT 0035c) and a 
number ofGP18 (CPT 0034c, 0052 and 0053) and GP19 (CPT 0045, 0058 and 
0175) structural genes. 
Comparison of the amplicon sequences to phage CP220 DNA sequences 
indicated that the putative lysin genes (CPT 0075, 120 and 142) were amplified 
successfully from the genomic DNAs of phages CPX, CP8, CP20, CP30 and 
CP34. The amplified DNA fragments for these genes are presented in Figures 
4.3, 4.4 and 4.5 respectively. In addition, CPT 0035c (Figure 4.6) with a 
possible transposase function, and structural genes corresponding to phage 
CP220 proteins: GP18 (CPT 0034c, 0052 and 0053) and GP19 (CPT 0045, 
0058 and 0175) respectively were also amplified and the DNA sequences 
compared (Figures 4.7 and 4.8). The DNA fragments of the genes that were 
successfully PCR amplified (Table 4.3) were gel purified (see methods section 
2.6.11) and the DNAs sequenced. The sequences obtained were analyzed using 
BioEdit and appear in Appendix 1. 
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Table 4.3 Bacteriophage PCR amplification with CP220 gene specific primers 
Amplified Bacteriophage 
Gene CPX CP8 CP20 CP30 CP34 
CPT 0075 + + + + + 
CPT 120 + + + + + 
CPT 142 + + + + + 
CPT 0035c - - + - -
GP 18 CPTs; 0034c, 0052, 0053 - - + - -
GPl9 CPTs; 0045, 0058,0175 - - + - -
+= Successful amplification of the expected DNA product 
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Figure 4.3 Phage CP220 CPT 0075 gene in other phages 
In order to detect the presence of the CP220 gene CPT 0075 in alternative 
phage genomes, their DNAs were PCR amplified using gene-specific primers. 
The PCR products were examined using 1 % agarose gel electrophoresis. 
Lanes representing 20 % of the amplified DNA fragments from the different 
phages are as follows: Lane 1; 1 kb marker, lane 2; CP220, lane 3; CPX, lane 
4; CP8, lane 5; CP20, lane 6; CP30, lane 7; CP34, lane 8; 100 bp marker. 
127 
Chapter 4 
Figure 4.4 Phage CP220 CPT 120 gene in other phages 
In order to detect the presence of the CP220 gene CPT 0120 in alternative 
phage genomes, their DNAs were PCR amplified using gene-specific primer. 
The PCR products were examined using 1 % agarose gel electrophoresis. 
Lane representing 20 % of the amplified DNA fragments from the different 
phages are as follows : Lane 1; CP220, lane 2; CPX, lane 3; CP8, lane 4; CP20, 
lane 5; CP30, lane 6; CP34, lane 7; 100 bp marker. 
Figure 4.5 Phage CP220 CPT 142 gene in other phages 
In order to detect the presence of the CP220 gene CPT 00142 in alternative 
phage genomes, their DNAs were PCR amplified u ing gene- pecific primers 
The PCR products were examined using 1 % agarose gel electrophoresis. 
Lanes representing 20 % of the amplified DNA fragments from the different 
phages are as follows: Lane 1; I Kb marker, lane 2; CP220, lane 3; CPX, lane 
4; CP8, lane 5; CP20, lane 6; CP30, lane 7; CP34, lane 8; 100 bp marker. 
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Figure 4.6 Pbage CP220 0035c gene in other phages 
In order to detect the presence of the CP220 gene CPT 0035c in alternative 
phage genomes, their DNAs were PCR amplified using gene-specific primers. 
The PCR products were examined using 1.5 % agarose gel electrophoresis. 
Lanes representing 20 % of the amplified DNA fragments from the different 
phages are as follows: Lane 1; negative control, lane 2; CP220,lane 3; CPX, 
lane 4; CP8, lane 5; CP20, lane 6; CP30, lane 7; CP34, lane 8, 100 bp marker. 
Figure 4.7 Pbage CP220 GP18 genes in other phages 
In order to detect the pre ence ofCP220 GP18 alleles 0034c, 0052 and 0053 in 
alternative phage genomes, their DNAs were PCR amplified using gene-
specific primers. The PCR products were examined using 1.5 % agarose gel 
electrophoresi . Lanes representing 20 % of the amplified DNA fragments 
from the different phages are as follows : Lanes 1 to 7; CP220 CPT 0034c, 
lanes 8 to 14; CP220 CPT 0052, lanes 15 to 21; CP220 CPT 0053 and lane 22; 
100 bp Marker. The order of the samples in lanes 1 to 7, 8 to 14 and 15 to 21 
are negative control, CP220, CPX, CP8, CP20, CP30 and CP34, respectively. 
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Figure 4.8 Phage CP220 GP19 genes in other phages 
In order to detect the presence ofCP220 GP19 alleles 0045,0058 and 0175 in 
alternative phage genomes, their DNAs were PCR amplified using gene-
specific primers. The PCR products were examined using 1 % agarose gel 
electrophoresis. Lanes representing 20 % of the amplified DNA fragments 
from the different phages are as follows: Lanes 1 to 7; CP220 CPT 0045, lanes 
8 tol4; CP220 CPT 0058, lanes 15 to 21; CP220 CPT 0175 and lane 22; 100 
bp Marker. The order of the samples in lanes 1 to 7,8 to 14 and 15 to 21 are 
negative control, CP220, CPX, CP8, CP20, CP30 and CP34, respectively. 
The sequences obtained from DNA amplifications using the 0075 primers were 
identical to CP220 CPT 0075 for phages CPX, CP8, CP30 and CP34. CP20 
however, had 14 nucleotide differences at the following positions: A42T, 
C54T, G67A, G93A, A132G, G142C, G143C, C153T, G156A, Gl74A, 
C182T, T207C, C252G and A264G), which translated to four amino acid 
differences (V231, 144M, G48P and A61 V). Phages amplified with the CPT 
120 primers showed identity with CP220 CPT 120 for CP8 and CP30. CPX 
showed three nucleotide differences (T72C, T92C, T445C) that translate to two 
amino acid differences (V31A, FI49L). CP20 showed 21 nucleotide 
differences ( A46G, T64C, A150G, T154C, A219G, T235A, A257G, A270G, 
C278A, A327G, C366T, T375C, G408A,A414G, T417G, T435C, T447C, 
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G465T, T468C, G525A, T568C) that translate to 7 amino acid differences 
(I16V, F22L, S79T, K86R, A93D, K155N, SI90P).The DNA sequence of the 
CPT120 of CP34 was incomplete when compared with CP220. The CPT 120 
PCR product lacked 132 bp from the end of the gene and contained the 
following substitutions within the conserved region (A33C, AI09T, C268 and 
A492C). CPX, CP20, CP30 and CP34 showed 100 % identity to CP220 CPT 
142 whereas CP8 showed two nucleotide differences (G36A, C108T) that are 
silent. 
CP20 was the only phage that could be amplified using the 0035c primers. The 
sequences showed two nucleotide differences (G 181 A, T222C) translating to 
one amino acid difference (V81A) compared to CP220 CPT 0035c. 
Amplification of genomic DNA with primers designed to amplify parts of 
several structural genes was carried out. CP20 was the only phage DNA that 
could be amplified with the GP18 (CPT 0034c, 0052 and 0053) and GP19 
(CPT 0045, 0058 and 0175) primers. The CP20 sequence showed 100 % 
identity to CP220 CPT 0052, 0053 but exhibited eight nucleotide differences 
(A772G, A775G, C777T, G800A, T804C, T817C, G823A, G825A) that 
translate to four amino acid differences (T258A, T259A, S267N, V275I) with 
CP220 CPT 0034c. Comparison with CP20 GP19 genes showed the following 
changes: two nucleotide differences (A258C, A261 T) for CPT 0045, one 
nucleotide difference (A525G) for CPT 0058 and four nucleotide differences 
(T252C, C288T, G303A, T312C) for CPT 0175 compared to CP220. These 
differences in nucleotides were silent and did not lead to any change in the 
protein sequences. 
131 
Chapter 4 
4.2.5.2 Comparison to CPtlO Bacteriophage 
Bacteriophage CPt lOis another group II Campylobacter phage that shows 
close sequence homology to phage CP220 for which the DNA sequence 
(accession number: FN667789) is available for use in sequence comparison 
studies. To extend the analysis, four genes were selected with the gene 
annotations indicating the following potential functions: head completion 
protein gene (CPtlO_0591), lipoprotein gene (CPt1O_0771), methyl transferase 
(CPtl0_1471) and a transposase (CPt1O_1761). 
The positive DNA amplification products are listed in Table 4.6 and the 
amplified products are shown in Figures 4.9 and 4.10. These DNA fragments 
were purified as described in methods section 2.6.13, and sequenced using the 
Eurofins MWG Operon value one service. DNA sequences were analyzed 
using the BioEdit program and appear in Appendix 2. 
Table 4.4 Bacteriophage PCR amplification with CPtlO gene specific primers 
Amplified Bacteriophage 
Gene CP220 CPX Cpg CP20 CP30 CP34 
CPtlO 0771 - - - + - -
CPt10 0591 - + - + - -
-
CPtlO 1471 - + - + - -
-
CPtlO 1761 + + - - - -
-
+= Successful amplification of the expected DNA product 
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Figure 4.9 Phage CPtlO (0771,0591) genes in other phages 
In order to detect the presence of selected CPt 1 0 genes 0071 and 0591 in 
alternative phage genomes, their DNAs were PCR amplified using gene-
specific primers. The PCR products were examined using 1.5 % agarose gel 
electrophoresis . Lanes representing 20 % of the amplified DNA fragments 
from the different phages are as follows : Lanes 1 to 6 show amplification 
reaction products with CPt 10 gene-specific primers to CPt 10_0771, lanes 7 
to 12 shows amplification reaction products with CPt 1 0 gene-specific primers 
to CPt 1 0_0591 and lane 13 100 bp marker. The order of the samples in lanes 1 
to 6 and 7 to 12 are negative control, CP220, CPX, CP8, CP20, CP30 and 
CP34, respectively. 
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Figure 4.10 Phage CPtlO (1471, 1761) genes in other phages 
In order to detect the presence of selected CPtlO genes 1471 and 1761 in 
alternative phage genomes, their DNAs were PCR amplified using gene-
specific primers. The PCR products were examined using I.S% agarose gel 
electrophoresis. Lanes representing 20 % of the amplified DNA fragments 
from the different phages are as follows: 
Lanes 1 to 6 show amplification reaction products with CPt 1 Ogene-specific 
pnmers to CPt 10_1471, lanes 7 to 12 show amplification reaction products 
with CPtlO gene-specific primers to CPt10_1761 and lane 13; 100 bp Marker. 
The order of the samples in lanes 1 to 6 and 7 to 12 are negative control, 
CP220, CPX, CP8, CP20, CP30 and CP34, respectively. 
CP20 was the only phage DNA that could be amplified with CPtIO_0771 
primer, the DNA sequence of which showed 100 % identity to CPtIO_077 I in 
the amplified region. Phages CPX and CP220 were amplified using the 1761 
primers with 100 % identity for phage CPX, with S nucleotide differences were 
recorded for phage CP220 (C222T, C242T, A311T, A313G, T314C), which 
led to three amino acid differences (A8IV, DI04V, IlOSA). Phage CPX and 
CP20 were amplified using the CPtlO_OS91 and 1471 primers. The amplified 
products showed 100 % identity to the original phage CPt10 DNA sequence. 
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4.2.6 PFGE of Bacteriophage DNAs 
In order to estimate the sizes of the DNA genomes from phage CP220, CPX, 
CP8, CP30 and CP34, phage DNAs were prepared in agarose blocks and 
subjected to pulsed fields gel electrophoresis (PFGE) calibrated with phage 
lambda DNA marker as described in methods section 2.6.7. 
PFGE of phage DNA preparations CPX, CP8, CP30 and CP34 revealed one 
band corresponding to a genome size of 145.5 kb (Figure 4.11). However, the 
genomic DNA sizes of CP20 and CP220 were estimated at 194 Kb. 
Figure 4.11 PFGE of genomic DNAs of selected Campylohacter phages 
In order to determine the genome sizes of Campylobacter phages, their DNAs 
were prepared and subject to PFGE. Gel lanes were loaded as follow: Lane 1; 
CPX, lane 2; CP8, lane 3; CP20, lane 4; CP30, lane 5; CP34, lane 6; CP220, 
lane 7; DNA marker (concatenated phage lambda DNA). 
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4.3 Discussion 
The work in this chapter was undertaken in order to characterize the potential 
lysin genes from phage CP220 and determine if they were conserved in other 
phages. In addition a transposase encoding gene and several structural genes 
were investigated together with selected genes from phage CPtiO. Potential 
lysin genes were amplified from CP220 and the other phage, and their 
sequences compared. These and' other genes were used to examine the 
relationships between the different phages with respect to the PCR 
amplification products from these genes. 
The absence of DNA amplification does not always indicate the absence of the 
gene, where situations such assequence divergence or DNA modification can 
prevent PCR amplification (Timms et al., 2010). 
Primers designed from CP220 genes were then used to amplify DNA prepared 
from the phages CPX, CP8, CP20, CP30 and CP34. Comparison of the PCR 
amplicons from these phages with CP220 showed that CP20 is more closely 
related to CP220 than any of the other phages selected. The same phages were 
also compared to phage CPt 10, which is similar to CP220 and revealed that for 
the selected genes CPX appeared to be more closely related to CP220 and 
CP20 than the other phage tested. This was surprising because CPX is a group 
III phage and CP220, CPtl 0 and CP20 belong to group II. This is intriguing 
when considering that the reason for characterizing CPX was because of its 
intimate relationship with CP220. 
136 
Chapter 4 
Genes that could have lytic activities (CPT 0075 and 120) were found in all the 
phages tested. Further studies involving expression and characterization of the 
protein products of these genes could potentially lead to the development of 
novel antimicrobial products. Equally, the product of the transposase gene 
could potentially result in development of a useful biotechnological tool, and 
provides evidence for the widespread presence of the transposase. The 
sequences of the structural genes allow different phages to be compared. The 
PCR primers designed for this study will be useful in further studies to monitor 
the presence of phage, for example in intervention trials. They may allow 
simple discrimination between different phages used together in a phage 
cocktail, in order to follow the intervention process through the chicken 
intestine. 
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CPX BACTERIOPHAGE 
Chapter 5 
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5.1 Introduction 
Genome sequencing is an important step towards understanding how phages 
function at the molecular level. Three T-even phages (T2, T4 and T6) 
discovered between 1920 and 1960 have been used as model systems to 
identify genes and genetic mechanisms of phage biology, which have provided 
insights into fundamental mechanisms applicable in higher organisms (Cairns 
et al., 1992). Among these phages, T2 was the first to be isolated and used in 
many studies until the mid 50's when T4 became preeminent. T4 was notably 
used in two studies by Benzer (1962) exploring the structure of two phage 
genes and in a collaborative study to collect and characterise T4 conditional 
lethal mutants (Epstein et al., 1963; Edgar 2004). The outcome of their studies 
led to T4 becoming the reference phage or prototype for its relatives (Petrov et 
al., 2010). Recently, examples of Campylobacter phage genome sequences that 
potentially fall within the T4-like group have been reported, these include 
phages: CP220, CptlO (Timms et al., 2010), CP81 (Hammerl et al., 2011), 
NCTC12673 (Kropinski et al., 2011), vB_CcoM-IBB_35 (Carvalho et al., 
2012) and CP21 (Hammerl et aI., 2012). 
The work in this chapter describes the purification, characterization and 
complete genome sequence of the phage known as CPX. This particular phage 
was of interest because it was recovered as a co-isolate of phage CP220 that 
was sequenced by Timms et af. (2010) from poultry carcass based on the 
observation that PFGE of phage genomic DNA preparations produced two 
bands, indicating the presence of a phage DNA of 220 kb with that of a 140 kb 
DNA despite plaque purification. The larger genome corresponds to the class II 
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phage CP220 and the smaller with the more frequently occurring class III 
phage of 140 kb. Whilst it was difficult to separate the co-existing phages, 
CPX was eventually separated from CP220 by picking multiple individual 
plaques and checking each for a single 140 kb or 220 kb genome by PFGE. 
The nucleotide sequence of phage CP220 genome was recently 
reported (Timms et al., 2010). A study of the sequence and host range of CPX 
was then undertaken to determine if it had any relationship to CP220 in order 
to investigate if there was any significance in their co-existence and also to 
generate more sequence data to increase our knowledge of Campylobacter 
phages. 
5.2 Results 
5.2.1 Transmission Electron l\1icroscopy of Bacteriophage CPX 
The phage CPX was propagated in the laboratory as described in methods 
section 2.6.3 and treated with ammonium acetate as described in methods 
section 2.6.5 before examination by electron microscopy. The phage 
preparation was titrated (see methods section 2.6.4) and found to contain 108 
PFU. 
Sample preparation and electron microscopy was performed by Dr. S. Hyman 
at Leicester University. Briefly, phage particles were absorbed onto a glow-
discharged carbon-coated Pioloform grids and fixed for 2 min by exposure to 
vapour from a 25 % v/v glutaraldehyde solution. After washing, the grids were 
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negatively stained using 0.5 % w/v uranyl acetate, followed by their 
examination using a JEOL 100CX transmission electron microscope operating 
at an acceleration voltage of80 kY. 
Examination of electron micrographs (Figure 5.1) revealed that CPX was a 
typical Campylobacter phage of the family Myoviridae with an icosahedral 
head measuring 101 nm and tail measuring 105 nm. 
'-_-----'1Of)rm - :J 
Figure 5.1 Transmission electron micrographs of CPX bacteriopbage 
5.2.2 CPX Purification Using Caesium Chloride Density 
Gradient Centrifugation 
The CPX phage was propagated on lawns of C. jejuni PT14, concentrated and 
titrated as described in sections 2.6.3 and 2.6.4 to produce a phage preparation 
containing lO" PFU rnr' . This phage preparation was mixed with cae ium 
chloride (CsCl) to a fmal concentration of 0.75 g mr' CsCl, loaded into 3.5 ml 
polyallomer tubes and centrifuged at 264,000 g, at 4 °C, for 24 h using a TLA 
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100.3 rotor in Beckman TL-I 00 Ultracentrifuge (see methods section 2.6.13). 
Following ultracentrifugation of CPX to form a caesium chloride density 
gradient two blue bands were clearly visible (Figure 5.2). Each band was 
carefully collected (200 I.d) for further analysis following dialysis. 
Excess caesium chloride wa removed by centrifugation usmg a Microcon 
30,000 Da molecular weight cut off filter (Millipore, Watford, UK) at 6,500 g 
for 10 minutes in a Biofuge Pico bench-top centrifuge (Kendro Laboratory 
Products). The retentate was washed twice with 100 III SM buffer (see section 
2.3.1), before the column was inverted and CPX recovered in 100 III SM buffer 
by centrifugation under the same conditions and stored at 4 °C until required. 
Upper band 
Lower band 
Figure 5.2 CPX Purification 
Image shows the two blue bands (upper and lower) resulting from CPX 
sedimentation using isopycnic caesium chloride gradient centrifugation. 
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5.2.3 Determination of Detection Threshold of Campylobacter 
Genomic DNA in CPX DNA Preparations 
Genomic DNA was prepared from the purified CPX phage (see methods 
section 2.6.8). To increase the concentration of the purified DNA and 
overcome problems associated with DNA modification, the samples were 
amplified using a REPLI-g mini prep kit (Qiagen) as described in the methods 
section 2.6.9. The quantities of DNA obtained from the phage recovered from 
the lower and upper bands after CsCI density gradient centrifugation were 
estimated to be 48.6 and 33.9 ng ~ r l , , respectively, and following genome 
amplification using a REPLI-g mini prep kit (Qiagen), were found to be 385.8 
and 391.4 ng ~ r l , , respectively. 
To determine the purity of the phage preparation, the level of Campylobacter 
DNA contaminating CPX was determined. Campylobacter phage DNA 
samples were amplified in parallel with a number of Campylobacter DNA 
preparations of known concentration using either Campylobacter phage CPt 1 0 
primers (CPtlO_009l) (Table 5.1) or primers used in previous studies to bind 
within Campylobacter genomic DNA. The primer sequences used for the 
detection of Campylobacter DNA are listed in Table 5.1. Primers AB were 
used to amplify part of a Campylobacter-specific oxidoreductase subunit gene, 
and therefore specific detection of C. jejuni (Nogva et aI., 2000). The U 
primers U515 (Moyer et al., 1998) and U1492 (Menghistu et aI., 2011) are 
universal primers used for the detection of 16s rDNA (Moyer et al., 1998). 
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Table 5.1 Primer sequences of Camplylobacter selected genes 
Name Primer Sequence Reference 
CPtJO_ F: 5'- GGC ACT ACT CT A GCC GTT GC -3' Timms et al., 2010 
0091 R: 5'- CAA AA T TTC CAC CAC CIT GC -3' 
AB F: 5'-CTG AAT TTG ATA CCT TAA GTG CAG C-3' Nogva et al., 2000 
R: 5'-AGG CAC GCC T AA ACC TAT AGC T -3' 
U515 F: 5'-GTG YCA GCM GCC GCG GT A A-3' Moyer et al., 1998 
Ul492 R: 5'-GGT TAC CIT GIT ACG ACT T -3' Mcnghistu et aI., 2011 
The DNA samples were PCR amplified (see methods section 2.6.10) in TC-
312 thermal cycler (Scientific Laboratory Supplies) using the following cycles: 
I C)de 96'C 3 mil 
35C)Cks 96'C 1 min 
61'C 1 min 
72'C I mil 
1 c;cle 72'C 7 mil 
The amplified DNA products were analyzed by electrophoresis on a 0.8 % 
agarose gel (see methods section 2.6.11) and the image recorded with a 
ChemiDoc XRS Imager using the Quantity one program (Bio-Rad). 
No products were obtained when the pure CPX DNA from either of the two 
bands from the CsCl density gradient were PCR amplified with Campylobacter 
AB Primers. However, PCR products were obtained when they were PCR 
amplified using phage primers (CPtl0 0091) and with the Universal primers. 
The detection threshold of Campylobacter DNA in both the purified phage 
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samples was less than 11 pg Ilrl, that corresponds to a contamination level 
<0.003 % (Figure 5.3). This low level of contamination of the phage DNA 
preparation with Campylobacter DNA was considered acceptable for sequence 
determinat ion. 
Following confirmation of the purity of the phage DNA preparation, a 5 Jlg 
sample of the DNA prepared from the lower band was used to determine the 
DNA sequence using Roche 454 pyrosequencing technology performed by 
DeepSeq in the School of Biomedical Sciences at the University of 
Nottingham. 
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Figure 5.3 Detection of Campylobacter DNA threshold level in pure CPX 
The image represents a 0.8 % agarose gel of pure CPX and Campy/abaeter 
DNA of different known concentrations amplified with Campylabaeter specific 
and 16 rDNA primers (AB and U respectively) and phage CPt10 0091 primers. 
Lanes 1-7; Campy/abaeter DNA of known concentration (109.84, 10.984, 
1.098 ng /lr', 110, 11, 1 and 0.1 pg J.lr') amplified with AB primers. Lane 8; 1 
kb marker (Promega). Lanes 9 to 14 representsphage CPX DNAs of lower and 
upper bands amplified with AB primers (lanes 9,10), CPtl0 primers (lanes 11, 
12) and U primers (lanes 13, 14). Lane IS; 100 bp marker (Promega). Lanes 
16-22; Campylabaeter DNA of known concentration (109.84, 10.984, 1.098 ng 
J.lr', 110, 11, 1 and 0.1 pg J.lr') amplified with U primers. 
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5.2.4 The Effect of CPX Phage Infection on Campylobacter 
Growth 
To examine the replication of phage CPX on C.jejuni PTI4, viable counts and 
phage titres were monitored over a 10 h period using an approximate 
multiplicity of infection (MOl) of I, with a starting inoculation of 107 CFU 
mrl for Campylobacter PTI4 and 107 PFU mr) for CPX (procedures described 
in methods section 2.7). 
The growth ofC.jejuni PTI4 infected with CPX phage compared with a non-
infected culture is shown in Figure 5.4. There was a sharp decrease of 3 loglO 
CFU mr) in the Campylobacter viable count 1 h after infection with CPX. The 
cell numbers remained low until the fifth hour, after which there was a steady 
increase in bacterial cell numbers until the last sampling point. CPX phage 
numbers increased over the period until the seventh hour when there was a 
small decrease in the numbers of phage followed by a period when numbers 
remained relatively stable until the tenth hour. 
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Figure 5.4 Effect of CPX bacteriophage on C. jejllfli PT14 
Graph shows the growth curve for uninfected Campy/abaeter PT 14 control, the 
effect of an MOl 1 of CPX infection of PTl4 recorded as the viable bacterial 
count (CFU mr') and the phage titer ofCPX (PFU mr') 
5.2.5 CPX DNA Sequences Analysis 
The sequence of the amplified CPX DNA was determined and assembled using 
the DeepSeq facility at the University of Nottingham. Genomic DNA was 
fragmented to 500 bp using a Covaris S2 sonicator (Covaris Inc. , USA) and 
libraries constructed using a NEBNext DNA Sample Prep Master Mix Set 2 
(New England Biolabs Cat. No. E6070S). The libraries were subsequently 
sequenced using the Roche 454 GS FLX system and a sembled using the 
integral program Newbler (Roche Diagnostics, USA) . 
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The sequenced phage CPX from the sonicated DNA fragments (36,269 reads 
of average read length 320 bp), resulted in the generation of a single contig of 
132,662 bp with minimum redundancy of 44 calls per nucleotide. The 
complete genome sequence of CPX was submitted to the NCBI Gene bank 
database where it appears under the accession number JN132397. 
5.2.5.1 Sequence Analysis 
Statistical analysis of CPX genome was performed usmg CLC Genomics 
Workbench 4. The CPX genome was revealed to be a double stranded DNA of 
132,662 bp in length, which is composed of 40 % thymine, 34 % adenine, 15 
% cytosine and 11 % Guanine. The nucleotide distribution is listed in Table 
5.2. The G+C content of CPX is 26.04 % compared to 30.6 % for the host 
genome of C. jejuni (NCTC 11168; Parkhill et al., 2000). 
Table 5.2 CPX genome nucleotides distribution 
Atom Count Frequency 
Adenine (A) 45,138 0.340 
Cytosine (C) 19,979 0.151 
Guanine (G) 14,570 0.110 
Thymine (T) 52,975 0.399 
C+G 34,549 0.260 
A+T 98,113 0.740 
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5.2.5.2 CPX Annotation 
The CPX genome was annotated using the Artemis program (Rutherford et al., 
2000), with the help from Dr. Andy Timms (University of Nottingham, School 
of Biosciences) and was found to contain 149 predicted protein coding 
sequences (CDS) with the majority of them lying on one DNA strand 
(126/149). All the open reading frames (ORFs) used ATG as a start codon and 
used TAA, TGA and TAG as stop codons at the following respective 
frequencies 67.11 %, 14.09 % and 18.12 %. Most of the CDSs (77/149) were 
identified as hypothetical phage proteins with no assigned function. However, 
many were similar to Campylobacter phage NCTC 12673 (Kropinski et a/., 
2011), and a few similar to CPt 1 0 (Timms et al., 2010). 
The genome was found to contain five transfer RNA (tRNA) genes with 
anticodons for the amino acids; tyrosine (Tyr, GTA), arginine (Arg, TCT), 
aspargine (Asn, OTT), leucine (Leu, TAA) and methionine (Met, CAT). 
A search for insertion sequences was performed using IS Finder (Siguier et al., 
2006). This phage does not possess intact insertion sequences, although there 
are some very short sequences with similarities to known insertion sequences 
from different microorganisms that CPX would be unlikely to infect. However, 
a short sequence match to IS607 was observed, which originates from 
Campylobacter fetus subsp venerealis. A BLAST search showed that similarity 
to a group of unrelated genes that have homing endonuclease-like function 
(Hef) from Campylobacter phage NCTC12673 was found in seven CDS's. In 
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addition to that, the CPX genome exhibited two repeat regions with a number 
of repeat units within. 
Some of the identified genes were similar to structural and enzymatic genes 
from T4 phage (Table 5.3). The rest of the genome contained genes identified 
to have possible functions such as packaging enzymes, reductases, 
decarboxylases, helicases, repair and recombination proteins, methylases, 
kinases, peptidases, topoisomerases or dehydrogenases. 
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Table 5.3 Putative structural and enzymatic genes similar to T4 phage encoded 
by bacteriophage CPX 
Location Gene Possible function 
C* 1454 ... 2191 gp2 DNA end protector protein 
C* 7987 ... 9897 gpl8 Tail sheath protein 
C* 11373 ... 12695 gp30 DNA ligase 
C* 19079 ... 20476 gp23 Major capsid protein 
C* 21264 ... 21893 gp21 Pro head core scaffold and protease 
C* 22058 ... 23764 gp20 Portal vertex protein 
24513 ... 25244 gp13 Neck protein 
26852 ... 27583 gp19 Tail tube protein III 
C* 843284 .. .45947 gp43 DNA polymerase 
C* 48558 .. .49502 gp61 DNA primase subunit 
50491 ... 50946 gp3 Tail completion and sheath stabilizer protein 
C* 56056 ... 57660 gp46 Reco mbination endonuclease 
C* 58123 ... 59118 gp47 Recombination endonuclease 
C* 59106 ... 59975 gp55 Sigma factor for T4late transcription 
C* 60067 ... 61029 gp23 Major head protein 
61039 ... 61686 gp14 Head completion protein 
63558 ... 64589 gp15 Tail sheath stabilizer and completion protein 
C* 77454 ... 77897 gp4 Head completion protein 
C* 90232 ... 9116 gp44 Sliding clamp loader subunit 
* C used to indicate that this gene is located on the complementary strand 
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The annotated genome showed some significant differences in 11 regions over 
the whole genome compared to available Campylobacter phage genome 
sequences. There was a need to confirm DNA sequences to check that in the 
gaps between the identified CDS regions there were no sequencing errors, and 
to check that in regions where two or more smaller CDS regions were 
identified compared to existing group III phage DNA sequences that there were 
no unintended frame shifts. To confirm the DNA sequences, PCR was carried 
out to amplify the DNA from these regions as performed earlier (see sections 
2.6.10 and 5.2.3) using primers designed for these regions (Table 5.4). The 
PCR products were analysed by gel electrophoresis (Figure 5.5), purified (see 
section 2.6.13) and the products sequenced and analyzed using BioEdit. The 
newly obtained sequences were identical to the sequenced genome. Thus no 
changes were made to that determined from the 454 contig assembly. The full 
annotation ofCPX is listed in Appendix 3. 
153 
Chapter 5 
Table 5.4 Primer sequences ofCPX genome irregular regions 
Region Position Primer Sequence 
number 
1 >2034 .. 2979 F: 5'-TTGCCCTGAT ACCATTGTTG-3' 
R: 5'-CCTTGTGACA T ATCAGAA T AA TCACC-3' 
2 >40602 .. 42087 F: 5'-CCTAAAGATCAAACTGCACTT A TT AAA-3' 
R: 5'-ACGCTTGCTCGTT A TCA TCA-3' 
3 >50160 .. 51168 F: 5'-CCT AAAGATCAAACTGCACTT A TT AAA-3' 
R: 5'-GAGCAAAACACAGTTGTATCAGC-3' 
4 >53902 .. 55371 F: 5'-GCAAAA TGGGGTGTTGGT AG-3' 
R: 5'-TGATTGCTCTTGTGTTCCATCT -3' 
5 >67891..69594 F: 5'-AGGCTTACCCCCAAAAGAAA-3' 
R: 5'-AAAAACTTTTCCTGTTGA TTTTCA-3' 
6 >73966 .. 75021 F: 5'-AGACGGTAAAATTGATTATGAAAAC-3' 
R: 5'-AATAGCCTTAAAGTTGGCTTAAAA-3' 
7 >76525 .. 77940 F: 5'-GCTGGTGTTCTT AAA TGGGCT A-3' 
R: 5'-TTGA TTCTTTT AACTTCTCTTGTTGC-3' 
8 >85576 .. 87972 F: 5'-CACATTTTTGAACATTCATGG-3' 
R: 5'-CCATTGTACCAACACAACT ACCA-3' 
9 >91393 .. 92808 F: 5'-AA TGGGCTCTGCTTGTT ACG-3' 
R: 5'-CACACAAT AAAATGAAGTCACCTCT -3' 
10 >127105 . .128079 F: 5'-GGCTCAAAGAACTT AA TCAAACAA-3' 
R: 5'-GCTTCAGATGT AAGAACTTTTAATGG-3' 
11 >128078 .. 128908 F: 5'-TCAAAT ACA TTT ACAGGTGA TCAAA-3' 
R: TCCGCAGATTCGTATGTATTTT-3' 
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Figure 5.5 CPX pure PCR products 
To confIrm the CPX genome sequence in region showing irregularities . DNA 
amplification was carried out using primer designed for them. PCR products 
were purified and examined using 0.8 % agarose gel electrophoresis. Lanes 
representing the 11 irregular region are as follows ; 
Lane 1; 1 kb marker (Promega), Lanes 2-12' purified PCR products of the 
irregular regions 1 to 11 
5.2.6 Mass Spectrometry (MS) of CPX Phage 
The purified CPX phage particles were TCA precipitated (see methods section 
2.12) before identification of the capsid protein equences using Ma s 
Spectrometry (Q-TOF MSIMS described in section 2.9) . 
The protein profile of the phage CPX particles is shown in Figure 5.6 . The 
major band was excised from the gel and cleaved with trypsin before 
identification of the peptides based on the rna s prediction of the translated 
CPX DNA sequence and de novo sequencing using mas spectrometry (Q-TOF 
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MSIMS) . The de novo peptide sequences obtained are listed in Table 5.5 . A 
BLASTP search of these peptide sequences within the NCBInr database 
showed that these peptide sequences produced significant matches with a 
hypothetical protein from Campylobaeter phage CP81 or gp23 major capsid 
protein from Campy/abaeter phage NCTC12673 . An example of the search 
output for one peptide (867) is shown in Figure 5.7. The sequences from phage 
CP81 and NCTC 12673 were aligned together with the identified peptides to 
show their relative positions (Figure 5.8). 
78kDa 
55kDa 
rkDa 
34 kDa 
Figure 5.6 Denaturing protein gel electrophoresis of TCA precipated CPX 
To identify the proteins in CPX particles , the phage was treated with TCA and 
examined using 10-20 % Novex Tricine gel. Lanes representing the treated 
samples are as follows ; 
Lanes 1-2; Purified CPX phage treated with TCA, lane 3; See Blue Plus Pre-
stained standard (Invitrogen) 
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Table 5.5 De novo Peptide Sequences 
Peptide 866 NDFN YTGTPlEVSFK it is not possible t o determine the order of the first 2 
residues- it could be NO or ON 
Peptide 700 QAGTDDWNVll R 
Peptide 867 lESNSTGSVAlGDEIDK it is not possible to determine the order of the fi rst 2 
residues- it could be LE or EL 
Peptide 878 ElADIlSAEVALEIOR 
Peptide 1021 VATVCTDFDVNSADGR parti al s ~ u e n c e e obtained for this peptide 
Peptide 867 .!&SUSTGSVAIGDEIDK 
~ I C B Z 4 ~ 3 ~ ~ _ 1 1 1 h y p o ~ ~ e t 1 1 ~ 1 1 prote in (Campyloba cte r pha qe CP61) 
Lenq:n.=4E5 
Score = 54 _1 b1ts ( 1 ~ ~ ) , , Expe ct = 2e-06 
I I e n t i t t e ~ ~ = 17/17 (100' 1 , P P ~ 1 t 1 1 e ~ ~ = 17 / 17 (100' ) , Ga p : ~ ~ 0 / 1 ~ ~ (0' ) 
Oue ry 1 LESN37GSVAlGOEIDK 1 i 
LESIOSrGSVAlGDEIOR 
Sbjct 1107 LES1'STGSVAIGOEIOK 183 
ref lY? 0 0 4 1 £ l E ~ i _ l l l ~ ~ 9 P ~ 3 3 major c ap s id proee1A (Campyloba ete r pha q e N c r c l ~ E ~ ~ ) )
g'b 1AEA.;E41S_1 1 ~ ~ 9 P ~ 3 3 ..... jor c a p s 1d prote :>.n (Campyloba ete r phag'e 1 ; C ' I ' C 1 ~ E 7 7 J J
Lenqth= 4E5 
GENE 10: lOBSEB91 N C T C 1 ~ E 7 7 _ 9 P 0 7 4 4 I 9 9 ~ a a maJor cap : 1d prote :>.n 
[ C a m p y l a a ~ e t t.. r phaq e N C T C 1 ~ E 7 3 ) )
Sc ore = 54_1 b:>.t : ( lZO ) , Expect = ~ e e o e e
Ident1t1e: = 1 1 / 1 ~ ~ (100' ) , P P : 1 t 1 1 e : : = 17 / 17 (100t l , Ga p : 
Que ry 1 LESIOSrGSVA.IG01:IDK 17 
L1:SNSTGSVAlGDEIDK 
Sbje t lE LESNSTGSVAIGO£UlR 16a 
Figure 5.7 NCBInr BLASTP Output 
0/17 [0'1 
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Figure S.S Sequence alignment of identified peptides against phage CPS1 
and NCTC12673 GP23 proteins 
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5.2.7 Comparison of CPX Genome to Other Campylobacter 
Bacteriophage Genomes 
CPX was compared to other available sequenced Campylobacter phages (Table 
5.6), which included; CP220, CPt10 (Timms et al., 2010), CP81 (Hammerl et 
al., 2011), NCTC 12673 (Kropinski et al., 2011) and CP21 (Hammerl et al., 
2012). CPX belongs to the same class (III) as CP81 and NCTC 12673, whereas 
CP220, CPt I 0 and CP21 belong to class II. CPX has fewer predicted CDS 
genes compared to the published phage sequences. Two DNA repeat regions 
were identified in CPX compared with eight in NCTC 12673,45 in CPt 10, 82 
in CP220, four in CP21 and none in CP81. CPX and CP81 contain five tRNAs. 
However, NCTC 12673 has three tRNAs, CP220 and CPtlO have two each and 
CP21 has one. All the phages are AT rich with similar GC content. Phage 
vB_CcoM-IBB_35 (Carvalho et al., 2012) is another available phage that 
belongs to group II but was not included in the analysis as it consists of five 
contigs which are not assembled. 
A comparison of CPX with other phages performed using Mauve genome 
alignment program (Darling et al., 2010) showed the greatest similarity of CPX 
phage to phage CP81 followed by phage NCTC 12673 (Figure 5.9), which like 
CPX are class III phages. CPX phage is different from CP220, CPtIO (Figure 
5.10) and CP21 (Figure 2.11) phages that are class II. 
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Table 5.6 Comparison of basic parameters from published phage genomes 
Phage Genome size Genome Number 
(bp) %G+C of CDS 
content 
Class II phages 
CP220 177 500 27.4 194 
CPtlO 175700 27.3 201 
vB _ CcoM-IBB _35 172 065 27.0 210 
CP2t 182833 27.2 259 
Class III phages 
CPX 132662 26.04 149 
CP8t 132500 26.1 188 
NCTC 12673 135000 26.2 172 
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Figure 5.9 Comparison of CPX to CP81 and NCTC 12673 
The graphs represents genome sequences comparison between A; CPX (TOP) and CP81 (Bottom), B; CPX (TOP) and NCTC 12673 
(Bottom). In each comparison block of the same colour between two similar regions within the genomes are connected by lines. The 
colours within these blocks show the strength of homology whereas the white regions are not aligned or might be specific to particular 
phage. Blocks above centre lines lies in the same orientation and the blocks below it lies in the opposite orientation. 
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Figure 5.10 Comparison of CPX to CP220 and CPtlO 
The graphs represents genome sequences comparison between A; CPX (TOP) and CP220 (Bottom), B; CPX (TOP) and CPtlO 
(Bottom). In each comparison block of the same colour between two simi lar regions within the genomes are connected by lines. 
The colours within these blocks show the strength of homology whereas the white regions are not aligned or might be specific to 
particular phage. Blocks above centre lines lies in the same orientation and the blocks below it lies in the opposite orientation. 
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Figure 5.11 Comparison of CPX to CP21 
The graph represents genome sequences comparison between CPX (TOP) and CP21 (Bottom). The blocks of the same colour 
between two similar regions within the genomes are connected by lines. The colours within these blocks show the strength of 
homology whereas the white regions are not aligned or might be specific to particular phage. Blocks above centre lines lies in 
the same orientation and the blocks below it lies in the opposite orientation. 
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5.3 Discussion 
The main purpose of the work described in this chapter was to obtain and study 
the sequence ofCPX to determine if it had any relationship to CP220 in order 
to investigate if there was any significance in their co-isolation, and to generate 
more sequence data to increase our knowledge of Campylobacter phage. 
As no studies of this phage had been previously carried out, the growth 
characteristics ofCPX phage were studied and it was found to exhibit a typical 
phage growth curve when infecting its host bacteria, C. jejllni PTl4 
(Loc Carrillo et al., 2005). Cairns et al. (2009) found that the increase in phage 
numbers could be seen only after Campylobacter had reached 7 log 10 CFU mr) 
(the phage proliferation threshold). Based on this finding and to study the 
effect of CPX on C. jejllni PT14 the initial concentration of 7 10glO CFU mr) 
was chosen with a multiplicity of infection (MOl) of 1. 
Campylobacter phages are divided into three groups based on their genome 
size (Sails et al., 1998). The first Campylobacter phages to be sequenced, 
CP220 and CPt10, belonged to group II (Timms et al., 2010). Sequences of 
phages that belong to group III have only recently been reported, and include 
CP81 (Hammer! et a/., 2011), NCTC 12673 (Kropinski et al., 2011) and CPX 
described here. There is no sequenced phage that belongs to group I. The 
reason why so few Campylobacter phage sequences have been available until 
recently is due to the technical difficulties of sequencing genomes consisting of 
non-standard bases when sequencing relied on being able to clone fragments of 
phage DNA into E. coli vectors. Recent developments in sequencing, including 
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pyrosequencing technology, which involves sequencing by synthesis in the 
Roche 454 GS FLX system that was performed by DeepSeq at the University 
of Nottingham, enabled the sequence of CPX phage to be determined. Before 
sequencing could commence it was important to produce good quality DNA, 
free from Campylobacter DNA contamination. Caesium chloride density 
gradient centrifugation was employed to separate the phage particles from 
lysed cell debris and methods were developed employing PCR primers, to 
check that the residual Campylobacter DNA content was at a level low enough 
not to affect the elucidation of the phage sequence. These methods will be 
useful for determination and quality control of other phage sequences in the 
future. 
When the sequence became available it was analyzed in terms of its 
relationship to phages from other bacteria and specifically to Campylobacter 
phage CP220 that was its co-isolate. There were no regions of extended 
nucleotide homology between the CP220 and CPX genomes, implying they are 
not derivatives of each other. The relationship between these phages, if any, 
could have a functional rather than evolutionary basis. Genomes of different 
phages have been shown to possess different numbers of tRNAs. The CPX 
genome exhibited five tRNAs similar to phage CP8I (Hammerl et al., 20 II), 
whereas CP220 and CPtlO (Timms et al., 2010) have two tRNAs and NCTC 
12673 has three tRNAs (Kropinski et al., 2011). For comparison the prototype 
E. coli phage T4 genome contains eight tRNAs (Miller et al., 2003). 
165 
Chapter 5 
Like phages CP220, CPt 1 0 (Timms et 01., 20 I 0), CP81 (Hammerl et at., 2011), 
NCTC 12673 (Kropinski et at., 2011) and indeed T4 (Miller et at., 2003), CPX 
is A+T rich, which might be due to the preference for A or U in the third 
position ofthe codons (Timms et at., 2010). 
In relation to T4-like phages that have genomic size ranges between 164 and 
255 kb, CP220 (177.5 kb) and CPtl0 (175.7 kb) can be classified as T4 related 
phages, whereas CP81 (132.5 KB) NCTC 12673 (135.0 KB) and CPX (132.6 
Kb) are not so similar since their molecular size is less than the smallest 
characterized T4 genome, even though they have some genes in common with 
T4 related phages (Hammerl et at., 2011). 
A large proportion of the putative CDSs (78/149) showed no significant 
matches to available sequences in data bases. This is simi lar to CP220 and 
CPt! 0 where 85 out of 194 and 95 out of 201 open reading frames did not 
show any similarities (Timms et 01., 20 I 0). 
Homing endonuclease encoding genes (Hef) have been identified in 
Campylobacter phages (Timms et 01., 2010). Of the group III phage, CPX has 
seven Hefs compared with NCTCI2673 that has twelve (Kropinski et al., 
201l), whereas CP81 has eight (Hammerl et al., 2011). Homing endonucleases 
are essentially selfish genetic elements that cleave chromosomes that do not 
contain them, and then get copied across to the broken chromosome as a 
byproduct of the repair process. In this way they can disseminate themselves 
and can instigate horizontal gene transfer (Belfort and Roberts 1997). 
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One reason why the genomes ofCP220 and CPtlO are larger than those of the 
group III phages is probably because they include proteins that are not encoded 
in CP81 (Hammerl et al., 2011), NCTCI2673 (Kropinski et al., 2011) or CPX. 
These include transposases, metabolic enzymes and notably S-
adenosylmethionine (SAM) domain proteins. 
The reason for the co-existence of CPX with CP220 remains unclear. The two 
phages did not appear to share significant sequence homology indicative of 
exchange of genetic material due to their close environmental proximity, 
although like many phages they do share genes with similar functions. It is 
likely that both phages have evolved separately to successfully exploit the 
same host and are able co-exist without competing with each other for 
resources, making it difficult to separate them using current phage isolation 
techniques. The efficiency of CPX in reducing Camplylobacter numbers in 
vitro together with the novel genome sequence that distinguishes it from 
CP220, makes this phage a unique and a promising agent for phage therapy, 
where it might be used in a cocktail of several phages to increase the possibility 
of reducing the viability of a wide range of Campylobacter hosts. 
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CHAPTER SIX 
GENE CLONING AND PROTEIN 
EXPRESSION FROM BACTERIOPHAGE 
CP220 
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6.1 Introduction 
The bacteriophage CP220 genome sequence (Timms et al., 2010) provided 
a resource to search databases for putative protein products that catalyse 
reactions with bacterial cell wall components with the potential to lyse 
bacterial cells. Two reading frames were identified encoded by CPT 0075 and 
CPT 120. CPT 0075 encodes a PAAR (perfect amino acid repeat) containing 
protein with 48 % identity to phospholipase Al from Agrobacterium vilis S4 
and Dickeya dadantii. This PAAR motif can be found either in a family of 
membrane proteins in pairs or in another family of hypothetical proteins as 
triplets of tandem repeats comprising the entire length. CPT 120 showed 42 % 
identity to a murein-degrading enzyme from Filifactor alocis A TCC 35896 
(annotated as soluble lytic transglycosylase or murein hydrolase B). This 
enzyme has bacteriolytic activity as it catalyses the cleavage of glucosidic 
bonds between N-acetyl muramic acid and N-acetylglucosamine residues in 
cell wall peptidoglycans. 
Gene CPT 0075 is 293 bp in size and encodes a protein with a predicted 
molecular weight of 9.5 kDa, whereas gene CPT 120 is 674 bp in size and 
encodes a protein with a predicted molecular weight of 26.3 kDa. In order to 
assess if these predicted protein products have lytic functions, the 
corresponding reading frames need to be expressed and the resulting proteins 
analysed. 
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To produce sufficient amounts of such proteins to enable their functions to be 
characterised, they must be expressed in a suitable host using an expression 
vector that is host compatible, contains a tightly controlled inducible promoter, 
a sequence that terminates the transcription and a ribosomal binding site. 
Different expression systems are available each with advantages and 
disadvantages. The widely used E. coli expression system pET was selected for 
this study. Transcription is directed from a T7 promoter present on the 
expression vector that is bound by T7 RNA polymerase expressed from the 
E. coli host chromosome under control of the lac promoter. The design of this 
system is such that the only target of the T7 polymerase is the gene to be 
expressed, and that any T7 polymerase expressed before induction is inhibited 
by the presence of T7 lysozyme (pLysE or pLysS) located and expressed from 
a separate plasmid. In this way the pET system enables the control of both the 
timing and the quantity of the protein to be expressed. 
To accomplish the aim of expressing the target genes from CP220, primers 
were designed to amplify the CPT 0075 and CPT 120 reading frames with the 
addition of specific restriction sites to be incorporated at the ends of the PCR 
products (NdeIlBamHI) to allow their sub cloning into the expression vector. 
The CP220 genes were PCR amplified before cloning and sequencing from the 
plasmid pCR2.1-TOPO using the non-expression host E. coli Top I 0 
chemically competent cells. Once characterised, the DNA fragments were 
subcloned from pCR2.l-TOPO into the pET expression plasmids before 
transforming these in to a number of E. coli expression hosts including BL21 
(DE3) pLysS, BL21 (DE3) pLysE and Rosetta 2 (DE3) pLysS. 
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6.2 Results 
6.2.1 Cloning of CP220 Potential Lysin Genes 
The reading frames of CP220 potential lysins CPT 0075 and CPT 120 were 
PCR amplified as described in methods section 2.6.9 and cloned into the 
plasmid vector pCR2.1-TOPO and transformed into E. coli TOP 10 chemically 
competent cells and plated on LB agar containing ampicillin (2.4.1) and the 
chromogenic substrate X-gal (see methods sections 2.8.2 and 2.8.3). Five white 
coloured ampicillin resistant colonies were selected from each of the 
transformation plates as prospective TOP 10 E. coli bearing plasmid pCR2.1-
TOPO in which the target PCR amplified DNAs were inserted within the 
cloning site and thereby disrupting the expression of lacZ. From these plasmid 
DNAs were prepared and digested using the restriction endonuclease EcoRI, 
sites for which flank the cloning site of plasmid pCR2.1-TOPO (see methods 
sections 2.8.4 and 2.8.5). The results of agarose gel electrophoresis of the 
digested plasmid DNAs are shown in Figures 6.1 and 6.2. From these, 4/5 
clones contained the DNA insert corresponding to CPT 0075 (Figure 6.1) and 
5/5 the DNA inserts for CPT 120 (Figure 6.2). The DNA sequences of two 
positive clones of each gene were determined through Eurofins MWG Operon 
and the sequences obtained analyzed using BioEdit. The sequences of CPT 
0075 and CPT 120 cloned in pCR 2.1-TOPO are listed in Appendix 4. 
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Figure 6.1 Plasmids digests of CP220 CPT 0075 clones in peR2.I-TOPO 
In order to check the presence ofthe correct insert in pCR2.1-TOPO, pia mid 
were prepared, digested with EcoRl and analyzed by 0.8 % agaro e get 
electrophoresis. Lanes representing these plasmids are a follows: 
Lanes 1-2; colony 1, lanes 3-4; colony 2, lanes 5-6; colony 3, lanes 7-8 · colony 
4, lanes 9-10; colony 5, lane 11; 1 kb marker 
* First lane of each sample was undige ted plasmid; the second lane wa 
digested with EcoRl 
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Figure 6.2 Plasmids digests of CP220 CPT 120 clones in pCR2.1-TOPO 
In order to check the presence ofthe correct insert in pCR2, I-TOPO, plasm ids 
were prepared, digested with EcoRI and analyzed by 0,8 % agarose gel 
electrophoresis, Lanes representing these plasmids are as follows: 
Lane 1; 1 kb marker, lanes 2-3 ; colony 1, lanes 4-5; colony 2, lanes 6-7; colony 
3, lanes 8-9; colony 4, lanes 10-11 ; colony 5 
* First lane of each sample was undigested plasmid; the second lane was 
digested with EcoRI 
6.2.2 Cloning of CPT 0075 and CPT 120 Genes in pET 3a 
The pCR2,I-TOPO plasmid vectors carrying CP220 genes CPT 0075 and CPT 
120 were subcloned into pET 3a, These plasmids were digested to release the 
inserts using NdeI and BamHI to get the right terminal sequences for their 
ligation in to similarly treated expression plasmid pET 3a (see methods section 
2,8,6.1), The digested plasmids (Figure 6,3) were run on 0,8 % low melting 
point agarose gels and purified using a gel extraction kit (see methods sections 
2,6,10 and 2,6,11), The DNA inserts were ligated into the vector using T4 
DNA ligase at a molar ratio of 3: 1 insertvector (see methods section 2,8 ,6.4) , 
The molar ratio was calculated using the following formula: [(100 ng vector * 
kb insert) / kb vector) * (3/1)] = A ng insert 
The reaction mixture used was: 
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Components CPT 0075 CPT 120 
CmcmIndim Vdunr Cmcentratioo Vdunr 
Vrocr (pET 3a) SOng 1.9 f.1I SOng 1.9 f.1I 
Jruut 9.8ng 5.9f.11 22ng 28f.11 
Ligase buffer (10 X) (Prom ega) IX 1.0f.1l IX 1.0 f.1I 
T4 DNA I i ~ ~ (Pnmcg;:I; IOU IJI'I) IU 1.01J1 IU 1.0 IJI 
Ntrlm'l: ice W<I1cr (Ql to 10.0 f.1I) 
- 021J1 - 3.3 IJI 
After incubation, the ligation mixture was transformed into E. coli TOPlO 
chemically competent cells (prepared as described in section 2.8.3). The 
plasmids were prepared from a number of clones to check for the insert 
presence in pET 3a. Figures 6.4 and 6.5 show respectively 4/8 positive clones 
for CPT 0075 (Figure 6.4) and 4/6 positive clones for CPT 120 (Figure 6.5). 
The positive plasmids from two of the clones were sequenced by Eurofins 
MWG Operon and analyzed using BioEdit. The sequences of CPT 0075 and 
CPT 120 in pET 3a are listed in Appendix 5. 
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Figure 6.3 Vectors and inserts digested with Ndel and BamHI 
Insert DNAs and plasmid vectors (pET) digested with NdeI and BamHI and 
electrophoresed on 0.8 % low melting point agarose gel. Lanes representing 
these fragments are as follows: 
Lane 1; pET 11a, lane 2; 1 kb marker, lane 3; CP220 CPT 120, lane 4; CP220 
CPT 0075, lane 5; pET 3a 
Figure 6.4 Restriction digest of CP220 CPT 0075 plasmid clones in pET 
3a 
In order to check the presence of the correct insert in pET 3a, plasmids were 
prepared, digested with NdeI and BamHI and analyzed by 0.8 % agarose gel 
electrophoresis. Lanes representing these plasmids are a follows: 
Lane 1; 1 kb marker, lanes 2-3; coLony 1, lanes 4-5; colony 2, lanes 6-7; coLony 
3, lanes 8-9; colony 4, lanes 10-11; colony 5, lanes 12-13; colony 6, lanes 14-
15; colony 7, lanes 16-17; colony 8 
* First lane of each sample was undigested plasmid DNA; the second lane was 
digested with NdeI and BamHI 
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Figure 6.5 Restriction digest of CP220 CPT 120 plasmid clones in pET 3a 
In oder to check the presence of the correct insert in pET 3a, pIa mid were 
prepared, digested with NdeI and BamHI and analyzed by 0.8 % agaro e gel 
electrophoresis. Lanes representing these pia mids are as follow: 
Lane I ; 1 kb marker, lanes 2-3 ; colony I, lanes 4-5 ; colony 2, lanes 6-7 ; colony 
3, lanes 8-9; colony 4, lanes 10-11 ; colony 5, lane 12-13 ' colony 6, lane 14-
15 ; colony 7, lanes 16-17; colony 8 
* First lane of each sample was undigested pia mid DNA; the second lane was 
digested with NdeI and BaniHI 
6.2.3 Expression of CPT 0075 and CPT 120 Proteins 
Expression plasmid DNAs carrying the gene encoding CPT 0075 and CPT 
120 were transformed into chemically competent E. coli expre ion ho t strain 
detailed in Table 6.1 to enable protein expression. The tran formation mixture 
were plated on LB agar plates containing ampicillin (see section 2.4.1) and 
chloroamphenicol (see section 2.4.2) to elect respectively for the pET and 
pLys plasmid. The plates were incubated at 37 °C for 24 h. The re ultant 
colonies were used for protein expre ion studies. Culture of the e 
transformants were induced with 0.1 mM IPTG (2 .3.8) for 4 h and total cell 
fractions were collected and examined a described in methods section 2.8.7. 
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Table 6.1 E. coli hosts 
Non Genotype Reason for Selection 
Expression 
Host 
TOPIO F- mcrA L1(mrr-hsdRMS-mcrBC) Standard host for 
chemically <l>80lacZL1M15 MacX74 recAl transformation 
competent cells araD139 L1(ara leu) 7697 galU 
galK rpsL (StrR) endAl nupG 
Expression Genotype Reason for Selection 
Hosts 
BL21 (DE3) F- ompT hsdSB(rB-, mB-) gal dcm Carries an IPTG-inducible T7 
pLysS 
(DE3) pLysS (CamR) RNA polymerase in a genetic 
background deficient in both 
Ion and ompT proteases. The 
pLys S plasmid carries the 
gene encoding T7 lysozyme, 
which can lower any 
background expression of the 
target genes without 
interfering with the 
expression level following 
IPTG induction. 
BL21 (DE3) F- ompT hsdSB(rB-, mB-) gal dcm As above but provides tighter 
(DE3) pLysE (CamR) control ofT7 RNA 
pLysE polymerase 
Rosetta 2 (DE3) F" ompT hsdSIl(rll· mil·) gal dcm (DE3) As above and is able to supply 
pLysS pLysSRARE2 (CamR) tRNAs for rare codons. 
The pET 3a expression plasmids were transformed into the E. coli expression 
hosts BL21 (DE3) pLysS and BL21 (DE3) pLysE. However, no protein 
expression was detected in either BL21 (DE3) pLysS or BL21 (DE3) pLysE by 
denaturing polyacrylamide gel electrophoresis (not shown) for clones carrying 
either CPT 0075 or CPT 120. A different E. coli expression host, Rosetta 2 
(DE3) pLysS was then chosen, as this host could supply tRNAs for rare 
codons. Whilst CPT 0075 did not yield any protein of the expected molecular 
mass 9.5 kDa, CPT 120 was expressed successfully producing a protein of26 
kDa (Figure 6.6) after induction with 0.1 mM IPTG. 
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Tricine (10-20 %) gels were run (see methods section 2.8.10) and stained for 
protein with colloidal Coomassie Blue. The additional protein band identified 
from the cultures expressing CPT 120 was excised before tryptic digestion and 
protein sequencing by mass spectrometry (Q-TOF) to confirm that it is the 
target (see methods section 2.9) . 
Figure 6.6 Protein expression of CP220 CPT 0075 and 120 
To examine the protein expression in pET 3a1Rosetta 2 (DE3) pLysS, total cell 
proteins from E. coli cultures harvested pre- and post-induction with 0.1 mM 
IPTG carrying either the CP220 target genes or .an empty vector control, were 
electrophoresed on 10-20 % Tricine gels. Lanes representing these samples are 
as follows: 
Lanes 1-2; CP220 CPT 120, lanes 3-4; CP220 CPT 0075 sample 1, lanes 5-6; 
CP220 CPT 0075 sample 2, lanes 7-8; negative control (pET 3a in Rosetta 
cells), lane 9; pre-stained See blue plus 2 protein marker 
* First lane of each sample is pre induction and the second lane is after 4 hours 
of induction with IPTG 
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6.2.4 CPT 0075 Cloning in pET lla 
CP220 gene CPT 0075 was not expressed in any of the three E. coli expression 
hosts tried carrying the T7 polymerase. T7 RNA polymerase can be expressed 
even in the absence of IPTG. If the target gene is toxic to E. coli, then its 
expression will be prevented. For this reason, pET Ila was selected as an 
alternative vector where the target gene can be cloned using the same cloning 
sites (NdeI and BamHI). This vector contains a T7 lac promoter, where the 
presence of lac operator is useful in blocking transcription of genes by 
preventing un induced T7 RNA polymerase expression. The plasmid carrying 
the CPT 0075 gene and pET Ila vector were digested with NdeI and BamBI 
(Figure 6.3) and ligated as described when pET 3a was the choice of vector 
(see sections 6.2.2 and 6.2.3) with the exception of the vector:insert ratio. The 
amount of vector and insert to be ligated was calculated and the following 
mixture was used: 
Components On:entratim Vmmr 
Vtrt:r (Jfllla) SOng 2 J ~ ~
hmt(CPTOO75) 8ng 3 . 0 ~ ~
Ligase buffer (10 X) (Promega) IX 1 . 0 ~ ~
T4 D N A J i ~ ~ {Ptunegfi; 10 V ~ ~ -I) IV 1 . 0 ~ ~
Ni.k:IaN: fire W<Itl:r (LV to 10.0 ~ ~ - 2 7 ~ ~
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The CPT 0075 gene was successfully cloned into pET Ila. The E. coli cultures 
resulting from the transformation of the plasmid into the expression hosts 
BL21 (DE3) pLysE and Rosetta 2 DE3 pLysS were examined for protein 
expression by denaturing polyacrylamide electrophoresis but did not yield any 
recombinant protein as determined by visualization on 10-20 % Novex Tricine 
gels (described in methods section 2.8.10). 
6.2.5 Mass Spectrometry 
Cellular protein of E. coli expressing CPT 120 from pET 3a in Rosetta 2(DE3) 
pLysS was loaded on a 10-20 % Novex Tricine gel and stained with colloidal 
coomassie blue (Figure 6.6) before excising the protein bands for identification 
of the tryptic fragments by Mass Spectrometry (described in methods section 
2.9). 
Tryptic digestion of the protein band recovered for CPT 120 expressed in pET 
3aIRosetta 2 (DE3) pLysS showed that this protein could be the required 
hypothetical phage protein from Campylobacter phage CP220 of predicted 
mass 26.3 kDa. The NCBI search output from the MASCOT database is shown 
in Figure 6.7. An additional search using the semi-trypsinised protein identified 
an additional peptide for the phage protein (Figure 6.8). The MS tryptic peptide 
spectrum is shown in Appendix 6. 
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Figure 6.7 NCBI search results of the expressed CP220 CPT 120 protein 
band tryptic digest 
q ~ 1 2 9 ~ a a e O S l l ~ $ $ : ~ E ~ S 5 5 S c o o e : 2 e ~ ~ ~ t c c e e : E ( 2 1 1 S ~ e r . c c $ : E ( 2 1 1
h y p o ~ ~ e ~ ~ c ~ l l phaq e p r r ~ ~ ~ [ C a m p y l o ~ c c e r r phaqe C?220] 
~ a t a h h to: q q 1 2 9 ~ 3 3 8 0 9 1 1 Score : 2 8 ~ ~
h ~ p o t r r... t ~ c c .. l pt-.... qe p T o o e ~ ~ . . ( C . . , . p ~ ' l l _ c c e r r ph .. q e CP220) 
Found 1n . e e r c h h of 1A ~ ? 0 9 1 1 1 1EMa rcl12011_pkl 
KOllUn .. l ....... . ( ( . I : : 26295; Ca lcul .. t e d pI 7 .. 1ue : 9.86 
l'CH BLAST .. earch of q:i.129433e091 " q;un" t nr 
Unfor.m.tte d ~ e q u e n c e e ~ t r i n q q fer p ~ ~ ~ ~ q q .nto othe r ~ p p l ~ ~ ~ e 1 0 0 ~ ~
~ ~ x o n o m m : : Campy1ob .. cter ph .. qe C P ~ ~ O O
V a r ~ ~ ~ e e m o d ~ f ~ ~ a t ~ o o . : : C a r b ~ d o m e t h y l l ( C I , O x ~ ~ ~ t ~ c n n ( ~ . .
3 e ~ - - p e ~ . f 1 c c c c e e ~ ~ q e , , (p e pe1de e ~ n n b e n o o - - p e e 1 £ ~ e e ~ t t one ~ e ~ U 5 5 or 
( ~ ~ e e 7 _ q e e by ~ ~ J r U . ! ' r y y ~ ~ n : : cu't..s C-ee. cn ~ 1 d d e e of KR. u n n e ~ ~ ~ n ~ t t r e e 1 d d e e 1 ~ ~
Se que nce Coveraqe : 27i 
~ ~ ~ ~ e d d p e p t ~ ~ e ~ ~ . hown 1n Bold Red 
1 XI,-YOY.l.l."EX: I n . l l l L S ~ ; V V y _ • . . D ~ m I T K K VK!'1.E !1t:OO t.Q:E U l1'-yJt 
51 ElloLrrRn;U. Hl.SSKVQD:.K ISL.v.Y.!:l"-3S11 YKI.SD.F.O:lS:' :::u..EDI"X SK 
101 KYK!UPAELV AVI. IK£ 3R!'R 1:[WI1{F.:?I'YV Rrl.YJreI A G Y . G A l l ~ - ; ; n ~ ~ ~
151 GOYJ..FJ!l."T3!. KSKKDlJQ,-... " KlTIEG:"AV!L SYLXSLFIUS 1;:T.l;KY£3A->' 
201 S R Y " " ~ l l YVll'Kn!'K!1; IU.NS 
Figure 6.8 The semi-tryptic digest NCBI search result of the expressed 
CP220 CPT 120 protein band. 
* The matched peptides are shown in red 
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6.2.6 Effect of IPTG on Bacterial Growth 
The effect of induction with 0.1 mM IPTG on the cell growth of CP220 CPT 
120 cloned in pET 3a and expressed in Rosetta 2 (DE3) pLysS was studied 
using expression clones cultured for 12 h with the OD 600 readings being 
taken on an hourly basis (see method section 2.8.9). The induction was 
initiated after 3 h incubation at 37 DC, 100 rpm when the OD 600 was between 
0.3-0.4. The cells continued to multiply for 4 h after which the cell 
concentration started to decrease until the end of the incubation period (Figure 
6.9). 
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Figure 6.9 Effect of IPTC on E. coli Rossetta expressing CP220 CPT 120 
growth 
1: pET 3aIRosetta 2 (DE3) pLysS Expressing CPT 120 
2: pET 3aJRosetta 2 (DE3) pLysS (empty vector control) 
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6.2.7 Isolation of Cell Fractions 
Cells from cultures exhibiting a protein of the estimated size (see section 6.2.3) 
were fractionated into periplasmic space, cytoplasm and membrane proteins 
and inclusion bodies to assess the location of the protein (see method section 
2.8.8). These fractions were examined by 10-20 % Novex Tricine gels as 
described in methods section 2.8.10 (Figure 6.10). The isolated cell fractions 
from E. coli expressing CP220 CPT 120 in pET 3a!Rosetta 2 (DE3) pLysS 
showed that the majority of the expressed protein was present in the cytoplasm 
(lane 4) even though there was a degree of contamination in the membrane 
protein and the inclusion bodies fractions (lanes 5 and 6). 
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Figure 6.10 Cellular fractions of E. coli Rosetta 2 (DE3) pLysS expressing 
CP220 CPT 120 from pET 3a 
To assess the location of the expressed protein within the cell, different 
fractions were isolated pre- and post-induction with 0.1 mM IPTG and 
electrophoresed together with a negative control on a 10-20 % tricine gel. 
Lanes representing the isolated fractions are as follows : 
Lanes 1-6 expressed CP220 CPT 120 
Lanes 1-2; total cell fraction, lanes 3-4; cytoplasm; lanes 5-6; membrane 
proteins and inclusion bodies. 
Lanes 7-12 pET 3a/Rosetta2 (DE3) pLysS (negative control) 
Lanes 7-8; total cell fraction, lanes 9-10; cytoplasm; lanes 11-12; membrane 
proteins and inclusion bodies, lane 13 ; pre-stained See blue plus 2protein 
marker. 
* First lane of each fraction was pre induction and the second lane was after 4 h 
of induction with IPTG. 
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6.2.8 Testing Lytic Activity of CPT 120 
The lytic activity of recombinant CP220 CPT 120 protein was tested against a 
number of strains including; Campylobaeter PT 14, E. eoli 311 0 and 
Salmonella Typhimurium DT 104 NCTC 13348 as described in methods 
section 2.11. The C. jejuni PT 14 plates were incubated at 42°C under 
microaerobic conditions whereas E. coli and Salmonella plates were incubated 
at 37°C aerobically on NZCYM medium. 
Dispensing droplets of a protein fraction containing protein CP220 CPT 120 on 
to the confluent plates of C. jejuni PT14 resulted in an area of lysis. A similar 
pattern of lysis was found for E. coli 3110 and Salmonella Typhimurium DT 
104 NCTC13348. The central regions of the lysed areas exhibited eventual re-
growth of the bacteria either due to binding and loss of protein function or 
possibly due to the development of resistance. The area of lysis produced was 
too diffuse to produce an image of sufficient quality to include but was clearly 
visible with the naked eye. 
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6.2.9 His Tag Addition to CPT 120 
Oligonucleotides were designed to add a six histidine protein tag as an N-
terminal translational fusion (His tag) to CP220 potential lysin encoding gene 
CPT 120 (Table 6.2). The histidine residues were added to enable one-step 
purification of the protein product using metal affinity chromatography. 
Table 6.2 His Tag Oligonucleotides 
Oligonucleotide Name Sequence 
His Tag: F 5'-T ATG CAC CAC CAC CAC CAC CA-3' 
His Tag: R 5'-T ATG GTG GTG GTG GTG GTG CA-3' 
DNA from the plasmid containing the CPT 120 gene in pET 3a was prepared 
and digested using NdeI before dephosphorylation using antarctic phosphatase 
as described in methods sections 2.10 and 2.8.6.2 respectively. The 
oligonucleotides (His Tag) were annealed and ligated into the vector (CPT 120 
in pET 3a in E. coli TOP 1 0 cells) at various ratios of insert:vector (3: 1, 10: 1, 
30:1) using T4 DNA ligase (Promega) as described in methods section 2.8.7.4. 
The ligation mixture was transformed into chemically competent E. coli 
TOP 10 cells before plating on LB agar plates containing ampicillin (2.4.1) to 
select for the plasmid (described in methods sections 2.8.3 and 2.1.5). 
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Colonies obtained were tested by direct DNA amplification using primers 
specifically designed to have the His tag together with a reverse primer 
designed for CPT 120 (Table 6.3). 
Table 6.3 Primer sequences to amplify the His tagged CP220 CPT 120 
CP220 Position Sequence 
Gene 
HisTaggcd 107127 ... F: S-M CAT AlG CAC CAC CAC CAC CAC CAe AlG MT TAC GAT 
CPT 120 107001 AMClGMT AM AlGGG-3' 
RS-MGGATCCGTATTMGAGTIT AGTTIA TIAMTTITGAC-3' 
Bacterial DNAs were liberated by boiling and used as a template for PCR 
using the following cycles: 
lC)de 96'C 3 min 
35C)de; 96'C 1 min 
65'C 1 min 
72'C 1 min 
lC)de 72'C 7 min 
PCR amplification products were examined usmg 0.8 % agarose gel 
electrophoresis and the gel image recorded on a ChemiDoc XRS Imager using 
the Quantity one program (Bio-Rad). However, none of the PCR products 
resulted in the required band (data not shown). 
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6.2.10 CP220 CPT 120 PCR Amplification with alternate His 
Tagged Primers and Cloning 
As an alternative strategy, the reading frame of CPT 120 was PCR amplified 
with the original primers carrying a His tag (Table 6.3) at the Ndel site as 
described in section 4.2.5, and the DNA product cloned into the plasmid vector 
pCR 2.1-TOPO, transformed into E. coli TOP 10 chemically competent cells 
and the plasmid selected on LB culture plates containing ampicillin (2.4.1) as 
described in the methods (see sections 2.8.2 and 2.8.3). Plasmid DNAs were 
prepared from ten colonies, and digested with EcoRl (described in methods 
sections 2.8.4 and 2.8.5). Of these eight had insert sizes consistent with the 
target DNA amplicon (Figure 6.11), from which six were selected for DNA 
sequencing and the insert sequences analyzed using BioEdit. Four sequenced 
clones were identical to CPT 120 and His tagged successfully. The DNA 
sequence of the His tagged CPT 120 gene is shown in Appendix 7. DNAs 
encoding the His tagged CPT120 were cut from the pCR 2.1-TOPO plasmid 
using NdeI and BamHI and subcloned in pET 3a and pET lla as described in 
methods section 2.8.6. However, none of the diagnostic digests indicated that 
the gene had been cloned in either pET 3a or pET l1a. 
188 
Chapter 6 
123456789101112131415 
W 
4kb ,-, _WI .W..,W . ---.,\II_W 
- .. -
-
-0.75 kb -
- - -
Figure 6.11 Restriction digests of His tagged CP220 CPT 120 plasmid 
clones in pCR 2.1-TOPO 
In order to check the presence of the correct insert in pCR2.1-TOPO, plasmids 
were prepared, digested with EcoRI and analyzed by electrophoresis on a 
0.8 % agarose gel. Lanes representing these plasmids are as follows : 
Lane 1; 1 kb marker, lanes 2-3; colony I, lanes 4-5 ; colony 2, lanes 6-7; colony 
3, lanes 8-9; colony 4, lanes 10-11; colony 5, lanes 12-13 ; colony 6, lanes 14-
15 ; colony 7 
* First lane of each sample was undigested plasmid; the second lane was 
digested with EcoRI 
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6.3 Discussion 
The bacteriophage CP220 open reading frames CPT 0075 and CPT 120 were 
PCR amplified and cloned successfully into pCR2.1-TOPO vectors and 
subcloned into pET 3a and pET lla (CPT 0075 only) using E. coli cells that 
will not permit expression of the genes from the T7 promoters of the pET 
vectors. 
Transformation of the cloned genes present in the pET plasmids into an E. coli 
expression host carrying T7 RNA polymerase was challenging. BL21 (DE3) 
strains were the first choice of hosts because they carry an IPTG-inducible T7 
RNA polymerase in a genetic background deficient in both Ion and ompT 
proteases. This occurs because the E. coli host contains the ADE3 lysogen that 
carries the T7 RNA polymerase gene as a stable chromosomal copy, which is 
controlled by lacUV5. Optionally the pLysS plasmid can be used that carries 
the gene encoding T7 lysozyme, which can lower any background expression 
of the target genes as it is controlled by the T7 promoter without interfering 
with the expression level following IPTG induction. The host BL21 (DE3) 
pLysS did not express either CPT 0075 or CPT 120 and was substituted with 
BL21 (DE3) pLysE, which provides tighter control of T7 RNA polymerase. 
This is an important consideration when the required protein is potentially 
toxic to the host. However, none of the genes could be expressed in this host 
strain. 
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The expression host was changed to Rosetta 2 (DE3) pLysS, which is a 
derivative of E. coli BL21 known to enhance the expression of eukaryotic 
proteins since it contains tRNAs for codons rarely used in E. coli. Such cells 
provide tRNAs for seven rare codons: AGA, AGG, AVA, CVA, GGA, CCC 
and CGG. Rosetta 2 cells were the host choice and the protein product of CPT 
120 was successfully produced in this background based on the identification 
of tryptic peptides using mass spectrometry. 
Protein expression could have been problematic for a number of reasons. One 
of the problems could be the incompatible codon usage of CP220 attuned for 
expression in Campylobacter species with low GC contents. Each amino acid 
can be encoded by more than one codon and different organisms prefer certain 
codons that often reflect the GC content of the genome. Such codon usage is 
affected by the availability of tRNAs in the organism and some phages carry 
tRNAs in their genomes, potentially to compensate for such compositional 
differences (Bailley-Bechet et al., 2007). However, the most likely cause of 
these difficulties is that the product has been selected to encode a putative lysin 
that will disrupt the host following its induction. The codon usage analysis for 
CPT 120 and 0075 was performed and showed that rare codons present in 
Rosetta 2 (DE3) pLysS were used in a percentage of 3.5 and 8.2 % for CPT 
120 and 0075, respectively. These rare codons in this host did not have any 
effect on CPT 0075 expression while their use for CPT 120 resulted in 
successful expression. 
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Alternative expression systems that do not rely upon a potentially sensitive 
bacterial host may be appropriate for lysin production, expression systems such 
as the methylotrophic yeast Pichia pastoris are possible candidates (Daly and 
Hearn, 2005). 
Maximum expression of gene CPT 120 was achieved after 4 h of induction 
with 0.1 mM IPTG. The lytic activity of the CPT 120 protein expressed in this 
manner was tested on the Gram-negative bacteria: Campylobacter jejuni, 
E. coli 3110 and Salmonella Typhimurium DT 104. This lysin was originally 
amplified from phage CP220 that is capable of lysing a wide range ofC.jejuni 
and C. coli strains (El-Shibiny et aI., 2009) with a view to generating a 
similarly wide ranging lysin activity. The CPT 120 protein showed some level 
of lysis with bacterial species other than Campylobacter. However, the area of 
lysis was subject to re-growth of bacteria, which could be due to the loss of 
protein activity due to binding to cell wall substrates from lysed cells or 
possibly due to the development of resistance. 
The spot test of lytic activity was a crude preliminary test of lytic activity and it 
indicated that potential lytic activity needs further investigation. This could 
only be done properly once the His tag problems are rectified, allowing larger 
quantities of pure lysin to be expressed. Further experiments would have to be 
carried out using many more strains and species, and using different 
approaches such as comparing viable counts before and after treatment. 
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When the His tag was added to the primers used for gene CPT 120 PCR 
amplification, the gene was amplified and cloned in pCR2.1-TOPO vector 
successfully using E. coli TOPlO chemically competent cells, but technical 
problems resulted in failure to subclone this gene into the pET system, 
although it had previously been cloned in it without the His tag. This last 
hurdle needs further attention because the His tag will provide a means to 
purify the protein away from cellular debris that could affect the function of the 
lysin. 
The presence of the outer membrane in campylobacters is a barrier that 
prevents lysins from accessing their cellular targets and lysing the bacteria 
directly. To prove the activity of the prepared CPT120 lysin, the outer 
membrane should be permeablized prior testing this lysin on campylobacters 
and other Gram negative bacteria. 
In a study performed by Walmagh et al. (2012), five endolysins from phages 
targeting the peptidoglycan cell wall of Gram negative bacteria were examined. 
These bacteria included: Burkholderia cepacia, E. coli, Salmonella enterica 
and Klebsiella pneumonia. The lysins were tested individually and in 
combination against Pseudomonas aemginosa PAOI (wild type), 
Pseudomonas aemginosa Br667 (multidrug resistant bum wound isolate), E. 
coli XLI-Blue MRF and Salmonella enteric a Serovar Typhimurium LT2 but 
did not result in any lysis. On the other hand, when the work was repeated in 
the presence of EDT A which permeablized the outer membrane, the lysins 
proved to be effective, lysing all the bacteria tested. 
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The work in this thesis describes the isolation and comprehensive 
characterization of bacteriophage candidates for future therapy applications to 
reduce Campylobacter contamination of poultry. 
Efforts to extend the number of available phages for phage therapy were made 
and three new phages were isolated, two of which (4a and 18b) were 
characterized with ten previously uncharacterized phages from our laboratory 
stocks. The two new phages were found to belong to class III of the 
Campylobacter phages and could be demonstrated to infect and lyse 
campylobacters in vitro. Their activity against campylobacters colonizing 
chickens in vivo needs to be investigated. 
All the phages characterized had different lytic profiles with no single phage 
able to lyse all the Campylobacter strains tested. To overcome this problem, a 
high number of phages should be tested to find ones that are effective against a 
wide range of pathogenic strains. A solution that can be applied in parallel is 
the use of a cocktail of phages to increase the effective host range and to target 
different surface recognition molecules and receptors, and thereby reduce the 
chance of the survival of Campylobacter phage resistant strains (Carlton, 
1999). From this work, candidate phages can be mixed and tested as a phage 
cocktail against campylobacters from different sources. For example, the 
cocktail could include the newly isolated phage 18b together with CP20 and 
CP30, as these phage showed a broad spectrum of activity against range of 
campylobacters compared to the other phages examined. Carvalho et al., 
(2010a) reported the use of three lytic phages against C. jejuni and C. coli in 
chickens, where they were tested using two routes of administration (oral and 
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feed) to successfully reduce colonization by 2 10glO CFU g-I_ Similarly, a 
number of studies have been performed for the control of other bacteria using 
phage cocktails. The control of E. coli infection and contamination using phage 
has been reported in different species including calves (Smith and Hugens, 
1983), beef meat (O'Flynn et 01., 2004) and mice (Tanji et 01., 2005). 
Moreover, Salmonella reduction in pigs and pork (Zhang et 01., 2010 and 
Hooton et 01.,2011), and biofilm formation by Pseudomonas on catheters (Fu 
et al., 2010) have all been successfully treated using phage cocktails. 
Phages can be found in niches where their hosts exist and proliferate. 
Campylobacter phages can be isolated from a number of sources including: 
chickens (Atterbury et al., 2003a and Connerton et 01., 2004), pig manure 
(Khakhria and Lior, 1992), sewage (Salama et of., 1989; Beaudoin et al., 2007) 
and slaughter house effluent (Salama et al., 1989). One example of phages 
isolated from chicken is phage W5, which was isolated from a chicken carcass 
and belongs to class III of the Campylobacter phages (Atterbury et 01., 2003a). 
In this study, W5 was characterized through its lytic profile, and its genome 
size was estimated using PFGE. The genomic DNA of W5 showed two bands 
when analysed by PFGE (a major band corresponding with a genome size of 
approximately 130 kb and a minor band estimated at 195 kb), implying the 
presence of two genomes, despite plaque purification. Attempts were made to 
separate these two genomes to investigate any potential genetic relationship. 
These attempts resulted only in the recovery of the phage with the smaller 
genome, possibly due to the greater representation of this class of phage in the 
sample. The observation that Campylobacter phages are recovered as co-
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isolates has also been recently reported from chicken faeces in Australia. In 
this report a genome estimated at 195 kb was observed together with one of 
about 140 kb, which remained associated after plaque purification (Owens et. 
al., 2012). 
Attention was further focussed on a second pair of co-isolates, which had been 
successfully separated, with the sequence of larger genome, CP220, having 
been determined previously (Timms et al., 2010). The co-isolate of CP220, 
CPX, is a class III phage with a genome somewhat smaller than CP220 which 
belongs to class II. These phages have different lytic profiles, thus they could 
potentially be of a greater therapeutic value when mixed together. Moreover, 
they have limited sequence similarity at the nucleotide level, indicating that 
there is no extended sequence relationship between them, despite their co-
isolation. The distinction between their activity against Campylobacter strains 
and the fact that they are genetically diverse make them complementary 
candidates for inclusion in phage cocktails. The use of diverse phages with 
different receptor requirements and functional activities against the target 
bacteria will limit the potential for the development of phage resistance, since 
more than one mutation in the bacterial population may be required to 
overcome infection by different bacteriophage. These mutations must also 
retain the fitness of the bacteria to compete with resident intestinal microflora 
and survive in the wider environment. 
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However, in the context of co-isolating phages, further work will be required to 
investigate the relationships between the phage, and whether they will co-infect 
permissible host bacteria or gain stability by association with each other. The 
maintenance of genetically distinct phages upon serial plaque passage clearly 
challenges the generally held belief that individual plaques represent individual 
phage clones. The fact that other examples of co-isolation exist, such as W5 
described in Chapter 3, indicates that this is not an isolated phenomenon and 
deserves further investigation. 
The molecular comparison of Campylobacter phage genomes became easier 
with the availability of phage CP220 genome (Timms et aI., 2010). PCR 
amplification of different phage DNAs based on primers designed on selected 
genes from phage CP220 enabled their comparison, and showed that among all 
the amplified genes, CPT 120, which this thesis has identified as a potential 
lysin, is present in all the phages examined, either as identical sequences or 
with few sequence differences that are either silent or lead to conservative 
changes and are not likely to change the function of the product protein. The 
lysin appears conserved throughout the different types of Campylobacter 
phage, which makes it an antimicrobial agent with potentially wide application 
(Chapter 4). This thesis has further demonstrated the lytic activity of CPT 120 
as a crude lysin against other Gram-negative bacteria including the foodbome 
pathogens E. coli and Salmonella Typhimurium (Chapter 6). 
This lysin gene was cloned and successfully expressed in the pET system of 
E. coli, yet DNA constructions aiming to add a histidine tag to enable rapid 
purification of the lysin were not successful (Chapter 6). To enable further 
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characterisation of the lysin it will be necessary to purify the protein, and if the 
lysin was to be used for any biotechnological application this would be 
essential. Affinity purification kits for histidine-tagged proteins are available 
from different commercial sources including: Qiagen, Sigma, Thermo 
Scientific, GE Healthcare, Bio-Rad and others. These kits are convenient, 
efficient, inexpensive and have been demonstrated to produce high yields of 
purified tagged proteins. If the pET system was to prove intractable for 
expression of phage proteins then a different system should be sought. For 
example, Pichia pastoris is an excellent expression system that may not have 
some of the drawbacks evident for a Gram-negative bacterium producing an 
active lysin. As a methylotrophic yeast, Pichia pastoris could be capable of the 
expression of phage proteins as they may not interfere with cell metabolism 
and growth as they are programmed to do for bacteria. Yeast systems benefit 
from prokaryote-like ease of handling and have robust well developed 
fermentation systems (Daly and Hearn, 2005). 
Determination of the genome sequence of phage CPX was undertaken for two 
reasons: firstly developments in sequence technology for the first time allowed 
the sequence determination of a group III Campylobacter phage, as at the time 
of starting this work, no complete genome sequences from this group were 
available. Secondly this phage was co-isolated with CP220 and any 
relationship at the sequence level between these two phages could only be 
investigated by having the sequences to compare. The sequence determination 
of CPX was finished around the same time that two further group III 
Campylobacter phage sequences became available (Hammer! e/ al., 2011; 
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Kropinski et at., 2011). Sequencing phages is increasing worldwide. This will 
allow the comparison of different phages to understand their relationships and 
to investigate the presence of similar genes of similar potential functions in 
different phages. The sequence of CPX revealed many interesting features. 
However, a large proportion of the putative CDSs like CP220 and CPt I 0 
showed no significant matches to available sequences in data bases (Timms et 
at., 2010). 
Like other Campytobacter phages, homing endonuclease encoding genes (lief) 
were identified in the CPX sequence (Timms et at., 20 I 0). Of the group III 
phage, CPX has seven Hefs compared with NCTCI2673 that has twelve in 
total (Kropinski et at., 2011), whereas CP81 has eight homing endonucleases 
(Hammerl et at., 20 II). Although CPX phage has nineteen genes that are 
similar to T4 phage, it is not classified together with the other class III phages 
as T4-related because it is smaller than the smallest characterized T4 genome. 
The genes that share protein sequence identity with T4 phage structural genes 
are scattered throughout the phage genome and are listed in chapter 5. The 
exception to this is a short gene cluster of three ORF's that lie on the negative 
strand and preserve the corresponding T4 order of gp20 (portal vertex protein), 
gp21 (prohead protease) and gp23 (major capsid protein). The T4-like modules 
would imply functional conservation of a virulent lifestyle but possibly without 
the need for temporal transcription units. 
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In summary, this thesis describes a closer examination of the molecular biology 
of Campylobacter bacteriophage than had previously been possible, 
significantly extending our knowledge in this area. Of particular importance is 
the detennination of DNA sequence ofCPX phage and the identification of an 
active potential lysin gene product from the CP220 DNA sequence. 
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Appendix 1 
Comparison of the nucleotide sequences of genes CP220 CPT 0075 and CP20 
0075 where the differences between the two sequences are indicated with star 
symbols 
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Comparison ofthe predicted amino acid sequences of genes CP220 CPT 0075 
and CP20 0075 where the differences between the two sequences are indicated 
with star symbols 
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Compari on of the nucleotide sequences of genes CP220 CPT 120 and CPX 
120 where the differences are indicated by star symbo ls 
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Comparison of the predicted amino acid sequences of genes CP220 CPT 120 
and CPX 120 where the differences are indicated by star symbols 
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Comparison of the nucleotide sequences of genes CP220 CPT 120 and CP20 
120 where the differences are indicated by star symbols 
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and CP20 120 where the differences between the two sequences are indicated 
with star symbols 
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Comparison of the nucleotide sequences of genes CP220 CPT 120 and CP34 
120 where the differences are indicated by star symbols 
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Comparison of the nucleotide sequences of genes CP220 CPT 142 and CP8 
142 where the differences are indicated by star symbols 
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Nucleotide sequence of gene CP220 CPT 0045 with the amplified region 
hown in blue 
AT GGCTGATATTATTCAAAATAAAATGAATCAAGTACTAGGTGATTTAGC 
TCGTCCCACTAAGTTTAAATGTCAAATATTTCCACCTAAAGAAATTAAGTG 
TGAATTGAGTATTTTAAATGAAGGTGATTCTGCAACATCCAGCACTTCTGA 
AATAAGCCAATATTTAGACTATTTTTGTCACGCTACAAGTTTTCCGGGATT 
GACTGTAGAAACAATAGATTTTAAATATCGTGGTAGGACTCTACCAGTTA 
AATCAGTACAAACTTATCAACAAAAATGGTCAGCAACTTTTTATAATGAT 
GAAAAACATGCAGTTAGAAAGTTATTTTTGGATTGGATGACTTATGATCA 
AGCACATCAATTTGAGGATAAAACTAAAGGTAATTTTGAAGGTATATTAC 
CCAGCATTTCTATATATCAATTAGATTTTGAAATGTCTAAAGATTGTGTTG 
TATATACTATGATGAATGTATTTCCAACAAATGTGGGAGAAATTTCAGTTC 
AATATGACGGGTTAAAT CAAATTGAAACTTTTACAGTTGAGTTT GCATATA 
CCCATTTTGAAATTAATACAATTTCTAGGGAAGGGTTAACGAGTTCTGAA 
GTCACTAGTTTGATTAAGAATACTATACAGAATACTATTAATAATGTTACC 
AATACTTTAAAGGATGCTGTATTTGGTGCTTTAGACGACCTAGTTTCACCT 
GTATTGGATTCGGTTTCAGATTCATTTGAAAATTTTATAAGTACAAAATAA 
Predicted amino acid sequence of gene CP220 CPT 0045 
MADIIQNKMNQVLGDLARPTKFKCQIFPPKEIKCELSILNEGDSATSSTSEISQY 
LDYFCHATSFPGLTVETIDFKYRGRTLPVKSVQTYQQKWSATFYNDEKHA VR 
KLFLDWMTYDQAHQFEDKTKGNFEGILPSISIYQLDFEMSKDCVVYTMMNV 
FPTNVGEISVQYDGLNQIETFTVEFAYTHFEINTISREGLTSSEVTSLIKNTIQNT 
INNVTNTLKDAVFGALDDLVSPVLDSVSDSFENFISTK 
Nucleotide sequence obtained from CP20 genomic DNA amplified with 
primers designed using the CP220 CPT 0045 sequence with the differences to 
CP220 CPT 0045 sequence shown in red 
CAAGTTTTCCGGGATTGACTGTAGAAACAATAGATTTTAAATATCGTGGTA 
G G A C T C T A C C A G T T A A A T T C G G T C A A ~ C T T A T C A A C A A A A A T G G T C A G C A A
ACTTTTTATAATGATGAAAAACATGCAGTTAGAAAGTTATTTTTGGATTGG 
AT GACTTATGATCAAGCACATCAATTTGAGGA 
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Nucleotide sequence of gene CP220 CPT 0058 with the amplified region 
shown in blue 
ATGTCTAACAAAATTGAAGAAATTAAAACCGCACTAAAATCTGGTGCAAA 
AGCTACAAAATACCGTGTTAAACTTTCATTTCCAACAGAAGTGCAACATA 
AAATGGAATTACAAAGCTTGAACTGCTTAGCTAAAGCTACTAGTTTTCCA 
GGTGTAACTATTGGACAAATTGAAGTATTTAACCAAGGAAGAAAGCTTCC 
TATACCTGGTGATACTTCGTATGATACACAATGGACCGTAACATTTTATAT 
GGATAATGCACACCAAACTCGTAAAGACTTCTTAAGTTGGATGAAAGCTT 
GTGACAACTTCCAAGCAAATACCCATTCTGGTAACCCAGGGGGCTTATTT 
ACAGAAGTTTCGGTTTGTCAATTAGATTCATTAGAAAATGAAGTTGCTGA 
ATATACTTTAAGAAACTGCTGGCCGAGTGGTGTTGGTGAAATTAGTGTTG 
GT GCTGATCAATTAGATACATTACAAGAAT GTGATATCACATTTAGCTTCT 
CAGATTGGATTATTTCTAATGGATCTGAATTTAATATGCCACAAGATGGTA 
AATCGGCTGCTACTAACGTAGTTTCTGTAGACCAATAA 
Predicted amino acid sequence of gene CP220 CPT 0058 
MSNKIEEIKTALKSGAKATKYRVKLSFPTEVQHKMELQSLNCLAKATSFPGV 
TIGQIEVFNQGRKLPIPGDTSYDTQWTVTFYMDNAHQTRKDFLSWMKACDN 
FQANTHSGNPGGLFTEVSVCQLDSLENEVAEYTLRNCWPSGVGEISVGADQL 
DTLQECDITFSFSDWIISNGSEFNMPQDGKSAATNVVSVDQ 
Nucleotide sequence obtained from CP20 genomic DNA amplified with 
primers designed using the CP220 CPT 0058 sequence with the differences to 
CP220 CPT 0058 sequence shown in red 
ACCCAGGGGGCTTATTTACAGAAGTTTCGGTTTGTCAATTAGATTCATTAG 
AAAATGAAGTTGCTGAATATACTTTAAGAAACTGCTGGCCGAGTGGTGTT 
GGTGAAATTAGTGTTGGTGCTGATCAATTAGATACATTACAAGAATGTGA 
TATCACATTTAGCTTCTCAGATTGGATTATTTCTAATGGGTCTGAATTTAAT 
AT GCCACAAGATGGTAAATCGGC 
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Nucleotide sequence of gene CP220 CPT 0175 with the amplified region 
hown in blue 
ATGGGTACTTTTTCATTTTCATTATCGGATATAAAGAAACAATTAGGTCCT 
GGTTTAGGAGTTAGATCAAAT GCTTACTTACTAGAAGTT GCTGTAGTAGGT 
GCTGTTTCTAAAAAATTAGCAGTTCTTTGTCAAAGCACAGCGTTACCTGAA 
AGAAATATTGGAACCACTGATATATTCTACAAAGGTAGAAAATATAAGAT 
G C G A G G T G ~ ~ C A G A C T T A A G T G G T A C T T A T A C T A T T A A T A T A A C T G A T G G
A T T C T G A A A T G ~ ~ C T T A G A A G A A T G T T C G A T A G C T G G A T G A G A G A A G T G G
GATAATACTACACCTAAAGGGACTAATGCTTTAGCAGGCTTATTTGGTGGT 
GCTATGGGTGATTTAATGGAGGTAGCTAACGGAACTTTGAAAGCGGTTAA 
TGAAATTAAATCTGCTTGGGAGTTTGATGGTGGTGTTTCTTGGCTTAAAAA 
TAT GAT TAT GGGCAAGC CACTGCCAGCAAATTATCAAACAACCGTAAATA 
TTTGGCAATTAACTAAAGTCAAAGAAAAACTATATGGGTATGCTTTGACT 
AATGCTTTTCCTATTGAAGTAGGTGCAGTAGAAGTTTCTGACGAAAATGA 
AAATCAGTTATCTATGTTTAGTGTAACTTTTGCATATTCAGATTTTGAACCT 
ATTGAAGATAAAGGTATAATCGGTCAAATAGTTGATACTGTAATAGGCCA 
AGAAGGTCAAGAAATTGCACAAGGTGTTGAAAATCTATTGGATTAA 
Predicted amino acid sequence of gene CP220 CPT 0175 
MGT FSF SLSDIKKQLGPGLGVRSNAYLLEVAVVGAV SKKLAV LCQSTALPER 
NIGTTDIFYKGRKYK:t.1RGETDLSGTYTINITDDSEMKLRRMFDSWMREVDNT 
T P K G T N A L A G L F G G A M G D L M E V A N G T L K A V N E ~ S A W E F D G G V S W L ~ ~
MGKPLPANYQTTVNIWQLTKVKEKLYGYALTNAFPIEVGAVEVSDENENQL 
SMFSVTFAYSDFEPIEDKGIIGQIVDTVIGQEGQEIAQGVENLLD 
Nucleotide sequence obtained from CP20 genomic DNA amplified with 
primers designed using the CP220 CPT 0175 sequence with the differences to 
CP220 CPT 0175 sequence shown in re 
AAGATGCGAGGTGAAACAGACTTAAGTGGTACTTATACTATTAATATAAC 
TGACGATTCTGAAATGAAACTTAGAAGAATGTTCGATAGTTGGATGAGAG 
AAGTAGATAATACCACACCTAAAGGGACTAATGCTTTAGCAGGCTTATTT 
GGTGGTGCTATGGGTGATTTAATGGAGGTAGCTAACGGAACTTTGAAAGC 
GG 
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Nucleotide equence of gene CP220 CPT 0034c with the amplified region 
shown in blue 
GTGCCAGTTCCAAGTGTTAGATTTATTGATAGTGATACCAGTTCAACATCA 
AATTATTCACAACCAAGAAGAGTATTCTATGCTGGATATTTCGATAAAGG 
TTCACCAGACACTTTAACACCCGTTTATTCTATATTAGATTTTAAAACAAA 
AT TTGGTAAACCAAACAAAAATAAT ATAAATGACT GGTT TCAAATTTAT A 
ATTATTTTTTATATGATAATAATGAAATAGTTATTTCGAGATCTATCGGTG 
AAAATTCAGTTAAC GCAAGTATTAGCTATC CATTTAATGACTTT GAT GTTA 
GAATAGATAACTTAGATGATTTTAGAAATAAACCCATAATTTCTGAAAAT 
AATTTCTTAAGAATCATTGCTAGAAACCCAGGAGAGTGGGGAAATGATTT 
AACAGTTTGTATTTTTACACAATATGAAGTTCTTAATAATATGCTAATACA 
CAGCAATTATTTAGCAAAAGATATTCAAAATTCAATGAGTTCAAATCAAT 
ATTGTATTTGTGTGTTCTTAAAAGATACATTAATGGAAAAATATATCTTAA 
AAGAATCTGAGGATATGGTAGATACTATTAATGAAAATTCTAATTATATA 
TT CAT TATT TTC GAT CCTAAAAAATACAAGTTATATGACGGCAATATCAAC 
TATGTAGACGGCTTAAATCGTTTAGCTGATGGAAATGAACCTAACTCAGA 
TAAAACAGTTTTTTATGGTTCTAATAGTCTTAAATTAAGTAACGGGTATGC 
AAGTTT GCCAAGTACAACCCAAATAGATGAAACATATAAAAGT GTTGGTG 
AATCTAATGATTATGTGTTTGATTTTATAATTGCTAATACACAAAGTCCAA 
ATTCTGCTATCAATTTAGCAGATACTCGTGGTGATTGTTGTGCTTTCATAG 
GTATACCTAGAGGTATTAAACCAGAAGAATATATTAAACAACTACAAATT 
TCAAACAATGCTGTTGTTTACTATGGTTCTAAATTACAATTAAATCCATTT 
AATAATCAAAATATATATGTTAATTGTATAGGAGATATTGTTGGTTTAAGA 
ACCAGATTAATTAATT CTCAAGAATTATCAGTATCTCACT GCAAAACAATT 
TATAGTTTCTTAAATACAATAGATTTGGATATATATCTAACGGAATCTCAA 
ATAAAAGATTTATATGATTTAAATATTAATATTGTTAAAAAAGGATATTCC 
GGTATATACGCTTTAAGTGAAAATACCTTAAAAGGATCTAAATTAACAAA 
TAGAATAATATATTTCAATTTAGTTCGAGAATGTGAAAACGTTGCATTATA 
TTATGTATTTGAAAATAATAATGAATATACAAGAAATGATTTAGCTTCAA 
AAATAAAAGAAATTTGCAGAAGTTATGTTGCAGATAATAATATAGAAGAT 
TTTAAAATAGTTTGTGATATTTCTAATAATCCTACTCAGGATAATAACATT 
TATGTAGATGTTTATTATAAACCTAAATATTTAATTGAAGAAGTTGTATTT 
AGAATTCAAGCAGCTAGTGAATTGCCTAGTTGA 
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Predicted amino acid sequence of gene CP220 CPT 0034c 
VPVPSVRFIDSDTSSTSNYSQPRRVFYAGYFDKGSPDTLTPVYSILDFKTKFGK 
PNKNNINDWFQIYNYFLYDNNENISRSIGENSVNASISYPFNDFDVRIDNLDD 
FRNKPITSENNFLRIIARNPGEWGNDLTV CIFT QYEVLNNMLIHSNYLAKDIQN 
SMSSNQYCICVFLKDTLMEKYILKESEDMVDTlliENSNYITIIFDPKKYKLYDG 
NINYVDGLNRLADGNEPNSDKTVFYGSNSLKLSNG YASLPSTTQIDETYKSVG 
ESNDYVFDFITANT QSPNSAINLADTRGD CCAFIGIPRGIKPEEYIKQLQISNNA 
VVY YGSKLQLNPFNNQNIYVNCIGDNGLRTRLINSQELSVSHCKTIY SFLNTI 
DLDIYLTESQIKDLYDLNlliNKKGYSGIYALSENTLKGSKLTNRIIYFNLVREC 
ENV ALYYVFENNNEYTRNDLASKIKEICRSYV ADNNIEDFK.IV CDISNNPTQD 
NNIYVDVYYKPKYLIEEVVFRIQAASELPS 
Nucleotide sequence obtained from CP20 genomic DNA amplified with 
primers designed using the CP220 CPT 0034c sequence with the differences to 
CP220 CPT 0034c sequence shown in re 
GGGTATGCAAGTTTGCCAAGT GCA GCTCAAATAGATGAAACATATAAAA A 
TGT CGGTGAATCTAA CGATTAT A TA TTTGATTTTATAATTGCTAATACACA 
AAGTCCAAATTCTGCTATCAATTTAGCAGATACTCGTGGTGATTGTTGTGC 
IT 
Predicted amino acid sequence obtained from CP20 genomic DNA amplified 
with primers designed using the CP220 CPT 0034c sequence with the 
differences to CP220 CPT 0034c sequence shown in red 
VPVPSVRFIDSDTSSTSNY SQPRRVFYAG YFDKGSPD TL TPVYSILDFK TKFGK 
PNKNNINDWFQIYNYFLYDNNEIVISRSIGENSVNASISYPFNDFDVRIDNLDD 
FRNKPIISENNFLRIIARNPGEWGNDL TVC IFTQYEVLNNMLIHSN YLAKDIQN 
SMSSNQYCICVFLKD TLMEKYILKESEDMVDTINENSNY IFIIFDPKKYKLYDG 
N INYVD GLNRLADGNEPNSDKTVFYGSNSLKLSNG YASLPS AA Q IDE TYK N V 
GESNDY IFDFIIANTQ SPNSA INLADTRG DCCAFIG IPRGIKPEEYIKQLQISNNA 
VV YYGSKLQLNPFNNQNIYVNCIGDIVGLR TRLINSQELSVSHCKTIY SFLNTI 
DLDIYLTESQIKDLYDLNINIVKK G YSG IY ALSENTLKGSKLTNRIIYFNLVREC 
ENVALYYVFENNNE YTRNDLASKIKEICRSYV ADNNIEDFKIVCDISNNPTQD 
NN IYVD VY YKPK YLIEEVV FRIQAA SELPS 
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ucleotide sequence of gene CP220 CPT 0052 with the amplified region 
hown in blue 
ATGTGGTTCGAGAGACTCTTTGTAATATCAAATCATATTAAAAGGATTAA 
AATGGCAAATTTACTTAGCCCTGGTATCCAGGTTTCTGAAGTAGATCAATC 
TCAAATCACACCAGTTGAAGGTGACTCTGCTGCTGTTTTTGGTGGTGATTT 
TGAGAAAGGACCTGTTGGTGTTCATACTTTAATCTCAAGTGTTCAAGAACT 
TAGAGACAATTATGGTATGCCTAATACAAAGAATTACAACGATTACTATC 
AAGTCCAAAATTTCTTAGCTTATAGCGGTGCAAT CTATGTTTC GCGGGCAG 
CTGATTTAAATGGGACGCCTACAAAATTAGACGGCTTACAATTTGAAGAA 
AATGCATATAAAACAAATGTTAATGCTACTAAAGTTGAAGGTGTTAAAGT 
TATCGAAGCTGACTCTGTAGACGTTAAATTCGAAAAAACTGATAAATTTC 
AAGTTGGTCAAGTTCTTAAATTCAACGATTCTAACAAAGAATATAAAATT 
AAATATGTTAGAAACGAAGTTAAACAAATACCAAACCCAGATTATCAACC 
ATTAACACAATTAGTAGTAGATCCAAGCCAAGCAAGTGCTTATGTTGATG 
AAGTTGTTAGCTACGTAGTAACAACCAATGCAGAATCTTATACTGTAGAA 
ACAGACAGGCCTGATGTAGTTCTTGTTAATAAATCTAATAAATCTTTAACT 
GCATTAAAAGTAGGAACTGCTATTGTAACTTTTAGAGCTACAAAAGAAGG 
TT CAAG GCCAAATA CTTTT GAATTTGTTTTAAAT GTT CAAGAAAAAGAACA 
AACTAAGCTAGTAGTAACACCAGAAACTGTAAATATTTTAGAAGGACAAA 
CTGCAATGCTTAATATAGATACAGATGCTGAAACTTATAGTATAGTATCTA 
AAAACTTAGCAATAGCAACCATAGCCGAAGATAAAAAAACTATCAATGG 
TTTGAGAATAGGTTCTTGTTTAGCCGAAGTATCAGCACAAGCTAATAATA 
AAACAGAAACTACTAAAATCATAAATGTCAATGTTATCACAGGTGTTGAA 
ACAGATTTAACAGTAAGCCCAGAAGGACCTGTAACTTTACACAAAAACGA 
AGAACAAATATTTGAAATCACTTCCAGTGGGGCTTCTATATTAGAAACTG 
CTAGTGAAGCTGATAAAGAATTTGTAACCGTAGACAAAACTGCTAAAAAA 
GTTACT GCAATAAAAGAAGGTAATGCTGTAGT CCGAGTC CGC GCAAAAGC 
TTTAGGTGCTGATGAAGTTATAAAAAGAATTCAAATAATTATTTTACCAGA 
AAAAATAAGTGCCACTGTTGAGCCTACTGAAATAAGTATTAATACAGACG 
CTGGCGACCAAACCTTAACGGTAACAACTGAAGCTACAAATATATCTGCA 
CGCGTTATAGATACTTCAGTCGCAAATGTGAGCACCCAAGAAAAAATAAT 
TACTGTAACACCATTAGCTGCTGGTAATACAGAGATTGAAATAACTGTTTC 
ATCAGAAGGTTATTCAAATAATGTTATCACTGTTCCTTTAACAGTTACTGC 
TGTAAATGCAGATCCAAGTGGTAGCACCAACCAAAAATCTAAAGCTAAGA 
AAGGATAA 
Predicted amino acid sequence of gene CP220 CPT 0052 
MWFERLFVISNHIKRIKMANLLSPGIQVSEVDQSQITPVEGDSAA VFGGDFEK 
GPVGVillLISSVQELRDNYGMPNTKNYNDYYQVQNrLAYSGAIYVSRAADL 
NGT PTKLDGLQFEENAYKT NVNAT KVE GVKV ffiADSVDVKFEKTDKF QVGQ 
VLKFNDSNKEYKIKYVRNEVKQIPNPDYQPLT QLVVDPSQASAYVDEVVSYV 
VTTNAESYTVETDRPDVVLVNKSNKSLTALKVGTAIVTFRATKEGSRPNTFEF 
VLNVQEKEQTKLVVTPETVNILEGQTAMLNIDTDAETYSIVSKNLAIATIAED 
KKTINGLRIGSCLAEVSAQANNKTETTKIINVNVITGVETDLTVSPEGPVTLHK 
NEEQlFEITSSGASILETASEADKEFVTVDKT AKKVTAIKEGNAVVRVRAKAL 
GADEVIKRIQIIILPEKISATVEPTEISINTDAGDQTLTVTTEATNISARVIDTSVA 
NVSTQEKIITVTPLAA GNTEffiITVSSEG YSNNVITVPLTVT AVNADPSGSTNQ 
KSKAKKG 
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Nucleotide sequence of gene CP220 CPT 0053 with the amplified region 
shown in blue 
ATGGCAGATATCTACGATATACCAGAGTTTATAACTCAAGAAGTAACTAT 
TGTTACTTTAGACAAAGAACCAGGTGAACTAAATGCAGACACTTCTGTAT 
ACTTACTAGAAGGTGAATCACAACCAGATTCTAACTATATTTTAAGTCTTA 
GAGGTGCTAACACTGAATTAAAACGTGGTGATATTATAGCATTTTCTGATG 
TTTTAACTGATCCTAGATTCAGAATCTTAGCAATCTCTGACAGTATAGTCA 
ATGGCGAAGCTTTCACAAATATTACTTATGAAGGCACAGAGGATTCTGAA 
GCCATTGTTGAAGCAACTAAAGGATTTCCAGTTTATTTAGTTAAATCTACT 
AAATCAGCTTGTGTTGAAGTTCCTGTAGAAGGTTCTGAAACCAAATACGA 
CTCATCAGAATATGAACTTTATGATCATACCATTAGTAACTTCAATACATT 
TGATGAAGATAAATTATCTAAACCATTTGTTTATAAAGATGCAAAATTAA 
AAATATTTGCTAAAACACCAGGAACTTGGGGAAATAAAATTGATGTTGCA 
ATAGCACACCCTGATGATTTTAACAAAGGTAAATATATCACTGATGGTAT 
ACCATTAGATTCTCAATTTGATTATATTCCTTACGGTGATCAATTTGCTGTT 
ATTGTTATCTACGCAAACGAAATTCAAGAATCATTTATTGTAAGTCTAGGA 
TTGACTGATAAAAATGAGAAAAATGAATTTACTTATATAGAAACAATGAT 
TAATGGTAAGTCAAGCTATATCTTAGTTTCTGTAAATGAAGCAGTTCAAGG 
TAAACCAAAAACTTGTTTAGGTGAAGATTTACTTAAACTTGAAAATGGTA 
TGGATTCAGCTCCAGGTATTGACGACATCATAGACGCTTATACAATTTTCG 
ACAACAAAGAAGAAATCGATGTTGATATCTTAATTTGTAACGAAACTTAT 
CCAAAAGCAGCTACTGATATT GCGATTACTC GTGGTGACTGTATAGCATTT 
AT GGGTGCTCCAAAAAGTTGTTCAGTGGGCTATAAATCTACAATTGCTAAT 
CAAAAAACACTTGATTTTAGAAAATCTTTAAATATAGATTCTAAATATGTA 
ACTTTGTGTAGCAATTACAAATATCAATATTGTGCTGAGCTTGGTGGTTAC 
AGATGGGTGAATCTAGCAGCAGATATTGCAGGTCTTAAAGCTCAAACAAA 
TTATAATCAAGCTAACTGGTATGCAGCTGCTGGTCTTAACAGGGGTCTCAT 
TAAAAACTGCGAGGCGTTGTCATATAGCCCAACTGGTGCGATGCGAGATA 
CACTTTACAAGAATGGTATAAATCCAGTGGTTATGTTTCCAAACACTGGTG 
CGGTTCTTTGGGGTCAAAAAACATTACAAACTAAAGCTTCAAGCTTCGAT 
CGCGTAAACGTTGTTAGCTTGTTTAACCATTTGGAAAGATCTTTAGGTCGT 
AT GTCGAAGTACAGTCTATTTGAGTTCAATGATAGTTTTACAAGAAATTAC 
CTTGTAAGTATTATCAAACCTTTCTTGGCTCAAGTAAAAGCTGGTCGCGGG 
AT CAGC GATTATTTAGT CATATGC GAT GCAT CAAACAATCCAGCAAGCGT 
AATCAGTGCAAACCAACTCGTCATAGACGTATATATTAAGCCGACTTATG 
TTGCAGAGTTCATTCATCTCAGATTCGTGAACGTCGGCACAAACGACTTTA 
GTGTTGTTGTAAGCTAA 
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Predicted amino acid sequence of gene CP220 CPT 0053 
MADIYDIPEFITQEVTNTLDKEPGELNADTSVYLLEGESQPDSNYILSLRGAN 
TELKRGDIIAFSDVLTDPRFRILAISDSIVNGEAFTNITYEGTEDSEAIVEATKGF 
PVYLVKSTKSACVEVPVEGSETKYDSSEYELYDHrISNFNTFDEDKLSKPFVY 
KDAKLKIFAKTPGTWGNKIDV AIAHPDDFNKGKYITDGIPLDSQFD YIPYGDQ 
FA VNIY ANEIQESFNSLGLTDKNEKNEFTYIETMINGKSS YILVSVNEA VQGK 
PKTCLGEDLLKLENGMDSAPGIDDIIDAYTIFDNKEEIDVDILICNETYPKAAT 
DIAITRGDCIAFMGAPKSCSVGYKSTIANKTLDFRKSLNIDSKYVTLCSNYKY 
QYCAELGGYRWVNLAADIAGLKAQTNYNQANWYAAAGLNRGLIKNCEALS 
YSPTGAMRDTLYKNGINPVVMFPNTGAVL WGQKTLQTKASSFDRVNVVSLF 
NHLERSLGRMSKYSLFEFNDSFTRNYLVSIIKPFLAQVKAGRGISDYLVICDAS 
NNP AS VIS ANQ L VIDVYIKPTYV AEFlliLRFVNVGTNDFSVVVS 
Nucleotide sequence of gene CP220 CPT 0035c with the amplified region 
shown in blue 
ATGTTGTCTAGAAAGATAAGAATTGATAACTTTATCTCTGATAAAGAAAA 
AGAAGAAATATATCAATATTCTAAATCTCTTTCTGCTATCTACAACGAATG 
TCTAGATCTTCTTAAAGAAAATTTGAATTTTAAAGATCTATCTAAAATCAC 
AAAA GGTGGATCAAAAGCAACAGGCTTGCATTCAAAACATATACAGAAT 
ACCTCTAGAGAGGTTATAAATGCTGTAAAATCTTATCTAGTGAAAAAGAA 
GAACGATAAGTCTGCTAGATTTCCAAAATTACATAGAGAATATAGTCCTA 
TCATTATGGTCGCAAATCTTTCCTCTAAGACGGAGGAGATTGTTAACTCTA 
GAACTGGAGAAGCGATTCTCGAAAAGAAATACTATCCAGGTGGAGGATTT 
AAACTAGAAGGTAAGAAAATAAACTTTACTTCAATAGGATTTGAATTAGA 
TTTAAGTAAATGCCCTTACTATGATATAGAACTTATCAACTATGAGACTTT 
AAAACAGATAGTCATCAAGATCGATGAGAATAAGAGAATAGATTGTATTT 
TTGTTTTCTCAGAGAAAAAACAAGAAAAAGCACCAAATCAAAATTTTCTT 
TCCATAGATCTAGGAATAAGCAGTATAGCATCTTGTTACTCAAACAAGAT 
TGATTGCTTGAAGATACAAACTAAGAGATTTAAAGGTCTAGAAAGAACTA 
TAAATGAGCTGAAGTCTAAAAGAGATAAGAAGAAAAAAGACTCAAGAGC 
ATATAAGAAACTTAACAAAACAATCAGAAGAAAGCAAGCAAAACTAACT 
AATAAAAGAAAAGACTATCTTCATAAGGCCTCAAAGACTGTAGTAGATCT 
CTGTATTCTTAATGGTATAGATAACATCATTTGTGGAGATATCAAGACTAA 
AAAATTAAAGAAAGACTATAAAACAAGTTTAAACAAATCAACCCAAAAT 
GAAGGACTATTGAGTAGATTTAAGGGTTTCTTAAAGTATAAAGCAGAGAA 
TAAAGGATTGAACTTTTTACTTGTGAATGAAGCATATACTTCTCAGACTAA 
CTGCCTTACAGGAAAAAGAGAGCTAGACTCGAATCTCAGTATCAGAGAGG 
TAGAATTAAGTCCAGGTTTCAAAGTTGATAGAGATATAAATTCAGCTGTC 
AATATAGCCAAAATATGTGGGGATTTATGGTTATCCCATATCTTTGAGAAG 
AATAGACTTCTCAAGATACAAAAAATGAATATTACTTTGTAA 
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Predicted amino acid sequence of gene CP220 CPT 0035c 
MLSRKIRIDNFISDKEKEEIYQYSKSLSA IYNECLDLLKENLNFKDLSK ITK GGS 
KA TGLHSKHIQNTSREVINAVKSYLVKKKNDKSARFPKLHREYSPIIMVANLS 
SK TEE IVNSR TGEAILEKKYYPGGGFKLEGKK INF TSIGFELDLSKCPY YDIELI 
NYE TLKQ IV IK IDENKRIDCIFV FSEKKQEKAPNQNFLSIDLG ISSIASCYSNKID 
CLK IQ TKRFKGLER TINELKSKRDKKKKDSRA YKKLNK TIRRKQAKL TNKRK 
DYLHKASK TVVDLC ILNGIDNIICGDIK TKKLKKDYKTSLNKSTQNEGLLSRF 
KGFLKYKAENKGLNFLLVNEA Y TSQ TNCL TGKRELD SNLSIREVELSPGFKV 
DRDINSAVN IAK ICG DLWLSHIFEKNRLLK IQKMNITL 
Nucleotide sequence obtained from CP20 genomic DNA amplified with 
primers designed using the CP220 CPT 0035c sequence with the differences to 
CP220 CPT 0035c sequence shown in red 
GGTGGATCAAAAGCAACAGGCTT ACATTCAAAACATATACAGAATACCTC 
TAGAGAGGTTATAAA CGCTGTAAAATCTTATCTAG CGAAAAAGAAGAACG 
ATAAGTCTGCTAGATTTCCAAAATTACATAGAGAATATAGTCCTATCATTA 
TGGTCGCAAATCTTTCCTCT 
Predicted amino acid sequence obtained from CP20 genomic DNA amplified 
with primers designed using the CP220 CPT 0035c sequence with the 
differences to CP220 CPT 0035c sequence shown in red 
MLSRKIRIDNFISDKEKEEIYQYSKSLSA IYNECLDLLKENLNFKDLSK ITK G GS 
KA TGLHSKHIQNTSREV INA VKSYLAK KKNDKSARFPKLHREYSPIIMVANLS 
SK TEEIVNSR TGEAILEKKYYPGGGFKLEGKK INFTSIGFELDLSKCPYYDIELI 
NYE TLKQ IV IK IDENKRIDCIFVFSEKKQEKAPNQNFLSIDLG ISSIASC YSNKID 
CLK IQ TKRFK GLER TINELKSKRDKKKKDSRA YKKLNK TIRRKQAKL TNKRK 
DYLHKA SK TVVDLC ILNG IDNIICGDIK TKKLKKDY KTSLNKSTQNEGLLSRF 
KGFLKYKAENK GLNFLLV NEA Y TSQ TNCL TGKRELD SNLSIREVELSPGFKV 
DRDINSAVNIAK ICGDLWLSHIFEKNRLLKIQKMNITL 
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Nucleotide sequence of gene CPt 1 0 CPT 0771 with the amplified region shown 
in blue 
ATGAACTTCTACAATTTAATTTATGAAAACAAAAAATATAAACCAAAAAC 
TAA AGCA GA TC TTA AAGAA TTA A TCAA TGA TCTTAGTA TTAAA TT AAG TG 
ATATAGATACTAGTGATATAACAGATTTTAATGAATTATTTTCTGGAACAA 
AAAGAACTGATTTCAAAGGTATTGGCACTTGGAATACCAGCAATGTTGTT 
ACTGCTAGACGTTGTTTTTATAATTTAAAAGATTTTAATGAAGATATTAGT 
AAATGGAATACTGCTAAACTTCAAGATGCTAGAGAAATGTTCTTCAAA 
TGCAAATCATTTAATCAAAATTTAAA TTCTTGGAATGTTGGAAATGTTAAG 
AATATGAATAAAATGTTTTATGAATGTACTAATTTTAAACAAATATTAAAC 
AAATGGAAAGTTGATAAATGTGAGAACTTTTCAGCAATGTTTTTAAATGTT 
AAATACGTAGAGGAACACTTTAAAGAATTTAAATGGAATACTAGAAATGC 
TGACGGTTATTCAGCAAACCCATTCAAAGCT TAG 
Predicted amino acid sequence of gene CPt! 0 0771 
MNFYNLlYENKK YKPK TKADLK ELIND LSIKLSDID TSD ITDFNELFSG TK R TD 
FK GIG TWNTSNVV T ARR CFY NLKDFNED ISKWNTA KLQDA REMFFK CK SFN 
QNLNSWNVGNVKNMNKMFYECTNFKQILNKWKVDKCENFSAMFLNVKYV 
EEHFKEFKWNTRNAD G YSANPFKA 
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Nucleotide sequence of gene CPt 10 1761 showing the amplified region in blue 
ATGTTATCTAGAAAGATAAGAATTGATAGCTTTATCTCTGATAAAGAAAA 
AGAAGAAATTTATCAGTATTCTAAATCTCTTTCTACCGTCTATAATGAATG 
TCTAGATCTTCTTAAAGAAAATTTGAATTTTAAAGATCTATCTAAAATCAC 
AAAAGGTA GATCAAAAGCAACAGGCTTACATTCAAAACATATACAGAAT 
ACCTCTAGAGAGGTTATAAACGCTGTAAAATCTTATCTAGCGAAAAAGAA 
GAACGATAAGTCTGCTAGATTTCCAAAATTACATAGAGAATATAGTCCT 
ATCATTATGGACATAAATCTTTCCTCTAAGACGGAGGAGA TTGTTAACTCT 
AGAACTGGAGAAGTGATTCTCGAAAAGAAATACTATCCAGGTGGAGGATT 
TAAACTAGAAGGTAAGAAAATAAACTTTACTTCAATAGGATTTGAATTAG 
ATTTAAGTAAATGCCCTTACTATGATATAGAACTTATCAACTATGAGACTT 
TAAAACAGATAGTCGTCAAGATTGATGAGAATAAGAGAATAGATTGTATT 
TTTGTTTTCTCAGAGAAAATACAAGAAAAAGCACTAAATCAAAATTTTCTT 
TCTATAGATCTAGGAGTAAGCAGTATAGCATCTTGCTACTCAAACAAGAT 
TGATTGCTTGAAGATACAAACTAAGAGATTTAAAGGTCTAGAAAGAACTA 
TAAATGAGCTGAAGTCTAAAAGAGATAAGAAGAAAAAAGACTCAAGAGC 
ATATAAGAAACTTAACAAAACAATCAGAAGAAAGCAAGCAAAACTAACT 
AATAAAAGAAAAGACTATCTCCATAAGACCTCAAAAACTATAGTAGATCT 
CTGCATTCTTAATGGTATAGATAACATCATTTGTGGAGATATCAAGACT 
AAAAAATTAAAGAAAGACTATAAAACAAGTTTAAACAAATCAACTCAAA 
ATGAAGGACTATTGAGTAGATTTAAGGGTTTCTTAAAGTATAAAGCAGAG 
AATAAAGGGTTGAACTTTTTACTTGTGAATGAAGCATATACTTCTCAGACT 
AACTGTCTTACAGGAAAAAGAGAGCTAGACTCGAATCTTGGTATTAGAGA 
GGTAGAATTAAGTCCAGGTTTCAAAGTTGATAGAGATATAAATTCAGCTG 
TCAATATAGCCAAAATATGTGGGGATTTATGGTTATCCCATATCTTTGAG 
AAGAATAGACTTCTCAAGATACAAAAAATGAATATTACTTTGTAA 
Predicted amino acid sequence of gene CPtl0 1761 
MLSRK IRIDSF ISDKEKEE IY QY SK SLSTV YNECLD LLKENLNFKDL SK ITK G RS 
KA TGLH SKHIQNTSREVINA VKSYLAKKKNDKSARFPKLHREYSPIIMD INLSS 
KTEEIVNSR TGEVILEKK YYPGGGFKLEGKKINFTSIGFELDLSKCPYYD IELIN 
YETLKQ IVVKIDENKRIDC IFVFSEK IQEK ALNQNFLSIDLGV SSIASCYSNKID 
CLK IQ TKRFKGLERTlNELKSKRDKKKKDSRA YKKLNK TIRRKQAKL TNKRK 
D Y LHK TSK TIVD LCILNG IDNIICGD IK TKKLK KD YK T SLNK ST QNEGLLSRFK 
GFLKYKAENKGLNFLLVNEAYTSQTNCLTGKRELDSNLGIREVELSPGFKVD 
RD INSAVNIAK ICGDLWLSHIFEKNRLLKIQKMNITL 
Nucleotide sequence obtained from CP220 genomIc DNA amplified with 
primers designed using the CPtlO 1761 sequence with the differences to CPtlO 
1761 sequence shown in red 
GATCAAAAGCAACAGGCTTACATTCAAAACATATACAGAATACCTCTAGA 
GAGGTTATAAA TGCTGTAAAATCTTATCTAG TGAAAAAGAAGAACGATAA 
GTCTGCTAGATTTCCAAAATTACATAGAGAATATAGTCCTATCATTATGG T 
CGC AAATCTTTCCTCTAAGACGGAGGAGA 
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Predicted amino acid sequence ofCP220 amplified with CPtlO 1761 primers 
showing the differences to CPtLO 1761 in red 
MLSRKIRID SF ISDKEKEE IYQ Y SKSLSTV YNECLD LLKENLNFKDL SK ITKG RS 
KA TGLHSKHIQNTSREVINAVKSYLAKKKNDKSARFPKLHREYSPIIM D INLSS 
KTEEIVNSR TGEV ILEKK YYPGGGFKLEG KKINFTSIGFELDLSKCPY YD IELIN 
YETLKQ IVVKIDENKRIDC IFVFSEK IQEK ALNQNFLSIDLGV SSIASCYSNKID 
CLK IQ TKRFKGLERTINELKSKRDKKKKDSRA YKKLNK TIRRKQAKL TNKRK 
DYLHKTSKTIVDLCILNG IDN I1CGD IKTKKLKKDYKTSLNKSTQNEGLLSRFK 
GFLKYKAENKGLNFLLVNEAYTSQTNCLTGKRELDSNLGIREVELSPGFKVD 
RD INSAVNIAK ICGDLWLSHIFEKNRLLKIQKMNITL 
Nucleotide sequence of gene CPt 1 0 0591 showing the amplified region in blue 
TTATTATACACAATTGATGAAAATAATTTCATCCAAAAATTATTATATATA 
AACGATAATAATATAAACTTTAAAGGTTATCATAATACTATTGCAAACCA 
GAAATTATTAAAAAAATTAAGACAGCTAGTTACTAACAATTTAAAAATAG 
AATTAAAACATTTTATAAGACTCTTAGCAAGTGGAAAAATTTTCTGTCCAG 
ATTGTGGTGATTTATTAGAAGCTGATCTTAATTGTAATTGTAAAAAGATAA 
AATGTAGTTGTTGTGACTACAAGGCCAATTCAATAAAAGGTATTAAA 
AATCATTATACAACAAAACATAAAACAAATTACGTTTACAAACCTACAGT 
GTATTGTTGTTATTGTGGTGAAAAATTAGCAGTTAATGAATACGGGTATGC 
TGGACAATGTTTTAATAAAGACTGCGATTCATTTAAATTTAGAATAGAAA 
CTTTTAGAACAAATATCACAAAAACTGTTAACAATTATACTAATATAAAA 
AGGATAGTAAGACACGTTCGGTATAGCCGAGCTGCTAAACTGAGAGAAGT 
TATGATGTGCAATACATACATAGGAGATAAAACGAAAAAAGAATTAGCC 
GGTATTAAAGCGGGTGCTAAATTATCAGTTATAATGAAAGAAAAAATAAA 
AAATGGTGAATTTACACCTTGTGTTACTAATAGCTGGTGCAGAAGCAGAA 
TATTATACAAGGGCAACGCTTTTC GCAGTTCATTCGAAGTATTGTTCAAAT 
TATTGGATACAGAAGACAAACTTTTATATGAAAAAACTGTAATACCTTAC 
GACCACTACGGAGTAGCCCGTAATTATATAGTTGATTTTACCGATTTTGAT 
AACAAAATATTATATGAAATTAAACCAAAATCTGAGATAAACAACGAT 
TTAAACAAAATAAAAGAAAATGCTGCAATTAAGTGGTGTAAAAACAATG 
GATTTGTATATAAAATAATAACCGAAGATTATTTAAAAAAATATAAAAAT 
AAAATTGTAGACAACTTCTTGGCTAATAAGGTGGCTTTTGACAACGAAAG 
TC TACG TAAAA TTA A TAA TTC GTTAAAAG G A TTAAAA TGA 
Predicted amino acid sequence of gene CPt 1 0 0591 
LLY TIDENNFIQKLLYINDNNINFKG YHNTIANQKLLKKLRQLV TNNLK IELKH 
FIRLLASGKlF CPDCGDLLEADLNCNCKK IK CSC CDYKANSIKG IKNH YTTKH 
KTNYVYKPTVY CCYC GEKLAVNE YGYA GQCFNKDCDSFKFRIETFRTNITKT 
VNN Y TN IKRIVRHVR Y SRA AKLRE VMMCN TY IGDK TKKELAG IKA GA KLSV I 
MKEK IKNGEFTPC V TN SWCRSRILYK G NAFRSSFEV LFK LLDTEDKLLYEK TV 
IPYDH YGVARNY IVDFTDFDNKILYEIKPKSEINNDLNKIKENAA IKWCKNNG 
FVYKIITEDYLKKYKNKIVDNFLANKV AFDNESLRKINNSLKGLK 
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ucleotide equence of gene CPt 10 1471 showing the amplified region in blue 
ATGTCAGTTGAAATAATTAATGATGATTGTTTAAACATATTGGAAAATATA 
AGAAATGTTGATTTAATTATAACAGACCCACCATACTTCGTAATTCCTAAA 
GGTAAAAAAACAAATAATGGATATGATAATTTTAAATGGGATAGTTTTGA 
CAATATGGATCATTTTTTAAAATTTACAAAAGAATGGTTTGATTTATGTTA 
TAAAAAATTAAATAATGATTCATTTATGTATATATTTTGGAGTCAAAAGTA 
TTTTTCATATGGTTTTGAAATTTTTAA TCCAAATCGTGTTTTGTTATGGCAC 
TATAGAAATTTAGTACTCGGTGGTAATGGAGATTTTGCATATGATTACGAA 
CCTATTTTTGTTATAAAGAAAGGTAATCCTAAATTAATAAAAGGCAAACA 
TAGTTCGATTTTAAATTTTACAAAACCTCAGAGTAATTTTAAGGCCGACAA 
ACTCGTTCACCCAACACAAAAA CCATTAAAATTAATAGAATACTTGATAT 
CAATATCAAATCTTAAAGAAAATGCTGTGATTTTGGATCCGTTTGGTGGTG 
CAGGGACAACAGCGTTAGCATCAAATAATTTAAAATATGATTGCATTACT 
ATAGAAAAAGAGACTGGGTATTGTAACTTAATAAACAATAGATTGTTAAT 
AAAGTAA 
Predicted amino acid sequence of gene CPt 1 0 1471 
MSVEIINDDCLNILENIRNVDLIITDPPYFV IPK GKKTNNG YDNFKWDSFDNM 
DHFLKFTKEWFDLC YKKLNNDSFMY IFWSQKY FSY GFEIFNPNR VLLWH YRN 
LVLG GNG DFA Y D YEPIFV IKKGNPKL IK GKHS SILNFTKPQSNFK ADK LVHP T 
QKPLKLIE YLISISNLKENA V ILDPFGGAG TT ALASNNLK YDCITIEKETG Y CNL 
INNRLLIK 
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Annotation ofCPX Bacteriophage 
Source Location Direction Note Feature 
CDS 
<1..1393 Reverse Similar to AEA86399.1 HefS3 [Campylobacter (R) phage NCTC12673J 
CDS Putative gp2 DNA end protector protein; similar to 
1454 .. 2191 R AEA86400.1 gp2 DNA end protector protein [Campylobacter phage NCTC12673] 
CDS 2200 .. 2553 R Hypotheticalprotein 
CDS Similar to YP 004322538.1 terminase DNA 
2602 .. 3318 R packaging enzyme large subunit [Prochlorococcus 
phage P-HMI] 
CDS 3355 .. 3828 R Similar to AEA86401.1 hypothetical protein [Campylobacter phage NCTC12673] 
CDS 3831 .. 4487 R Similar to AEA86402.1 Thymidylate synthetase [ C a m J > Y I o b a c t e r ~ h ~ e e NCTC12673J 
CDS Forward 
Similar to AEA86404.1 HefS9 [Campylobacter 
4683 .. 5990 (F) phage NCTC12673] 
CDS Similar to AEA86405.1 Hcf60 [Campylobacter 
6149 .. 7972 F phage NCTC12673] 
CDS 7987 .. 9897 R Similar to AEA86406.1 gp 18 tail sheath protein [ C a ~ o b a c t e r r phage NCTCI26731 
CDS Similar to AEA86407.1 hypothetical protein 
10061 .. 10408 R [Campylobacter phage NCTCI2673] 
CDS 10398 .. 11351 R Similar to AEA86408.1 hypothetical protein [Campylobacter phage NCTCI26731 
CDS 11373 .. 12695 R Similar to AEA86409.1 gp30 DNA ligase l C a ~ o b a c t e r r phage NCTCI26731 
CDS 12867 .. 13166 R Similar to AEA86411.1 hypothetical protein lCampylobacter p h a ~ e e NCTC12673] 
CDS Similar to AEA86412.1 hypothetical protein 
13156 .. 13656 R [Campylobacter phage NCTC12673] 
CDS 13674 .. 14066 R Similar to AEA86413.1 hypothetical protein [Campylobacter phage NCTC12673] 
CDS Similar to AEA86414.1 hypothetical protein 
14166 .. 14924 R [Campylobacter phage NCTC12673] 
CDS 14935 .. 15567 R Similar to AEA86415.1 hypothetical protein lCampylobacter l J h ~ e e NCTC126731 
CDS Similar to AEA864 16. 1 Henl [Campylobacter 
15612 .. 16694 F phage NCTC12673] 
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Source Location Direction Note Feature 
CDS Similar to YP _003785013.1 ribonucleotide-
diphosphate reductase subunit alpha [Brachyspira 
16714 .. 17637 R pilosicoli 95/1000]; pfam02867, ribonucleotide 
reductase barrel domain: aa 11 .. 290, score 5.64e-62 
CDS Similar to AEA864 I 8. I Het74 [Campylobacter 
17663 .. 18982 R phage NCTC12673] 
CDS 19079 .. 20476 R Similar to AEA86419.1 gp23 major capsid protein [Campylobacterphage NCTC 12673] 
CDS 20507 .. 21253 R Similar to AEA86420.1 hypothctical protein [Campylobacter phage NCTC12673) 
CDS Similar to AEA8642 I. I gp21 prohcad core scaffold 
21264 .. 21893 R and protease [Campylobacter phage NCTC12673] 
CDS 22058 .. 23764 R Similar to AEA86423.1 gp20 portal vcrtcx protcin [ C a m ~ o b a c t e r r phage NCTC126731 
CDS 23809 .. 24510 F Similar to AEA86424.1 hypothetical protein [Campylobacter phage NCTC12673] 
CDS 24513 .. 25244 F Similar to AEA86425.1 gp 13 neck protein [Campylobacter phage NCTC12673] 
CDS Similar to CBJ94203.1 Putative phage DNA 
packaging protein (terminase) [Campylobacter 
25271 .. 26599 F phage CPtl0] & C8J93810.1 putative phage DNA 
packaging protein (terminase) [Campylobacter 
phage CP220] 
CDS Similar to AEA86426.1 hypothctical protein 
26628 .. 26849 F [Campylobacter phage NCTCI2673] 
CDS 26852 .. 27583 F Similar to AEA86427.1 gp 19 tail tube protein III l C a m ~ l o b a c t e r r phage NCTCI267n 
CDS Similar to AEA86428.1 Hcf85 [Campylobactcr 
27578 .. 29023 R phage NCTC12673] 
CDS Similar to AEA86429.1 phosphatidylserine 
28995 .. 29762 R decarboxylase [Campylobacter phage NCTCI2673] 
CDS 29773 .. 30069 R Similar to AEA86430.1 co-chaperon in GroES [ C a m p y l o b a c t e r j ) h ~ e e NCTCI26731 
CDS 30125 .. 30634 R Similar to AEA8643 I. I hypothetical protein lCampylobacter phage NCTC12673J 
CDS 30637 .. 31134 R Similar to AEA86432.1 hypothetical protein [Campylobacter ~ h a g e e NCTC 126731 
CDS 31345 .. 33708 R Similar to AEA86434.1 putative DEAD/DEAH box helicase lCarnpylobactcr phage NCTCI2673] 
CDS 33765 .. 35156 R Similar to AEA86435.1 DNA hclicase UvsW [ C a m p y l o b a c t e r ~ h a g e e NCTCI2673J 
Similar to AEA86436.1 putative repair and 
CDS 35325 .. 35744 R recombination protein [Campylobacter phage 
NCTC12673] 
CDS 35746 .. 36471 R Similar to AEA86437.1 hypothetical protein l C a m p y l o b a c t e r p h ~ e e NCTC 126731 
270 
Appendix 3 
Source Location Direction Note Feature 
Misc Signal peptide predicted for CPX_0380 by signal P 3.0 
feature 36262 .. 36471 R (signal peptide probability: 0.982) with cleavage site J ' f o b a b i l i ~ ~0.920 between aa positions 17 and 18 
CDS 36643 .. 38025 R Similar to AEA86438.1 hypothetical protein [Campylobacter phage NCTC126731 
codon recognized: UAC; cove score 58.55 predicted 
tRNA- 38268 .. 38350 R by tRNAscan-SE 1.21" Tyr 
/anticodon=(pos:complemcnt(383 14 .. 383 16),aa:Tyr 
Codon recognized: AGA; cove score 66.75 predicted by 
tRNAscan-SE 1.21" 
tRNA- 38364 .. 38437 R Arg anticodon=(pos:complement(38404 .. 38406),aa:Arg) 
tRNA- Codon recognized: AAC; cove score 67.75 predicted by 38450 .. 38522 R tRNAscan-SE 1.21" Asn /anticodon=(pos:complement(38488 .. 38490),aa:Asn 
Codon recognized: UUA; cove score 58.26 predictedby 
tRNA- 38875 .. 38949 R tRNAscan-SE 1.21" Leu lanticodon=(pos:complement(38912 .. 38914),aa: Leu 
38958 .. 39029 Codon recognized: AUG; cove score 79.75 predicted by 
tRNA- R tRNAscan-SE 1.21" Met 
/anticodon=(pos:complemen!{38995 .. 3899TI,aa:Met 
CDS 39213 .. 39860 R Similar to AEA86439.1 hypothetical protein [CalTlPylobaeter phage NCTCI2673 
CDS 39841..41019 R Similar to AEA86440.1 putative methylase [Campylobacter phage NCTCI2673 
CDS 41766 . .42110 R Similar to AEA86442.1 hypothetical protein [ C a ~ o b a c t e r r phage N C T C I 2 6 7 ~ " "
CDS 42167 . .42781 R Similar to AEA86443.1 hypothetical protein [Campylobacter phage NCTCI2673 
CDS 43284 . .45947 R Similar to AEA86445.1 gp43 DNA polymerase [Campylobacter phage NCTCI2673 
CDS 45992 . .46921 R Similar to AEA86446.1 putative methyltransferase [Campylobacter phage NCTCI2673 
CDS 47017 .. 47430 R Similar to AEA86447.1 hypothetical protein [Campylobacter phage NCTCI2673 
Similar to AEA86448.1 hypothetical protein 
[Campylobacter phage NCTC12673]; proteim motif: 
pfam07087, protein of unknown function (DUFI353); This 
CDS 47427 . .47867 R family 
consists of several hypothetical bacterial proteins of around 
100 residues: aa 24 .. 125, score 2.17e-21 " 
Similar to AEA86449.1 Thymidine kinase [Campylobacter 
CDS 47869 . .48372 R phage NCTCI2673]; proteim motif: pfam00265, 
thymidine kinase: aa 2 .. 161, score 2.20e-17 
271 
Appendix 3 
Source Location Direction Note Feature 
Similar to AEA86451.1 gp61 DNA primase 
subunit 
CDS 48558 .. 49502 R [Campylobacter phage NCTCI2673]; proteim 
motif: PHA02540, 
DNA primase; Provisional: aa 24 .. 314, score 1.34e-
22 
CDS 49486 .. 50010 R Similar to AEA86452.1 hypothetical protein [Campylobacter ~ h a g e e NCTC 12673 
Signal peptide predicted for CPX_0500 by signal P 
Misc 
3.0 (signal peptide probability: 0.980) with 
feature 49801..50010 R cleavage site probability 0.473 between aa 
positions 26 and 27 
CDS 50082 .. 50405 R H ~ o t h e t i c a l ~ o t e i n n
Similar to AEA86453.1 gp3 tail completion and 
CDS 50491..50946 F sheath stabilizer protein [Campylobacter phage 
NCTC12673] 
CDS 50947 .. 51228 R Similar to AEA86454.1 hypothetical protein [ C a m ~ o b a c t e r ~ h a g e e NCTC12673] 
CDS 51414 .. 52079 R Similar to AEA86456.1 hypothetical protein [Campylobacter phage NCTCI26731 
CDS 52116 .. 52820 R Similar to AEA86457.1 hypothetical protein Campylobacter phage NCTC12673] 
CDS 52947 .. 53582 R Similar to AEA86457.1 hypothetical protein [Campylobacter phage NCTCI2673j 
CDS 53778 .. 54377 R 
Similar to AEA86460.1 hypothetical protein 
[ C a m 1 ' } ' l o b a c t e r ~ h ! l £ e e NCTC12673] 
CDS 54523 .. 54732 R HypotheticaljJl'otein 
CDS 54695 .. 56032 R Similar to AEA8646 I. I hypothetical protein [ C a m p y l o b a c t e r ~ h , ! g e e NCTC12673] 
Similar to AEA86462.1 gp46 recombination 
endonuclease [Campylobacter phage NCTCI2673]; 
CDS 56056 .. 57660 R proteim motif: PHA02562, endonuclease subunit; 
Provisional: aa 
1 .. 532, score 4.1ge-44 
CDS 57744 .. 58064 R Similar to AEA86463.1 hypothetical protein [ C a m ~ o b a c t e r r phage NCTCI26731 
Similar to AEA86464.1 gp47 recombination 
endonuclease [Campylobacter phage NCTCI2673]; 
protein motif: pfamOOl49, this family includes a 
diverse range of phospho est erases, including 
CDS 58123 .. 59118 R protein phosphoserine phosphatases, nucleotidases, sphingomyelin 
phosphodiesterases and 2'-3' cAMP 
phosphodiesterases as well as nucleases such as 
bacterial SbcD or yeast MRE 11: aa 5 .. 180, score 
5.48e-05 
Similar to AEA86465.1 gp55 Sigma factor for T4 
CDS 59106 .. 59975 R late 
transcription l C a m ~ o b a c t e r r~ h ~ e e NCTCI2673J 
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Similar to AEA86466.1 gp23 major head protein II 
[Campylobacter phage NCTCI2673]; proteim 
motif: pfam07068, 
CDS 60067 .. 61029 F major capsid protein Gp23; This family contains a 
number 
of major capsid Gp23 proteins approximately 500 
residues: 
aa 68 .. 147, score 2.6ge-03 
CDS 61039 .. 61686 F 
Simil.ar to AEA86467.1 gp14 head completion 
protem 
[Campylobacter phage NCTC12673] 
Similar to AEA86399.1 Hef53 [Campylobacter 
CDS 61683 .. 63449 R phage 
NCTC12673] 
Similar to AEA86469.1 gp 15 tail sheath stabilizer 
CDS 63558 .. 64589 F and completion protein [Campylobacter phage 
NCTC126731 
CDS 64586 .. 65041 F Similar to AEA86470.1 hypothetical protein [Campylobacter phage NCTC12673] 
CDS 65038 .. 65589 R Hypothetical protein 
CDS 65800 .. 66102 R Similar to AEA864 72.1 hypothetical protein [Campylobacter phage NCTC12673] 
CDS 66388 .. 66771 R Similar to AEA86474.1 hypothetical protein [Campylobacter phage NCTC12673] 
CDS 66894 .. 67334 R Similar to AEA86475.1 hypothetical protein [Campylobacter phage NCTC12673] 
CDS 67569 .. 68228 R Similar to AEA864 76.1 hypothetical protein [Campylobacter phaKe NCTC126731 
CDS 68800 .. 69033 R Similar to AEA86480.1 hypothetical protein [Campylobacter phage NCTC12673] 
Signal anchor predicted for CPX_0740 by signal P 
Misc 
feature 68824 .. 69033 R 
3.0 (signal anchor probability: 0.485) with cleavage 
site probability 0.217 between aa positions 20 and 
21 
Similar to CBJ94264.1 hypothetical protein 
CDS 69173 .. 69700 R [Campylobacter phage CPtl0] & AEA86481.1 putative exonuclease [Campylobacter phage 
NCTC12673] 
CDS 69895 .. 70311 R Similar to AEA86482.1 hypothetical protein 
rCampylobacter phage NCTC12673] 
CDS 70308 .. 70649 R Similar to AEA86483.1 hypothetical protein [Campylobacter phage NCTC12673] 
Similar to AEA86484.1 hypothetical protein 
CDS 70633 .. 71151 R [Campylobacter phage NCTC12673] & CBJ94266.1 hypothetical 
protein rCampvlobacter phage CPtl0] 
CDS 71148 .. 71513 R Similar to AEA86485.1 hypothetical protein [Campylobacter phage NCTC12673] 
CDS 71570 .. 72295 R Similar to AEA86486.1 hypothetical protein 
rCampvlobacter phage NCTC126731 
CDS 72306 .. 72590 R Similar to AEA86487.1 hypothetical protein 
rCampylobacter phage NCTC12673] 
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CDS 72624 .. 73478 R Similar to AEA86488.1 hypothetical protein [Campylobacter phage NCTC12673] 
Similar to AEA86489.1 hypothetical protein 
[Campylobacter phage NCTC12673] & 
CDS 73517 .. 74059 R EFV0983 1.1 hypothetical 
protein CSS _ 0089 [Campylobacter jejuni subsp. 
jejuni 305] 
CDS 74217 .. 74513 R Similar to CBJ94273.1 hypothetical protein [Campylobacter phage CPt I 0] 
CDS 74428 .. 74649 R Similar to CBJ94272.1 hypothetical protein LCamHobacter phage CPtIO] 
Similar to CBJ94271.1 hypothetical protein 
CDS 74651.. 75265 R [Campylobacter phage CPtIO] & AEA86490.1 hypothetical protein [Campylobacter phage 
NCTC12673] 
Similar to AEA8649 1. I hypothetical protein 
CDS 7540 1 .. 75649 R [Campylobacter phage NCTC12673] & CBJ94270.1 hypothetical 
protein [Campylobacter phage CPtlO] 
CDS 76220 .. 76627 R Similar to AEA86494.1 hypothetical protein [Campylobacter phage NCTCI2673J 
Similar to AEA86495.1 gp4 head completion 
CDS 77454 .. 77897 R protein 
[ C a m p ~ o b a c t e r r phage NCTC 12673] 
Repeat 77902 .. 77941 F predicted by Tandem Repeats Finder 
region 
CDS 77917 .. 78627 R Similar to AEA86496.1 hypothetical protein [Campylobacter phage NCTC12673] 
CDS 78782 .. 79078 R Similar to AEA86497.1 hypothetical protein [ C a ~ o b a c t e r r phage NCTC12673] 
CDS 79081 .. 80202 R Similar to AEA86498.1 mlA; RNA ligase [CamHlobacter phage NCTC12673] 
CDS 80422 .. 80715 R Similar to AEA86500.1 hypothetical protein [Campylobacter phage NCTC12673] 
CDS 80722 .. 80961 R Similar to AEA8650 1.1 hypothetical protein jCart.:!EYlobacter phage NCTC I 2673] 
Signal peptide predicted for CPX_0930 by signal P 
Misc 80752 .. 80961 R 3.0 (signal peptide probability: 0.999) with feature cleavage site 
probability 0.931 between aa positions 16 and 17 
Similar to AEA86504.1 putative poly A 
CDS 81532 .. 82593 R polymerase 
[Campylobacter phage NCTC12673] 
82633 .. 84018 R Similar to AEA86505.1 ribonucleotide reductase CDS large subunit [Campylobacter phage NCTC12673] 
Similar to AEA86506.1 ribonucleotide reductase 
CDS 83993 .. 85126 R 
small subunit [Campylobacter phage NCTC12673] 
Similar to AEA86507.1 hypothetical protein 
CDS 85139 .. 85498 R [Campylobacter phage NCTC12673] 
Appendix 3 
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Signal anchor predicted for CPX_0970 by signal P 
Misc 85289 .. 85498 R 3.0 (signal anchor probability: 0.7725) with feature cleavage site 
probability 0.151 between aa positions 28 and 29 
CDS 85491 .. 85862 R Similar to AEA86508.1 hypothetical protein 
rCampylobacter phage NCTC12673] 
CDS 87603 .. 88646 R Similar to AEA865 1 1.1 RecA [Campylobacter phage NCTC12673] 
CDS 88648 .. 88884 R Similar to AEA865 12.1 hypothetical protein 
rCampylobacter phage NCTC12673] 
CDS 88941 .. 89240 R Similar to AEA86513.1 hypothetical protcin 
rCampylobacter phage NCTC126731 
Signal peptide predicted for CPX_IOIO by signal P 
Misc 89031 .. 89240 R 3.0 (signal peptide probability: 0.997) with feature cleavage site 
probability 0.695 between aa positions 23 and 24 
CDS 89203 .. 89547 R Similar to AEA865 14.1 hypothetical protein 
rCampylobacter phage NCTC126731 
Misc 
Signa! anchor predicted for CPX_I020 by signal P 
89338 .. 89547 R 3:0 (SIgnal anchor probability: 0.700) with cleavage feature sIte 
probability 0.031 between aa positions 27 and 28 
CDS 89551..90219 R Similar to AEA86349.1 hypothetical protein 
rCampylobacter phage NCTC126731 
CDS 90232 .. 91116 R Similar to AEA86351.1 gp44 sliding clamp loader 
subunit [Campylobacter phage NCTC 12673] 
CDS 91241..91798 R Similar to AEA86352.1 hypothetical protein 
rCampylobacter phage NCTC12673] 
Similar to AEA86354.1 putative dUTP 
CDS 92061 .. 92507 R pyrophosphatase 
[Campylobacter phage NCTC126731 
CDS 92495 .. 92887 R Similar to AEA86355.1 hypothetical protein 
rCampylobacter phage NCTC126731 
Similar to AEA86356.1 putative NAD(FAD)-
CDS 92899 .. 94167 R utilizing dehydrogenase [Campylobacter phage 
NCTC12673] 
CDS 94220 .. 94624 R Similar to AEA86357.1 hypothetical protein 
rCampylobacter phage NCTC126731 
CDS 94858 .. 95424 R Similar to AEA86359.1 hypothetical protein 
rCampylobacter phage NCTC126731 
Misc 
Signa! peptide predicted for CPX_IIOO by signal P 
feature 95215 .. 95424 R 
3.0 (SIgnal peptide probability: 0.982) with 
cleavage site 
probability 0.369 between aa positions 21 and 22 
CDS 95443 .. 96078 R Similar to AEA86360.1 hypothetical protein 
rCampylobacter phage NCTC126731 
CDS 96292 .. 97608 R Putative DNA topoisomerase II 
Similar to AEA86361.1 Heft5 [Campylobacter 
CDS 97643 .. 99268 R phage NCTCI2673]: 
CDS 99278 .. 101128 R Similar to AEA86362.1 topoisomerase II large 
subunit [Campylobacter phage NCTC 12673] 
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Similar to AEA86363.1 hypothetical protein CDS 101205 .. 102407 R [Campylobacter phage NCTC12673] 
R Similar to AEA86364.1 hypothetical protein CDS 102458 .. 102718 [Campylobacter p h ~ e e NCTCI26731 
Similar to AEA86365.1 hypothetical protein 
CDS 102773 .. 103174 F [Campylobacter phage NCTC12673] 
R Similar to AEA86366.1 hypothetical protein CDS 103192 .. 103710 [Campylobacter phage NCTC12673J 
R Similar to AEA86367.1 hypothetical protein CDS 103743 .. 104459 [Campylobacter phage NCTC12673] 
F Similar to AEA86368.1 hypothetical protein CDS 104430 .. 105083 [Campylobacter phage NCTC12673] 
Similar to AEA863 70.1 hypothetical protein CDS 105269 .. 105742 F lCampylobacter phage NCTCI267l]" 
1 05735 .. 108350 F Similar to AEA86371.1 putative peptidase CDS [Campylobacter phage NCTCI2673]" 
Repeat 1 07864 .. 107974 F Predicted by Tandem Repeats Finder 
region 
Similar to AEA863 72.1 hypothetical protein CDS 108352 .. 109308 F [Campylobacter phage NCTC12673] 
F Similar to AEA86373.1 hypothetical protein CDS 109324 .. 109677 [Campylobacter phage NCTC12673] 
F Similar to AEA86374.1 hypothetical protein CDS 109685 .. 110446 [Campylobacter p h ~ e e NCTC12673] 
Similar to AEA86375.1 hypothetical protein 
CDS 11 0467 .. 11 0928 F [Campylobacter phage NCTC12673] 
Similar to AEA86376.1 hypothetical protein 
CDS 11 0918 .. 112054 F [Campylobacter phage NCTC12673] 
Similar to AEA86377.1 gp5 baseplate hub 
subunit and 
CDS 112051..112737 F 
tail lysozyme [Campylobacter phage 
NCTC12673] 
Similar to AEA86378.1 hypothetical protein 
CDS 112724 .. 113065 R [Campylobacter phage NCTC12673] 
Similar to AEA86379.1 putative gp5.4 
conserved 
CDS 113049 . .113336 R hypothetical protein [Campylobacter phage 
NCTC12673] 
similar to AEA86380.1 Hef34 [Campylobacter 
phage 
CDS 113320 . .114942 R 
NCTC12673] 
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Similar to AEA86381.1 hypothetical protein 
CDS 114954 .. 115400 R [Campylobacter phage NCTC12673] 
Similar to AEA86382.1 hypothetical protein 
CDS 115460 .. 116032 R [Campylobacter phage NCTC12673] 
Similar to AEA86383.1 gp 19 tail tube protein 
CDS 116049 .. 116591 R [Campylobacter phage NCTC12673] 
Similar to AEA86384.1 gp 19 tail tube protein 
II 
CDS 116604 .. 1l7182 R 
[Campylobacter phage NCTC12673] 
Similar to AEA86385.1 hypothetical protein 
CDS 117184 .. 117744 R [Campylobacter phage NCTC12673] 
Similar to AEA86386.1 hypothetical protein 
CDS 117728 .. 119284 R [Campylobacter phage NCTC12673] 
Similar to AEA86388.1 gp6 baseplate wedge 
subunit 
CDS 119281..121374 R 
[Campylobacter phage NCTC12673] 
Similar to AEA86390.1 gp45 sliding clamp 
protein 
CDS 121753 .. 122463 R 
[Campylobacter phage NCTC12673] 
Similar to AEA86391.1 Aminidotransferase 
CDS 122512 . .123495 R [Campylobacter phage NCTC12673] 
Similar to AEA86392.1 gp41 DNA primase-
123576 .. 124817 R helicase subunit [Campylobacter phage CDS 
NCTC12673] 
Similar to AEA86393.1 hypothetical protein 
CDS 124817 . .125539 R [Campylobacter phage NCTC12673] 
Similar to AEA86394.1 hypothetical protein; 
CDS 125675 . .127576 R putative tail fibre [Campylobacter phage 
NCTC12673] 
Similar to AEA86394.1 hypothetical protein; 
CDS 127570 . .128502 R putative tail fibre [Campylobacter phage 
NCTC12673] 
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Similar to AEA86394.1 hypothetical protein; 
CDS 128483 .. 129772 R putative tail fibre [Campylobacter phage 
NCTC12673]" 
Similar to AEA86395.1 putative RNaseH 
CDS 129823 .. 130848 R [Campylobacter phage NCTC12673] 
Similar to AEA86397.1 gp62 clamp loader 
subunit 
CDS 130966 .. 131352 R 
[Campylobacter phage NCTC12673] 
Similar to AEA86398.1 gp32 ssDNA binding 
protein 
CDS 131404 .. 132321 R 
[Campylobacter phage NCTC12673] 
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Nucleotide Sequence of gene CP220 CPT 0075 cloned in to TOPO vector with 
EcoRl restriction sites highlighted in yellow, the introduced NdeI restriction 
site is highlighted in green and the BamHI site is highlighted in blue 
GAATTCGCC AACTAGAGTTGGTGTTGATT 
TTAGTACAGGACATTCTTCATTCCCACCTAATGTAGTTTCGAGTGGT 
TCTACGAATGTCTTGACTAATTCAATTAGTACAGTTAGACAAGGTGA 
TCCTATAATACCACACGGAAGTCCTAGCCCGTCACCACCACACGGT 
GGGAGTATTGCTACAGGTTCTGGGACTGTTATGGTTAATTCAAAACC 
TGCTTGTAGAATAGGTGATGCCATTAGTTGTGGCCAAGCTGTAGCA 
CAAGGATCTGGAAATGTTATTTGTGGAT GGGCGA 
ATTC 
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ucleotide Sequence of gene CP220 CPT 120 cloned in to TOPO vector with 
EcoRI re triction sites highlighted in yellow, the introduced NdeI restriction 
ite i highlighted in green and the BamHI site is highlighted in blue 
GAATTCGCCCTT TTACGATAAACTGAATAAAATGGG 
AATAATTTTGATTATTATTTTATCAGTTGTTTATTTTATGCTTGATAT 
TAATAATACAAAAGTTAAAAATTTAGAATTTAAAATTCAAGATCTT 
CAAATAGAACTTAATAAAACCAAAAAAGAATTAAATGATACCAAA 
ATTAATTTAAATCATTTAAGTTCTAAAGTTCAAGATTTAAAAATATC 
TTTAATGAAAGATATGTCGTCAATGTATCACTTAAGTGATAAACAA 
CAATCTCTAATACTTGCTGAAATATGGAAACAATCTAAAAAATACA 
AAATAAACCCAGCATTTTTATACGCAGTATTATGGAAAGAATCAAG 
ATTTAGAAACGACGTTATTCATAAACCTACTTATGTTAGAACACTTA 
AAAAAGAGATACAAGCTCAAGGTATGGGTGCTATTGTTTGGGATTT 
TTGGGGAGATAAACTTAAGTCTAATACAAGTTTAAAATCTAAAAAA 
GATCTTAAAAATTGGAAAAAGAATATAGAAGGGACTGCATATATAC 
TTAGTTATTTGAAATCTTTACCAAAGATATCTAATACAAAAAATAAG 
TACGAATCAGCAGCTTCAAGATACTACGGAAAATATCAAGCAAATT 
ACGTGAATAAAACAATGTCAAAATTTAATAAACTAAACTCTTAATA 
AAGGGCGAATTC 
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Nucleotide Sequence of gene CP220 CPT 0075 cloned in to pET 3a vector 
with ribo ornal binding site highlighted in pink, the introduced NdeI restriction 
ite i highlighted in green and the BamHI site is highligbted in blue 
ATTTTGTTTAACTTT TATAllllllccTCCTTTAACT 
AGAGTTGGTGTTGATTTTAGTACAGGACATTCTTCATTCCCACCTAA 
TGTAGTTTCGAGTGGTTCTACGAATGTCTTGACTAATTCAATTAGTA 
CAGTTAGACAAGGTGATCCTATAATACCACACGGAAGTCCTAGCCC 
GTCACCACCACACGGTGGGAGTATTGCTACAGGTTCTGGGACTGTT 
ATGGTTAATTCAAAACCTGCTTGTAGAATAGGTGATGCCATTAGTTG 
TGGCCAAGCTGTAGCACAAGGATCTGGAAATGTTATTTGTGGATAA 
GCT 
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Nucleotide Sequence of gene CP220 CPT 120 cloned in to pET 3a vector with 
ribosomal binding site highlighted in pink, the introduced NdeI restriction site 
is highlighted in green and the BamHI site is highlighted in blue 
CTTT TATAllllliAATTACGATAAACTGAATAAAA 
TGGGAATAATTTTGATTATTATTTTATCAGTTGTTTATTTTATGCTTG 
ATATTAATAATACAAAAGTTAAAAATTTAGAATTTAAAATTCAAGA 
TCTTCAAATAGAACTTAATAAAACCAAAAAAGAATTAAATGATACC 
AAAATTAATTTAAATCATTTAAGTTCTAAAGTTCAAGATTTAAAAAT 
ATCTTTAATGAAAGATATGTCGTCAATGTATCACTTAAGTGATAAAC 
AACAATCTCTAATACTTGCTGAAATATGGAAACAATCTAAAAAATA 
CAAAATAAACCCAGCATTTTTATACGCAGTATTATGGAAAGAATCA 
AGATTTAGAAACGACGTTATTCATAAACCTACTTATGTTAGAACACT 
TAAAAAAGAGATACAAGCTCAAGGTATGGGTGCTATTGTTTGGGAT 
TTTTGGGGAGATAAACTTAAGTCTAATACAAGTTTAAAATCTAAAA 
AAGATCTTAAAAATTGGAAAAAGAATATAGAAGGGACTGCATATAT 
ACTTAGTTATTTGAAATCTTTACCAAAGATATCTAATACAAAAAATA 
AGTACGAATCAGCAGCTTCAAGATACTACGGAAAATATCAAGCAAA 
TTACGTGAATAAAACAATGTCAAAATTTAATAAACTAAACTCTTAA 
TA CTG 
282 
Appendix 6 
Appendix 6 
MS peptide sequencing ofCP220 CPT 120 expressed protein band in Rosetta 2 
(DE3) pLys S 
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Appendix 7 
ucleotide Sequence of His tagged gene CP220 CPT 120 cloned in to TOPO 
vector with EcoRl restriction sites highlighted in yellow, the introduced NdeI 
restriction site is highlighted in green and the Bam HI site is highlighted in blue 
and the His tag is highlighted in pink 
GAATTCGCCCTTA TGAATTA 
CGATAAACTGAATAAAATGGGAATAATTTTGATTATTATTTTATCAG 
TTGTTTATTTTATGCTTGATATTAATAATACAAAAGTTAAAAATTTA 
GAATTTAAAATTCAAGATCTTCAAATAGAACTTAATAAAACCAAAA 
AAGAATTAAATGATACCAAAATTAATTTAAATCATTTAAGTTCTAA 
AGTTCAAGATTTAAAAATATCTTTAATGAAAGATATGTCGTCAATGT 
ATCACTTAAGTGATAAACAACAATCTCTAATACTTGCTGAAATATG 
GAAACAATCTAAAAAATACAAAATAAACCCAGCATTTTTATACGCA 
GTATTATGGAAAGAATCAAGATTTAGAAACGACGTTATTCATAAAC 
CTACTTATGTTAGAACACTTAAAAAAGAGATACAAGCTCAAGGTAT 
GGGTGCTATTGTTTGGGATTTTTGGGGAGATAAACTTAAGTCTAATA 
CAAGTTTAAAATCTAAAAAAGATCTTAAAAATTGGAAAAAGAATAT 
AGAAGGGACTGCATATATACTTAGTTATTTGAAATCTTTACCGAAG 
ATATCTAATACAAAAAATAAGTACGAATCAGCAGCTTCAAGATACT 
ACGGAAAATATCAAGCAAATTACGTGAATAAAACAATGTCAAAATT 
TAATAAACTAAACTCTTAAT AAGGGCGAATTC 
284 
